Dr. James Earl Crowe Jr. (born 1961)
Wikipedia NONE
Wikipedia NONE
James Earl Crowe, Jr., M.D. OFFICE ADDRESS: Vanderbilt Vaccine Center Vanderbilt University Medical Center 11475 MRB IV 2213 Garland Avenue Nashville, TN 37232-0417 telephone: (615) 343-8064 fax: (615) 343-4456 email: james.crowe@vanderbilt.edu websites: Crowelab.com; VVCenter.org BIRTH: August 14, 1961; Nashvi
dvfdsvfds1CURRICULUM VITAE January 22, 2016NAME: James Earl Crowe, Jr., M.D.OFFICE ADDRESS: Vanderbilt Vaccine CenterVanderbilt University Medical Center11475 MRB IV2213 Garland AvenueNashville, TN 37232-0417telephone: (615) 343-8064fax: (615) 343-4456email: james.crowe@vanderbilt.eduwebsites: Crowelab.com; VVCenter.orgBIRTH: August 14, 1961; Nashville, TN, USACITIZENSHIP: United StatesPERSONAL: Married to Elizabeth H. Crowe, MD, since May 1987Son, Stephen Crowe, age 25; Daughter, Catherine Crowe, age 22UNIFORMED SERVICE: Active duty, U.S. Public Health Service, Nov 1990-Oct 1995;Inactive Reserves, U.S. Public Health Service, Nov 1995-Mar 2010PERSONAL INTERESTS: Haitian, tribal and outsider art; endurance sports include ultrarunning -Western States and Arkansas 100 mile races, Grand Canyon Rim2Rim2Rim,Comrades 89k, South Africa, and others, cycling and multisport; three-timeIronman finisher.EDUCATION AND RESEARCH TRAINING:1979 - 1983 B.S., Magna Cum Laude, Davidson College, Davidson, NC1983 - 1987 M.D., U.N.C. School of Medicine, Chapel Hill, NC1987 - 1990 Pediatric internship and residency, N.C. Memorial Hospitals (University ofNorth Carolina, Chapel Hill, N.C.)1990 – 1993 Medical Staff Fellow, Respiratory Viruses Section, Laboratory of InfectiousDiseases, NIAID, NIH, Bethesda, MD. Mentors: Robert Chanock and BrianMurphy1993 - 1995 Sr. Research Investigator, Respiratory Viruses Section,Laboratory of Infectious Diseases, NIAID, Bethesda, MD1995 - 1996 Clinical Fellowship, Infectious Diseases, (as Instructor in Pediatrics), Division ofPediatric Infectious Diseases, Department of Pediatrics, Vanderbilt UniversityMedical Center, Nashville, TN2LICENSURE: Tennessee Medical License #27245; 8/18/1995 to present; current through8/31/2017.DEA registration (2,2N,3,3N,4,5); current through 08/31/2016North Carolina Medical license, 1987 – 1997; I chose voluntarily to not renewmy NC license, because I was no longer practicing in that state.BOARD CERTIFICATION: American Board of Pediatrics (ABP ID # 217691)CurrentGeneral Pediatrics, Certificate No. 44335, through 12/31/2016Pediatric Infectious Diseases, Certificate No. 538, through 12/31/2024PreviousGeneral Pediatrics 11/13/1990-12/31/199701/01/1998-12/31/200401/01/2005-12/31/2011Pediatric Infectious Diseases 08/05/1997-12/31/200401/01/2005-12/31/2011ACADEMIC APPOINTMENTS:1995-1996 Instructor, Department of Pediatrics, Division of Pediatric Infectious Diseases,Vanderbilt University Medical Center, Nashville, TN1996-2001 Assistant Professor, Department of Pediatrics, Division of Pediatric InfectiousDiseases, Vanderbilt University Medical Center, Nashville, TN1998-2005 Assistant Professor of Microbiology and Immunology, Vanderbilt UniversityMedical Center, Nashville, TN2001-2004 Associate Professor (with tenure), Department of Pediatrics, Division ofPediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville,TN2004-present Professor (with tenure), Department of Pediatrics, Division of PediatricInfectious Diseases, Vanderbilt University Medical Center, Nashville, TN2005-2006 Associate Professor of Microbiology and Immunology, Vanderbilt UniversityMedical Center, Nashville, TN2006-present Professor of Pathology, Microbiology and Immunology (dept. was termedMicrobiology and Immunology 2006-11), Vanderbilt University Medical Center,Nashville, TNENDOWED CHAIRS32005-2013 Ingram Professor of Cancer Research, Vanderbilt University2013-present Ann Scott Carell Chair, Vanderbilt UniversityHOSPITAL APPOINTMENTS1990 Attending Physician, Pediatric Clinic, Wake Medical Center, Raleigh, NC(Affiliate Teaching Hospital with UNC-CH).1990 Attending Physician, Tarrboro, NC1996-present Vanderbilt University Medical Center/Vanderbilt Children’s Hospital;Attending Physician, Pediatrics1999-2005 Stallworth Rehabilitation Hospital, Nashville, TN, Consulting Privileges,Infectious Diseases.OTHER APPOINTMENTS AT VANDERBILT1999-present Associate Member, Experimental Therapeutics Research Program in theVanderbilt-Ingram Cancer Center2001-present Scientific Director, Flow Cytometry Core Laboratory, Vanderbilt UniversityMedical Center, Nashville, TN2003-present Scientific Director, Immunology Core Laboratory, Vanderbilt University2003-present Scientific Director, Flow Cytometry and Cell Sorting Shared Resource of theVanderbilt-Ingram Cancer Center2003-2011 Associate Director, Immunopathogenesis Core Laboratory, Center for AIDSResearch, Vanderbilt2004-present Senior Faculty Fellow, Vanderbilt Institute for Integrative Biosystems Researchand Education2004- present Director, Vanderbilt Alliance for Nanomedicine (Vanderbilt University MedicalCenter, Vanderbilt University, and Oak Ridge National Laboratory)2005- present Director, Vanderbilt Vaccine Center (formally the Vanderbilt Program in VaccineSciences)2005- present Investigator, Digestive Diseases Research Center, Vanderbilt2005- 2011 Faculty member, Program in Human Genetics, Vanderbilt2009- present Faculty member, Chemical and Physical Biology Program2012- 2015 Scientific Director, Vanderbilt Technologies for Advanced Genomics(VANTAGE)42013- 2014 Executive Committee of the Executive Faculty, Vanderbilt Medical School ofMedicine, MemberAWARDS AND HONORS1979 - 1983 Edward Stuart Scholarship (full 4-year merit scholarship), Davidson College,Davidson, NC1983 Phi Beta Kappa, Omicron Delta Kappa, Alpha Epsilon Delta, Davidson College1990 Outstanding Pediatric Resident, Wake Medical Center, Raleigh, NC1990 Edward Curnen Award, UNC Pediatrics1996 Pfizer Faculty Scholar, Pfizer, Inc., New York, NY1998 Basil O’Connor Scholar Research Award, March of Dimes1999 Dade MicroScan Young Investigator Award, American Society for Microbiology1999 Turner Scholar Award, Vanderbilt University2000 Young Investigator Award, Pediatric Infectious Diseases Society2001 Young Investigator Award, Society for Pediatric Research2002 Judson Daland Prize for Outstanding Achievement in Patient-Oriented ClinicalResearch, American Philosophical Society, Philadelphia, PA2005, 2008 Teacher of the Year Award, Vanderbilt University School of MedicineInterdisciplinary Graduate Program2005 Oswald Avery Award for Early Achievement, Infectious Diseases Society ofAmerica2006 E. Mead Johnson Award for Excellence in Pediatric Research, Society forPediatric Research2006-10 America's Top Pediatricians, Consumers Research Council2007 Outstanding Investigator Award, American Federation for Medical Research2007 F. Peter Guengerich Award for Mentoring Postdoctoral Fellows, VanderbiltUniversity Medical Center2007 Ernest W. Goodpasture Faculty Research Award, Vanderbilt University MedicalCenter2007 Chancellor's Research Award, Vanderbilt University52010 Norman J. Siegel New Member Outstanding Science Award, American PediatricSociety2012 Mentor of the Year Award, Vanderbilt Postdoctoral Association2014 Elected Member, National Academy of Medicine [formally the Institute ofMedicine (IOM)]PROFESSIONAL ORGANIZATIONSSelective Societies (By Election)1994 American Society of Microbiology1997 American Society for Virology; Full Member1997 Infectious Diseases Society of America member; 2007 Fellow1998 Society for Pediatric Research; 2009 Council1999 American Association of Immunologists [FASEB]2003 American Federation for Medical Research2004 American Society for Clinical Investigation, Fellow2009 Association of American Physicians, Fellow2010 American Pediatric Society, Fellow2010 American Association for the Advancement of Science, Fellow2010 American Academy of Microbiology, FellowOther SocietiesPediatric Infectious Diseases Society, since 1996International Society for Vaccines, since 2008HIV Medicine Association, since 2000Society for Mucosal Immunology, since 2007The Antibody Society, since 2009International Society for Infectious Diseases, since 2014NAMED INVITED LECTURES62005 Henry Shinefield Lecture, CDC-National Immunization Program, Clinical Immunization SafetyAssessment (CISA) Network National Meeting, June 13-14, 2005, Nashville, TN.2006 Danny Thomas Lecture, St. Jude Children’s Research Hospital, Memphis, TN; June 22, 2006.2007 Jack Light Lecture, Cedars Sinai Medical Center/UCLA Pediatrics, Los Angeles, CA; September 27, 2007.2013 The Edwin Lennette Lecturer, American Society for Virology 32nd Annual Meeting, Pennsylvania StateUniversity, July 24, 2013.2014 23rd Alexis S. Hartmann M.D. Visiting Professor, Washington University at St. Louis, March 27-28, 2014.PROFESSIONAL ACTIVITIESBiotechFounder, Corbeau Biotech LLC, Nashville, TN, 2010-presentIntramural Committee Activity at Vanderbilt• Member, Vanderbilt Institutional Biosafety Committee, 2002-2005.• Chair, Vanderbilt Institutional Biosafety Committee, 2003- 2005.• Member, Vanderbilt Animal Care Committee, 2000-2003.• Member, Department of Pediatrics Appointments and Promotion Committee, 2003- present.• Member, Oversight Committee of the Molecular Recognition Core Laboratory 1998-2006.• Member, Pediatric Infectious Diseases Fellowship RRC Committee 1996-2005.• Director, Clinical Fellowship Program, Pediatric Infectious Diseases, 2007-2009.• Interviewer, Medical School Admissions Committee 1998-2002, 2013-present, the InterdisciplinaryGraduate Program, and the Medical Scientist Training Program 1998 to present.• Faculty Advisor, numerous Pediatric Residents and Pediatric Infectious Diseases Fellows, 1996- present• Member, Vanderbilt Office of Research Taskforce on New Tools, 2002-2003.• Head, Pediatric Research Training Taskforce, 2002.• Chair, Search Committee, Pediatric Infectious Diseases Division Head, 2006-2007.• Member of the Executive Faculty, Vanderbilt Medical Center, 2008-present.• Chair, Search Committee, Pediatric Allergy, Immunology, Rheumatology Division Head, 2006-2007.• Chairman, Internal Advisory Board, Vanderbilt Institute for Clinical and Translational Research(VICTR) (CTSA); member 2008 – present; Chair 2009-2011, 2013.• Executive Committee Member, Vanderbilt Institute for Nanoscale Science and Engineering (VINSE),2008-present.• Workshop Leader, “Preparing Research Team Leaders”, Office of Biomedical Research Education andTraining, June 2, 2009.• Member, Search Committee, Petersen Chair, 2009, Department of Pediatrics.• Member, Faculty Awards Committee of the School of Medicine, 2009-2012.• Member, Genome Technology, Internal Advisory Committee, 2010-2012.7• Chair, Technology Review Committee of Vanderbilt University. August 2012 – June 2015; committeemember 2010-2012.• Member, Vanderbilt International Scholars Awards Program Committee, 2010• Reviewer, Vanderbilt Clinical and Translational Science Program grant reviews, Sept. 7, 2010.• Faculty Advisory Group Regarding Faculty Equity in Technology Transfer, 2011- present.• Member, Search Committee for the Chair of Biochemistry, 2011-12.• Member, Search Committee for the Stahlman Professor of Pathology, Microbiology and Immunology,2011.• Genome Sciences Resource oversight committee, 2012.• Search Committee for the Director of the Division of Infectious Diseases, 2012.• Chancellor’s Academic Planning Group for Trans-Institutional Programs, 2013.• Search Committee for Vanderbilt leader in Human Genetics/Genomics Research, 2013-14.• Genetics Executive Council, Vanderbilt University Medical Center, 2014-present.• Review Committee, Dorothy and Laurence Grossman Chair in Cardiology, 2014.• Internal Advisory Committee for the Center for Structural Biology, 2015-present.• Faculty Advisory Committee, Vanderbilt Antibody and Protein Resource Core, 2015-present.• Review Committee, Elliott Chair in Ophthalmology, 2015.REVIEWER:Scientific Reviewer for Sections, GovernmentPermanent Member, NIH Study sectionsNIAID Study Section Permanent Member, Microbiology and Infectious Diseases Research Committee(MIDRC), 2004-2008.Chair, NIH Study SectionsAncillary Studies in Immunomodulation Clinical Trials, ZAI1-PA-I-(M1), January 19, 2010.Special Emphasis Panel/Scientific Review Group 2014/01 ZAI1 SV-A (J3) 1, “Innovation for HIV VaccineDiscovery (R01)”, January 2014.Special Emphasis Panel, NIAID Clinical Trial Planning Grants (R34; PAR-13-150) and Implementation Grantsand Cooperative Agreements (R01, PAR-13-149; U01, PAR-13-151); April 23, 2014.Ad hoc Member, NIH and DoD Study Sections• Hyperaccelerated Awards in Immune Modulation, NIAID Hyper-ID Scientific Review Group (SSS-J-01), Nov. 2002; Dec. 2002.• NIDCD Otitis media RFA-DC-02-002 Study Section, 2002 and 2003.• Impact of Microbial Interactions on Infectious Diseases, ZRG1 SSS-J 02 1, Nov. 2002.• Experimental Virology Study Section, Feb. 2002.• Regional Centers of Excellence for Biodefense, ZA11-KLW-M-M3, 2003.• Biodefense and Emerging Infectious Diseases, ZAI1-AR-I-S1, May 2004.8• Innate and adaptive immunity of neonates, NIAID Special Study Section, May 2004.• Innate and Adaptive Immune Systems in Premature Neonates, ZAI1-AWA-I-J2, July 28, 2004.• Regional Centers of Excellence for Biodefense and Emerging Infectious Disease Research (RCEs), 2005.• Immunity and Host-Defense (IHD), October 02-03, 2008.• Challenge Grants Panel 9, 2009/10 ZRG1 IDM-C (58) R RFA09-003.• Challenge Grants Editorial Panel 17, 2009/10 ZRG1 IMM-E (58) R.• Microbiology and Infectious Diseases Research Committee, NIAID, 2009/10 ZAI1 AWA-M (S1) 1, July2009.• S10 Flow Cytometry Shared Instrumentation Grants, 2009/10 ZRG1 IMST-C (30), 7/09.• Small Business Innovation Research (SBIR) Contract Proposals, NIAID, 2/24/10.• Cell Biology and Molecular Imaging (IMST 16) Study Section, 3/11/10.• HIV Vaccine Research and Design Program or HIVRAD (PAR-09-134), NIAID, NIH, 11/2010.• NIAID P01 review, SEP ZAI1-RRS-A-M2, 04/27/2011.• NIAID P01 review, SEP ZAI1-RWM-M-S1, 05/12/2011.• NIAID R01/R21 reviews, ZRG1 IDM-U 02 M, Topics in Microbial Pathogenesis and Immunity, August18 & 19, 2011.• NIAID-AI-11-010, The Infant Immune System: Implications for Vaccines and Response to Infections(R01), Dec. 1-2, 2011.• NIAID P01 review, SEP ZAI1 JKB-M (M2) 1, 03/26/2012.• NIAID R01 reviews, SEP ZAI1 DR-A (M1) 1, Innovation for HIV Vaccine Discovery, 04/03/2012.• NIH, ZRG1 CB-J (30) I Study Section, S10 flow cytometer application reviews, August 8-9, 2012.• American Institute of Biological Sciences, US Army Medical Research and Materiel Command,September 2012.• NIH, NIAID Allergy, Immunology, and Transplantation Research Committee (AITC). February 12-14,2013.• NIH NIAID DAIDS Vaccine Development Resources Group of Vaccine Research Program (VRP).Review Committee Member, 2013-present.• Defense Threat Reduction Agency, Department of Defense. 2013.• Investigator Initiated Program Project Applications, NIH NIAID Special Emphasis Panel, 2014/01 ZAI1LGR-I (J1) 1; 09/16/2013-09/17/2013.• “Southwest National Primate Research Center”, NIH P51 Special Emphasis Panel, , 2014/01 ZOD1 CM-6 (03), November 2013.• “Innovation for HIV Vaccine Discovery (R01)”, Special Emphasis Panel/Scientific Review Group2014/01 ZAI1 SV-A (J3) 1, January 2014.• “HIV Functional Glycomics in HIV Vaccine Design” Special Emphasis Panel (2014/05 ZAI1 BLG-M(M1) 1), April 10, 2014.• “NIAID Clinical Trial Planning Grants (R34) and Implementation Grants and Cooperative Agreements(R01, U01)” (2014/05 ZAI1 BLG-M (M1) 1), April 10, 2014.• Special Emphasis Panel/Scientific Review Group 2015/01 ZAI1 BLF-A (J2) 1. “Innovation for HIVVaccine Discovery” (R01), RFA-AI-14-006, November 2014.• NIAID Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) [SpecialEmphasis Panel 2015/10 ZAI1 RB-A (S1)], June 2015.• Special Emphasis Panel 2016/01 ZAI1 DR-A (J1). P01 reviews.• Special Emphasis Panel 2016 ZAI1PA-M-C2, SBIR Phase II Proposals.Scientific Reviewer for Study Sections - Organizations9Permanent MemberMarch of Dimes Birth Defects Foundation, Committee C grant study section, 2006- 2012; Reappointed 2013-2016Ad Hoc Member• Thrasher Foundation, 2002-03.• World Health Organization Grants Program, 1998-2000.• U.S. Civilian Research and Development Foundation 2000-2002.• Wellcome Trust grants program reviewer, 2002, 2006, 2007, 2015.• University of Siena Research Program, 2002.• The Swiss National Science Foundation, 2001-2002.• BioAdvance/Greenhouse technical reviews, 2003-2008.• Health Research Board of Ireland Grants Program, Referee, 2004.• Maryland Industrial Partnerships grants reviewer, 2004.• Genome British Columbia, grant reviewer, 2004.• Society for Pediatric Research, Young Investigator Award Selection Committee, 2003 to 2006.• Pediatric Infectious Diseases Society/MedImmune Young Investigator Grant Award Program, 2005.• The United States-Israel Binational Science Foundation, 2006, 2008.• US Immunodeficiency Network (USIDNET), 2006, 2007.• Infectious Diseases Society of America Awards Committee, 2006-2009.• American Institute of Biological Sciences (AIBS), US Army Medical Research and Materiel Command(USAMRMC), 2006.• Abstract reviewer for the 2007 Pediatric Academic Societies Annual Meeting in Toronto, Canada.• Agency for Science, Technology and Research’s Biomedical Research Council (BMRC), Singapore, 2007.• External Advisory Board Member, The New York Influenza Center of Excellence (NYICE), an NIHCenter of Excellence in Influenza Surveillance and Research. 2008-12.• Duke-National University of Singapore Program, 2009.• M.J. Murdock Charitable Trust, 2009.• The Danish National Research Foundation, 2009.• The Danish Council for Strategic Research, 2009.• 2010 Pediatric Academic Societies Annual Meeting in Vancouver, Canada, 2010.• Instituto Pasteur-Fondazione Cenci Bolognetti, Italy, Grant Reviewer, 2010.• 2011 PAS/ASPR Joint Meeting and the 2011 Eastern SPR Annual Meeting.• Health Research Board, Ireland, 2011, grants reviewer.• Food and Health Bureau (FHB) of the Hong Kong SAR Government [Research Fund for the Control ofInfectious Disease (RFCID) and the Health and Health Services Research Fund (HHSRF)], 2012, grantreviewer.• National Fellowships Committee for Sigma Delta Epsilon, Graduate Women in Science, 2012.• Swiss National Science Foundation, 2012.• Oak Ridge Associated Universities grant program, New York Capital Research Alliance, 2012.• French National Research Agency (Agence Nationale de la Recherche), 2013.• Israel Science Foundation, 2013.• Medical Research Council, U.K., 2013, 2014.• ICAR grants program, International Pediatric Research Foundation, 2013.10• Human Vaccines Project Working Group, 2014 – present.• Advisory Committee of Experts, Second W.H.O. Integrated Meeting on development and clinical trialsof influenza vaccines that induce broadly protective and long-lasting immune responses. 5th – 7th May2014. Geneva, Suisse.• Meharry Medical College, 2014, SCORE grant reviewer.• University of Nebraska-Lincoln, Biomedical Research Grants, 2014.• Member, RSV Expert Working Group, GISRS, Influenza Viruses and Vaccine Support, Global InfluenzaProgramme, W.H.O.Scientific Reviewer for Study Sections, Vanderbilt• Grant reviewer, Turner Scholar Grant Program, 2006 to present.• Grant reviewer, Digestive Disease Research Center, 2007.• Grant reviewer, Center for AIDS Research Developmental Core Award applications, 2007.• Study Section Head and Reviewer, Vanderbilt Medical Center Discovery Grants, 2007.• Grant reviewer, Diabetes Research and Training Center, 2009.Scientific Editor/Reviewer for Peer Reviewed Journals:Editor• Nanomedicine: Nanotechnology, Biology and Medicine, (2004-2007)Associate Editor• WIRES: Nanomedicine and Nanobiotechnology, 2005 – present• PLoS Pathogens, 2010-presentEditorial Boards:• Nanomedicine, 2005 – present• Virology, 2010 – 2015.• Journal of Virology; three terms: (2004 – 2006), (2006 – 2009), (2010 – 2012)• Faculty of 1000 Faculty Member (Microbiology) (2002 – 2014)Special Editor:• Pediatric Infectious Diseases Journal, Nov 2004, Supplemental Issue on Respiratory Virus Infections.• Seminars in Pediatric Infectious Diseases, Oct 2006, “Emerging Vaccines for Mucosal Infections”.• Proceedings of the National Academy of Sciences USA, 2011.Ad Hoc Reviewer:Acta PaediatricaAmerican Journal of PathologyAmerican Journal of PerinatologyAmerican Journal of Respiratory and Critical Care Medicine11Antiviral ResearchArchives of Diseases in ChildrenArchives of VirologyASM Press Virology TextbooksBiotechniquesBMC Systems BiologyCell Host & MicrobeCellular ImmunologyClinical and Diagnostic Laboratory ImmunologyClinical and Experimental ImmunologyClinical Infectious DiseasesClinical Microbiology ReviewsEmerging Infectious DiseasesEuropean Journal of ImmunologyExperimental Lung ResearchExpert Opinion on Emerging Drugs.Expert Opinion on Investigational DrugsExpert Review of Anti-infective TherapyExpert Review of VaccinesF1000ResearchImmunologyInfections in MedicineJournal of American Family PractitionerJournal of the American Medical AssociationJournal of Bioinformatics and Sequence AnalysisJournal of Clinical MicrobiologyJournal of Clinical InvestigationJournal of Clinical VirologyJournal of General VirologyJournal of Experimental MedicineJournal of Immunological MethodsJournal of ImmunologyJournal of Infectious DiseasesJournal of Leukocyte BiologyJournal of Medical PrimatologyJournal of Medical VirologyJournal of Virological MethodsLancetLancetIDmAbsNature BiotechnologyNature CommunicationsNature ImmunologyNature MethodsNature ProtocolsOMICSPediatricsPediatric Infectious Diseases JournalPersonalized MedicinePLoS MedicinePLoS OnePLoS Pathogens12Proceedings of the National Academy of Sciences USARespiratory ResearchScienceScience ReportsScientific ReportsSwiss Medical WeeklyThomson Current Drugs, Meetings ReviewerVaccineViral ImmunologyVirus GenesVirus ResearchTextbook ReviewerJaneway’s Immunobiology, Seventh Edition, 2008.Janeway’s Immunobiology, Eighth Edition, 2010.Janeway’s Immunobiology, Ninth Edition, 2012.Advisory activities, Government• Scientific Advisory Board Member, NIH/NIAID Immune Epitope Database and Analysis Resource(IEDB), La Jolla Institute for Allergy and Immunology (LIAI). 2004 -2009.• U.S.-Japan Foundation Acute Respiratory Infections, Panel Advisor, 2003.• NIAID/NICHD Funding Priority Panel: Developing Immune System: Frontiers in Knowledge, 2000.• NIH/NIAID Orthopoxvirus Research Group 2000-2004.• 'Reach-Back' Service, Department of Homeland Security, Office of Weapons of Mass Destruction, 2006-present.• U.S.-Japan Foundation HIV Panel Advisor, 2008.• Panel Advisor, “Immunological Content Review of the Immune Epitope Database and AnalysisResource Meeting (IEDB)”, NIAID, Bethesda, MD, 6/17/10.• Scientific Advisory Board Member, NIH/NIAID Immune Epitope Database and Analysis Resource(IEDB), La Jolla Institute for Allergy and Immunology (LIAI). 2011- present.• Scientific Advisory Working Group member, NIH Vaccine Research Center, 2013-present.• Steering Committee Member, Campaign for AIDS Vaccine Discovery, (Bill and Melinda GatesFoundation) grant to IAVI and the Neutralizing Antibody Center at the Scripps Research Institute, LaJolla, CA, 2013-present.• Scientific Advisory Board member, Integrated Preclinical/Clinical AIDS Vaccine Development(IPCAVD) Program, NIH/NIAID. 2014-present.• U.S. Chair for US-Japan Cooperative Medical Sciences Program (USJCMSP). 17th International Conferenceon Emerging Infectious Diseases (EID) in the Pacific Rim, Taipei, Taiwan, January 25-29, 2015.• Intelligence Science and Technology Experts Group (ISTEG) of the National Academies of Sciences,Engineering, and Medicine; supports the Office of the Director of National Intelligence (ODNI).Provides advice to agencies of the U.S. Intelligence Community.Advisory Activities, Industry: Scientific Advisory Boards• MedImmune, Gaithersburg, MD, 2002 – 2007.• Vaxin, Scientific, 2004 – 2005.• Enumeral Technologies, Inc., Cambridge, MA, 2010 – 2015.13• PaxVax, Inc., 2014 – present.• CompuVax, La Jolla, CA, 2014 – present.• GigaGen, Inc. San Francisco, CA, 2015 – present.• Meissa Vaccines, Inc., 2015 – present.• Rensavir, Inc., 2015 – present.Advisory Activities, Industry: Consultant• Ablynx, 2008.• Absalus, 2003 – 2004.• Anaptys, 2008 – 2010.• Aviron, Consultant, 2000 – 2001.• Biomedical Primate Research Centre, Rijswijk, Netherlands, 1996.• BLiNK Therapeutics Limited, 2012.• Council of Advisors, 2001 – present.• Ebon Research Systems, Bethesda, MD, 1994.• Epicyte, 2002 – 2004.• Evogenix, 2006.• Gilead Sciences, 2010.• Glaxo SmithKline, 2012.• ImmunoBiosciences, Raleigh, NC, 2009 – 2011.• Mapp Biopharmaceuticals, 2004 – 2010.• MedImmune, Inc, Gaithersburg, MD, 2002 – 2009.• Morphotek, 2004.• Novartis, 2008 – 2009.• Planet, 2009.• Sanofi, 2005 – 2010.• Symphogen, Denmark, 2004.• Syngenta, 2004 – 2005.Advisory activities, Organizations• The Brighton Collaboration. Neonatal Infection Working Group, 2004 – 2007.• Council Member (for Infectious Diseases), Society for Pediatric Research, 2009 – 2012.• Program Committee, Infectious Diseases Society of America, 2009 – 2012.• Organizing Committee, AIDS Vaccine 2010 Conference, Atlanta, GA.• Abstract reviewer, 2011 ASCI/AAP Joint Meeting, Chicago, IL.• American Society for Microbiology, Raymond W. Sarber Award Selection Committee, 2011 – 15.• Founder and Director, Society for Pediatrics Young Investigator Coaching Program, 2012 – 2013.• E. Mead Johnson Award Selection Committee, Society for Pediatric Research Council, 2012 – 2015.Chairman 2016.• AIDS Vaccine 2013: Abstract Reviewer.• FASEB Excellence in Science Award Selection Committee, 2013 – 15.• WHO RSV Expert Working Group, 2014 – present.14Meetings Organizer, Moderator• Moderator, “Respiratory Viral Infection: Advances in epidemiology and pathobiology” Symposium.40th meeting, Infectious Diseases Society of America, October 2002, Chicago, IL.• Scientific Advisory Committee, Viral Vaccine Meeting, October 2003, Barcelona, Spain.• Chair, Third International Congress of Respiratory Viruses, Chicago, IL, April 2004.• Moderator, "Vaccines" session, 42nd Annual Meeting of IDSA, Sept 2004, Boston, MA.• Founder and Chair, Frontiers in Neonatal and Infant Immunology, Madrid, Spain, March 2005.• Program Review, "Neonatal Infectious Diseases", 2005 PAS Annual Meeting in Washington, DC.• Session Moderator, 6th International RSV Symposium, Marco Island, FL, October, 2007.• Group leader, Virology Poster Discussion Round, 47th Annual IDSA Annual Meeting, October 2009,Philadelphia, PA.• Co-chair, “Regulation of HIV-specific B cell responses” scientific session, The Search for BroadlyProtective Anti-HIV Antibodies NIH meeting, June 2010, Bethesda, MD.• Moderator, "Neutralizing antibodies to viruses" session, 49th Annual Meeting of IDSA, Oct 2011, Boston,MA.• Moderator, "Influenza" and “Correlates of Protection against Disease Caused by Virus Infection”sessions, 50th Annual Meeting of IDSA, Oct 2012, San Diego, CA.• Scientific Advisory Committee, RSV Vaccines for the World 2013, Oct 2013, Porto, Portugal.• Session Chair, Virus-Host Interactions Workshop, Keystone Symposium on Pathogenesis of RespiratoryViruses, Jan 2014, Keystone, CO.• Member, International Advisory Committee, XVIth International Congress of Virology, Montreal, Quebec,July 2014.• Member, Program Committee, The American Association of Immunologists, 2013-2016.• Member, Organizing Committee, 2014 Spring Immunology Symposium, Emory University, Atlanta, GA,June 2014.• Rapporteur, Medical Countermeasures Panel Discussion, Gaps and Opportunities in ChikungunyaResearch: Expert Consultation on Chikungunya Disease in the Americas, June 30-July 2, 2015. (NIAID,WHO), Rockville, Maryland.RESEARCH SUPERVISIONStaff awardsFrances Smith-House, MS, my laboratory manager, was selected as the recipient of the 2013 Edward Price, Jr.,Research Staff Award for Excellence in Basic Research, the highest staff research award in the university.Faculty career awards for junior faculty, for whom I serve(d) as the mentor or co-mentor• John Williams, M.D. K08 AI056170 “Determinants of Protective Immunity to Metapneumovirus.”08/01/03 to 07/31/06 [John also obtained a related grant R03 AI054790 “Human MetapneumovirusInfections in Children” while a fellow in my laboratory].• Timothy Peters, M.D. K08 AI058006 “Mechanisms of Human Metapneumovirus Replication.” July 04–June 07.• Brannon Alberty, M.D., NASPGHAN-CDHNF Fellow to Faculty Transition Award 2006, “GuthomingRegulatory T Lymphocytes in Crohn’s Disease.”15• Brett McKinney, Ph.D., K25 AI64625 “Cytokine signaling network response to smallpox vaccine.”Mentored Quantitative Research Career Development Award. 2006 – 2009.• Hendrik Weitkamp, M.D., K08 HD061607, “Development of Intestinal Immune Regulation in HumanInfants.” 2009 – 2014.• Michael Rosen, M.D., NASPGHAN-CDHNF Fellow to Faculty Transition Award, “The Role of IL-13and Natural Killer T-Cells in New Onset Pediatric Ulcerative Colitis.” 2009.• Mark Hicar, M.D., Ph.D., K08 AI 083078, “Antibodies Recognizing Quaternary Differences in HIVEnvelope Glycoproteins.” 2009-2014; Also, 2009 Infectious Diseases Society of America (IDSA) WyethYoung Investigator Award in Vaccine Development: “Trimer-specific antibodies influence on HIVenvelope diversity.” Now Assistant Professor on tenure track, SUNY Buffalo.• Scott Smith, MD, PhD. K08 AI 103038. Adult infectious diseases fellow. 2008-2012. Scott studiedhuman B cell responses to dengue viruses. He was a Harrison Society Scholar, and obtained acompetitive position on the Molecular Basis of Infectious Diseases Training Grant Program, 2009-11. Healso was awarded an IDSA/NFID Pfizer Young Investigator Award in Vaccine Development for theresearch project “Human Antibody Response to Chikungunya Virus Infection.” Now AssistantProfessor on tenure track, Vanderbilt, Dept. of Medicine.• Gopal Sapparapu, Ph.D. Research Postdoctoral Fellow. 2009-2012. Gopal is an antibody engineeringexpert who is developing novel bispecific scFv diabody antibodies that target antiviral antibodies to theendosomal compartment via pIgR binding. Now Research Assistant Professor of Pediatrics, Vanderbilt.• John Bates, Ph.D. Research Postdoctoral Fellow. 2010-2014. John is a viral immunologist who studiednovel human antibodies to paramyxoviruses. Now Instructor, Dept. of Microbiology and Immunology,University of Mississippi Medical Center, Jackson, MS.• Brian Engelhardt, MD. K23 HL122143, "Metabolic and CD4+ T Cell Dysregulation in Post-TransplantDiabetes Mellitus.” 2014-2019. Now Associate Professor of Medicine, Vanderbilt.Current postdoctoral fellows:• Jarrod Moussa, Ph.D., Research Postdoctoral Fellow. 2015-present. Jarrod is a structural biologist whois studying structure/function of human antibodies to paramyxoviruses.• Amandeep Sangha, Ph.D. Research Postdoctoral Fellow. 2015-present. Amandeep is a computationalbiologist who is studying structure/function and design of human antibodies to filoviruses. Comentoredwith Jens Meiler, Ph.D.Former postdoctoral fellows trained at Vanderbilt:• Koichi Kusuhara, MD (1997-1998). Now Associate Professor, Department of Pediatrics, GraduateSchool of Medical Sciences, Kyushu University, Fukuoka, Japan.• Hendrik Weitkamp, MD (1998-2002). Now Associate Professor, Department of Pediatrics, Division ofNeonatology, Vanderbilt University Medical Center. Hendrik was awarded a 1999-01 DeutscheForschungsgemeinschaft Program Award for his fellowship, the 2001-02 Bayer/Harold NeuPostdoctoral Fellowship Award (Infectious Diseases Society of America), a Travel award, MeadJohnson Nutritional Perinatal & Developmental Medicine Symposium "Emerging Infections in theNewborn Period", Aspen, Colorado, May 2001, and a Young Investigator Award, Society for MucosalImmunology, 2002. He received a 2002 “IDSA Special Citation for Fellows in Training”, a YoungInvestigator Award at the 2005 Society for Pediatric Research, and the 2004-05 Marshall Klaus PerinatalResearch Award of the American Academy of Pediatrics. He now holds a K08 award.• Rahaman Suara, MD (1998-2001), First, Asst. Professor of Pediatrics, Meharry Medical College,Nashville, TN; now in medical practice in TN.16• Madhav Sharma, PhD (1999-2000). Now Senior Research Scientist in the Department of Pediatrics inthe Medical College of Georgia at Georgia Regents University.• Michael Rock, PhD (2000-2002). Now Research Associate Professor, Vanderbilt University MedicalCenter, 100% NIH research funded. Michael obtained funding through the NIH contract N01 AI-25462,Vaccine Treatment and Evaluation Unit, NIAID/NIH, and his own R21 AI059365 "Vaccinia virusspecificT-cell phenotypes".• John V. Williams, MD (2001-2003). Now Professor with tenure, Pediatrics, University of Pittsburgh, PAand Division Head, Infectious Diseases. NIH R01 funded investigator.• Cuixia Tian, MD. Research Postdoctoral Fellow, 2003-2006. Cuixia studied rotavirus specific B cellrepertoires from B cells in human intestine. Now Assistant Professor, Child Neurology, CincinnatiChildrens Hospital.• Sujin Lee, PhD. Research Postdoctoral Fellow, 2003-2007. Now Asst. Professor of Pediatrics, EmoryUniversity.• Sunita Dwivedi, PhD. Research Postdoctoral Fellow, 2004-2006. Sunita studied the role of transitionalB cells and Toll like receptors on B cells in immunity to viruses. No longer in science.• Brannon Alberty, MD. He is now Asst. Professor of Pediatrics at the University of Kentucky. ResearchPostdoctoral Fellow, 2004-2006. Brannon studied the role of T regulatory cells in control of theinflammatory process in the intestine of humans with inflammatory bowel disease. He was selected forthe 2006 NASPGHAN-CDHNF/Centocor Fellow to Faculty Transition Award in Inflammatory BowelDiseases. He won the Centocor Poster Award at the 2006 AGA meetings.• Xiaocong Yu, PhD. Research Postdoctoral Fellow. 2004-2008. Xiaocong generated prophylacticantibodies to infectious agents (1918 H1N1 and avian H5N1 influenza, and RSV). Now Instructor,Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA.• Christopher Keefer, MD. 2005-2008. Pediatric Infectious Diseases Fellow. Chris was awarded aPediatric Scientist Development Program Award 2005-2008, a Pediatric Infectious Diseases SocietyFellowship Award for 2005-2007 (declined), and a MedImmune Fellowship Award for 2005-2007. Hestudied structure-function relationships in RSV antibodies that neutralize virus. Now, AssistantProfessor in Pediatrics at Meharry Medical College, Nashville, TN.• Keipp Talbot, MD, Adult Infectious Diseases Fellow, 2004-2006, now Asst. Professor of Medicine,Vanderbilt University. Keipp studied the role of newly identified coronaviruses in serious respiratorydisease. She was awarded an NIH K12 award and an NIH R03 while in my laboratory.• Sam Kuhn, Ph.D. Research Postdoctoral Fellow. 2006-2007. Sam generated nanovaccines andbiosensors based on nanotechnology. He is currently Scientist with HemCon Medical Technologies,Portland, OR.• Aaron Derdowski, Ph.D. Research Postdoctoral Fellow. 2006-2007. Aaron studied the cell biology ofmetapneumovirus infection in polarized epithelial cells. Currently postdoctoral fellow, BrownUniversity, awarded NRSA F32 fellowship.• Sunny Mok, Ph.D. Research Postdoctoral Fellow. 2005-2008. Sunny generated and tested alphavirusbased vaccines for RSV and MPV. Currently Staff Scientist at MedImmune, in California.• David Vigerust, PhD. Research Postdoctoral Fellow. 2007-2009. He is a first-generation MexicanAmerican scientist. David studied the cell biology of RSV infection in polarized epithelial cells. He wasawarded a competitive NIH Diversity supplement, numerous travel grant awards, and a MARCresearch award. First, was Health Research Scientist at Department of Veteran Affairs, VA MedicalCenter in Nashville, and Research Assistant Professor, Dept. of Pathology, Vanderbilt. Now, VicePresident at Silverstaff Clinical Labs.• Mark Hicar, M.D., Ph.D. Pediatric Infectious Diseases Fellow. 2006-2009. Mark studied the B cellrepertoire of HIV infected long-term non-progressors. Mark was awarded the prestigious PediatricInfectious Diseases Society-St. Jude Children's Research Hospital Fellowship Program in Basic Research2006-2009.”and an NIH K08 award. He is now Assistant Professor of Pediatrics, SUNY Buffalo.17• Catherine (Prudhom) Gineste, PhD. Research Postdoctoral Fellow. 2007-2009. Catherine is a peptidechemist; she developed fusion inhibitor drugs for RSV and MPV. Co-Mentored with David Wright,PhD. She obtained a competitive position on the ITTD Training Grant Program, 2007-09. She is nowResearch Scientist at SRI International, Harrisonburg, Virginia.• John Stone, PhD. Research Postdoctoral Fellow. 2008-present. John is a gold nanomaterials expert; heis developing gold nanoparticle based vaccines for RSV and MPV. He obtained a competitive positionon the ITTD Training Grant Program, 2008-10. He is now Assistant Professor of Chemistry atArmstrong Atlantic State University, Savannah GA.• Jens Krause, M.D., Pediatric Infectious Diseases Fellow. 2008-2011. Jens studied the human antibodyresponses to influenza viruses. He was awarded a Pediatric Infectious Diseases Society fellowship2008-2010. He was awarded Postdoctoral Research Fellow of the Year 2011 at Vanderbilt. He obtained aResearch Assistant Professor position at Mount Sinai School of Medicine in 2011. Now, faculty memberat the Children's Hospital of the University of Freiburg Medical School in Germany.• Natalie Thornburg, PhD. Research Postdoctoral Fellow. 2007-2012. Natalie studied the role of dendriticcells in alphavirus vector vaccine induced immunity for RSV. She was awarded her own individualNRSA award F32 AI 080117, “Human Host Responses to Respiratory Syncytial Virus Infection.” 2009-2011. Now Research Assistant Professor, Emory University.• Jennifer Pickens Ph.D. Research Postdoctoral Fellow. 2012-2015. Jennifer studied the cell biology ofRSV infection. She obtained a faculty position as Assistant Professor at Sewannee University.• Iuliia Gilchuk, Ph.D. Research Postdoctoral Fellow. 2012-2015. Iuliia is a viral immunologist whostudied novel human antibodies to poxviruses. Now Staff Scientist, Vanderbilt University Med Ctr.Visiting Scientists in the Crowe Laboratory• Reiko Saito, M.D., Ph.D., Assistant Professor, Niigata University, School of Medicine, Niigata, Japan;Mini-sabbatical, April 2004. Reiko studied the molecular epidemiology of respiratory viruses.• Jung-Yun Hong, M.D., Ph.D., Assistant Professor of Pediatrics, College of Medicine, Cheju NationalUniversity of Korea, Jeju City, Korea, sabbatical August 2005-Oct 2006.Graduate students:Current PhD Candidates training with Dr. Crowe• Valentine Chukwuma, 2010-present. Department of Microbiology and Immunology. Valentine isstudying human B cell responses to HIV. URM student.• Andrew Flyak, 2012-present, Department of Pathology, Microbiology and Immunology. Andrew isstudying structure-function aspects of neutralizing antibodies to emerging viruses and biothreats,including Ebola and Marburg viruses. He won the 2015 Sidney P. Colowick Award for OutstandingPre-doctoral Achievement, Vanderbilt University, the Kathryn Edwards Fellowship Award ofVanderbilt, and the best poster presentation at the international FILO 2013 meeting.• Jessica Finn, 2012-present, Department of Pathology, Microbiology and Immunology. Jessica is usingcombined computational and wet-laboratory studies to study the role of unusual antibodies to virusesthat incorporate long HCDR3 loops with secondary structural elements.• Sandhya Bangaru, 2013 – present, Department of Pathology, Microbiology and Immunology. Sandhyais studying human antibodies to influenza viruses with pandemic potential.• Alberto Cisneros, 2013 – present, Chemical and Physical Biology Program. Alberto is developing novelmicrofluidics techniques for large-scale interrogation of human antibody repertoires. URM student.18• Alex Sevy, 2014 – present, Chemical and Physical Biology Program. Alex is using combinedcomputational and wet laboratory techniques to study human antibody recognition of viral antigens.• Gabriela Alvarado, 2014 – present, Department of Pathology, Microbiology and Immunology. Gaby isstudying human antibodies to viruses. URM student.• Marion Sauer, 2015 – present, Chemical and Physical Biology Program. Marion is using single particleEM and computational modeling techniques to study the basis for neutralization of viruses by humanmonoclonal antibodies.• Clayton Wandishin, 2015 – present, Chemical and Physical Biology Program. Clayton is using neutronand x-ray scattering and computational modeling techniques to study the basis for neutralization ofviruses by human monoclonal antibodies. URM student.• Laura Powell, 2015 – present, Department of Pathology, Microbiology and Immunology. Laura isstudying the human B cell response to rabies vaccination or infection.• Monique Bennett, 2015 – present, Department of Pathology, Microbiology and Immunology. Moniqueis studying the human B cell response to Staphlococcus aureus.•Former PhD Candidates who trained with Dr. Crowe• Sean Brock, 1999-2003, Department of Microbiology and Immunology, PhD thesis successfullydefended December 2003, PhD awarded 2004. Attended U.T. School of Law, now serving as a scientificintellectual property lawyer in Philadelphia.• Marietjie Venter, MS 2000-2003, PhD in Microbiology and Immunology, University of theWitwatersrand, Johannesburg, South Africa (Crowe as mentor); PhD awarded 2003. Now SeniorLecturer (faculty member), University of Pretoria, South Africa.• Nicole Kallewaard, 2000-2005, Department of Microbiology and Immunology. Nicole performedstructure/function studies of human rotavirus specific monoclonal antibodies. Defended June 2005.Now, Staff Scientist, MedImmune, Inc.• Alec Weisberg (MSTP) 2001, Department of Microbiology and Immunology, (returned to medicalschool). Alec studied rotavirus cell biology. Attended residency in Internal Medicine, Boston. Nowinternist, Boston.• Amber Bowen 2002-2006, Department of Microbiology and Immunology. Amber performedstructure/function studies of RSV specific human monoclonal antibodies. She was awarded a Mastersdegree in May 2006. No longer in science.• Gabriella Cseke, Department of Chemistry, 2003-2006, co-mentored with David Wright of Chemistryand John Williams, MD. Gabi studied the structure/function relationships of metapneumovirus Fprotein. Currently postdoctoral fellow, University of London.• Thomas Utley 2003-2008, Department of Microbiology and Immunology. Tom studied the molecularand structural determinants of trafficking of RSV proteins in polarized epithelial cells. Currently,Licensing Analyst, Vanderbilt University.• Michael Lindquist, 2005-2011, Department of Microbiology and Immunology. Michael studied theinteraction of stress granules and the PKR pathway with RSV in polarized epithelial cells. He is now apostdoctoral research fellow at the United States Army Medical Research Institute for InfectiousDiseases, Ft. Detrick with Dr. Connie Schmaljohn.• Fyza Shaikh, 2007-2012, MSTP and Department of Microbiology and Immunology. Fyza studied thecell biology of RSV infection and obtained her PhD with us. She is currently in a heme-onc fellowshipat Johns Hopkins University.• Bryan Briney, 2008-2012, Department of Microbiology and Immunology. Bryan studied structurefunctionaspects of neutralizing antibodies. He was awarded a competitive position in the Vanderbilt19Immunobiology of Blood and Vascular Systems Research Training Program, 2008-10. He was awardedthe 2012 Sidney P. Colowick Award for Outstanding Pre-doctoral Achievement, Vanderbilt University.He is now Assistant Professor of Immunology, The Scripps Research Institute.• Mohammed Aiyegbo, 2006-2013, Department of Microbiology and Immunology. Mohammed studiedstructure/function relationships of antiviral antibodies. He won a competitive diversity supplement,and a number of national and international travel awards. Now post-doctoral fellow at NYU.• Jordan Willis, 2009-2014. Chemical and Physical Biology Program. Jordan studied supercomputingdocking modeling methods and molecular biology of antigen-antibody interactions. He was awarded acompetitive position in the Vanderbilt HIV/AIDS Research Training Program, 2009-10. Nowpostdoctoral fellow, The Scripps Research Institute (Bill Schief laboratory).Rotating Vanderbilt graduate students who trained in Crowe for 3 -6 months:Vanderbilt Interdisciplinary Graduate Program1999 Craig Forrest, Jason Hammonds2000 Angela Singleton2001 Rachel Graham, Nicholas Shinners2002 Butch Granada, Rachel Henry, Daniel O’Brien2003 Elizabeth Johnson2004 Adrian Pineda, Jud Schneider2005 Megan Johnson2006 Amanda Hafer, Laura Johns, Paul Miller, Nuruddeen Lewis, Tom Beckerman2007 Michael Irvin2008 Laura Ooms, Jamie Ausborn, Ernest Yufenyuy2009 Yaoyi Chen2010 Matthew Varga, Bradley Voss2011 Laurel Jackson, Katie Nicholas, Ryan Craven, Jennifer Malinowski2012 Kate Bradley, Allison Oberholtzer, Martha Wall2013 Alexander Sevy, Gabriela Alvarado2014 Stephanie Lamb, Evan Perry2015 Lauren WilliamsonVanderbilt Bioengineering1999 Molly JamesVanderbilt Medical Scientist Training Program2007 Indriati Hood2008 John Erickson2010 Matthew Surdel2011 Meredith RogersHigh School Students in the Crowe laboratory• Charles Spencer, summer student 1997. Obtained PhD, faculty member.• Leland Brown, summer student 2010, 2011.• Jonathan Ferrell, summer student 2011.Undergraduate Students in the Crowe laboratory• Michael Jolly, from Dept. of Molecular Biology, 1997-2000, 10 hours a week in the academic year andtwo full-time summers; was resident in orthopedics.20• Darren Kies, from Dept. of Molecular Biology, 2000-2002, 10 hours a week in the academic year, fulltimesummer of 2001, current undergraduate at Vanderbilt, also I taught him as mentor in the 2001Molecular Biology 283 Senior Thesis course. Attended medical school at Tulane University.• McLean Coble, Dept. of Bioengineering, Summer Student, Senior Honors Student 2002-03. Now inbiomedical industry.• Joshua Heck, Dept. of Molecular Biology, 2002-2008, 10 hours/week, work-study. Josh was awarded anationally competitive ASM Undergraduate Research Fellowship for this work. Now, resident inradiology, Vanderbilt.• Josie Vitale, Dept. of Molecular Biology, 2002-2003, 10 hours/week, work-study.• Ashley Long, Dept. of Molecular Biology, 2003-2005, 10 hours/week, work-study.• Kevin Dischert, Dept. of Molecular Biology, 2003-2005, 10 hours/week, work-study.• Matt Crozier, Dept. of Molecular Biology, 2004-2005, 10 hours/week, work-study.• Emily Deckelman, Dept. of Biology, 2004-2006, 10 hours/week, work-study and Germs and DefenseSummer Research Program, supported by the Immunobiology of Blood and Vascular Systems TrainingProgram (T32 HL069765). 5/1/06 - 7/31/06.• Ann Rice, Dept. of Biology, 2004-2005, 10 hours/week, work-study.• Christian Fuchs, University of Pennsylvania, Germs and Defense Summer Research Program,supported by the Cellular and Molecular Microbiology Training Program (T32 AI049824).• Jon Hedgecock, Dept. of Biology, 2007-2008. Jon studied alphavirus vaccines for MPV. Jon wasawarded an ASM Undergraduate Research Award for his work and presented his work at the nationalASM meeting.• Nicholas Ware, Dartmouth College, summer student 2007 as part of the Vanderbilt Summer ScienceAcademy.• Chelsey Huffman, Cumberland University, summer student 2009, as part of the Vanderbilt SummerScience Academy and Germs and Defense Summer Research Program, supported by the Cellular andMolecular Microbiology Training Program (T32 AI049824). Also summer student 2010. Now in medicalschool, University of Tennessee.• Luke Starner, Belmont University, summer student 2010.• Ma'Recha Gay, Oakmont University, summer student 2010. 2nd place VUMC poster award 2010.Selected for Annual Biomedical Research Conference for Minority Students (ABRCMS) presentation,November 10-13, 2010, Charlotte, NC.• Sarah Sweitzer, Gordon College, post-baccalaureate summer student 2010.• Liliane Ernst, Vanderbilt University, summer student 2010.• Amanda Chen, Vanderbilt University, work-study student 2010-11; summer student 2010.• Sarah Hayward, Wake Forest University, summer student 2011, 2012. Now graduate student EmoryUniversity.• Leland Brown, East Tennessee State University, summer student 2012, 2013, 2014.• Mason Sanders, Rice University, summer student 2011; now in medical school.• Graham Englert, Purdue University, 2013.• John Shannon, Colorado State University, 2013. John won the best poster competition in the VanderbiltInstitute for Nanoscale Science and Engineering, and a travel award to present his work at the 2014Keystone Conference on Respiratory Virus Pathogenesis.• Abigail Bray, Sewanee, The University of the South, summers of 2014 and 2015.• Alexander Pak, Nazarbayev University, Astana, Republic of Kazakhstan Vanderbilt InternationalScholars Program, summer 2014.• Steven Wood, Biomedical Engineering, Vanderbilt University, summer 2014.• Ghazia Abbas, Forman Christian College, Lahore Pakistan, summer 2015.21• Giovanni Zepeda-Dominguez, Taos, NM, summer 2015. URM student.Medical Students in the Crowe laboratory• Robert Matthias, 6-month research elective student, spring 1997.• Angela Singleton, summer 1998.• Brandon Strange, Meharry Medical Student, summer 1998.• Elizabeth Bures, summer 2001, senior Nebraska University medical student.• Joyce Pingsterhaus, summer 2001, senior Washington University St. Louis medical student.• Lauren Weigand, 2006-2007. Emphasis Research Program student. Lauren worked on nanoparticlevaccines for RSV.• Josh Heck, 2006-2007. Emphasis Research Program student. Josh worked on the cell biology of RSV.• Alexander Thurman, summer 2009, medical student, Indiana University School of Medicine. Alex wasawarded a competitive APS/SPR Student Research Program position.• Ilyas Eli, 2010-present. Vanderbilt Emphasis Research Program student. Ilyas worked to determinecryo-EM structures of human antibody complexed with rotavirus particles.• Garrett Sauter, summer 2011. Wayne State University. SPR award, worked on RSV immunology.• Shyam Deshpande, 2011-2013. Vanderbilt Emphasis Research Program student. Shyam worked togenerate and characterize human monoclonal antibodies to H5 influenza. He was awarded theVanderbilt Founders Medal (top student at graduation).• Ebony Mullen, Meharry Medical School, summer 2014.MPH Students in the Crowe laboratory• Vidisha Singh, Emory University, summer 2015.Principal Investigator, Vanderbilt Predoctoral Training ProgramT32 AI 089554, NIAID, NIHVirology Training Program05/01/10 – 04/30/15Annual Costs $297,482PI: CroweRole: PI of the Training Program, and Faculty MentorMentor on Vanderbilt Predoctoral/Postdoctoral Training ProgramsCurrentT32 AI 07474, NIAID, NIHMolecular Basis of Infectious Diseases Training Program07/01/10 - 06/30/15PI: Spyros Kalams, M.D.Role: Faculty Mentor and Member of the Executive CommitteeT32 AI07611, NIAID, NIHCellular and Molecular Microbiology Training ProgramPI: Jacek Hawiger, M.D., Ph.D.09/01/2006 – 08/31/201122Role: Faculty MentorT32 AI 49824, NIAID, NIHCellular and Molecular Microbiology Postgraduate Training ProgramPI: Jacek Hawiger, M.D., Ph.D.Role: Faculty MentorT32 GM 08554, NIGMS, NIHCellular, Biochemical and Molecular Sciences (CBMS) Training ProgramPI: James Patton, Ph.D.Role: Faculty MentorT32 HL069765, NHLBI, NIHImmunobiology of Blood and Vascular Systems Training ProgramPI: Jacek Hawiger, M.D., Ph.D.04/01/2007 – 03/31/2012Role: Faculty MentorT32 DK 007673, NIDDK, NIHDigestive Diseases Training GrantPI: Richard Peek, M.D.07/01/2008 – 06/30/13Role: Faculty MentorT32 GM 062758, NIGMSVanderbilt/Meharry Genetics Training Program: Implications of VariationPI: John A. Phillips, III, M.D.Role: Faculty MentorK12 programBuilding Interdisciplinary Research Careers in Women’s Health (BIRCWH)2010 to presentPI: Nancy Brown, MDRole: Faculty MentorT32 Program, HD 060554, NICHD, NIHPI; Jonathan Gitlin, MDConducting Child Health Care Research in Vulnerable Populations05/01/2009 – 04/30/2014Role: Faculty MentorT32 Program, CA154267, NCI, NIHPI; Deborah Friedman, M.D.07/01/2011 – 06/30/2016.Role: Faculty MentorT32 Program, AI007281, NIAID, NIHPI: Fernando Villalta, Ph.D., Meharry Medical CollegeMolecular Microbial Pathogenesis Training ProgramRole: Faculty MentorFormer23T32 CA09385, NCI, NIH1997 - 2005Viruses, Cancer and Nucleic Acids Training Program,PI: Earl Ruley, Ph.D.T32 AI060571, NIAIDHIV/AIDS Research Training Program09/01/04-08/31/09PI: Christopher Aiken, PhDRole: Faculty MentorT32 HL007256, NHLBI, NIHPediatric Cardiopulmonary Research Training ProgramPI: Scott Baldwin, M.D., Ph.D.07/01/02 - 06/30/08Role: Faculty MentorK12 DH 000850, DHHSPI: Sean Moore (Yale)Pediatric Scientist Development Program07/01/2005 – 06/30/2008Role: Faculty MentorT90 DA 022873, NIDAIntegrative Training in Therapeutic DiscoveryPI: Larry Marnett, Ph.D.09/30/06 - 07/31/11Role: Faculty MentorK12 Program CA090625, NCI, NIHVanderbilt Clinical Oncology Research Career Development Program (VCORCDP)PI: Kenneth Hande, MD08/17/2006-06/30/2011Role: Faculty MentorMentor, Undergraduate Training ProgramsVanderbilt University Summer Research Experiences for Undergraduates (REU) ProgramNational Science Foundation2010-presentPI: McCabeRole: Faculty MentorMentor, NIH F or K on Foundation Career AwardsF32 AI080117, NHLBI, NIHNatalie Thornburg, PhDHuman host responses to RSV infection09/30/2009- 09/29/2011Role: Faculty Mentor24F32 AI 080108, NIAID, NIHBernardo Mainou, PhDRole of beta1 integrin in mammalian reovirus infection07/01/2008 – 06/30/2010Role: Scholarship Oversight CommitteeK01 HL103179, NHLBI, NIHKyra Richter, PhDThe role of CD8 T cells in chronic granulomatous disease08/05/2010 – 05/31/2015Role: Scholarship Oversight CommitteeK08 HD061607, NICHD, NIHJoern Hendrik Weitkamp, MDDevelopment of intestinal regulation in human infants07/09/2010 – 04/30/2014Role: Faculty Mentor2009 IDSA ERF/NFID Wyeth Young Investigator Award in Vaccine DevelopmentMark D. Hicar, M.D., Ph.D.Trimer-specific Antibodies: Influence on HIV Envelope Diversity07/01/2009 – 06/30/2010Role: Faculty Mentor2014 K23Brian Engelhardt, MDK23Metabolic and CD4+ T Cell Dysregulation in Post-Transplant Diabetes MellitusRole: Faculty mentorIsaac Thomsen, MDK23Evaluating the Functional Antibody Response to Pediatric S. aureus InfectionsRole: Scholarship Oversight CommitteeChair, Ph.D. Thesis Committees in the Graduate SchoolKenneth Martin, Department of Microbiology and Immunology, 2003-2011Ph.D. Thesis Committees in the Graduate School, Committee MemberDepartment of Microbiology and ImmunologyJodi Connelly, 1997-2001Don Wyma, 1999-2002Jason Hammonds, 1999-2005John Rutigliano, 2000-2003Philip Budge, 2000-2003Hassan Ahmed, 2001-2003 (withdrew)Carlos Acevedo-Suarez, 2002-2006Jackie Campbell, 2001-2006Saif Lalani, 2006-2008Mingli Qi, 2006-200825Joseph Conrad, 2006-2011Ernest Yufenyuy, 2010-2014John Erickson, 2010-2014Katie Winarski, 2012-presentKatherine Nicholas, 2012-presentChike Abana, 2015-presentProgram in Human GeneticsDavid M. Reif, 2005-2006William S. Bush, 2006-2008Emily Holzinger, 2010-2013Department of Cell and Developmental BiologyTwila Mason, 2010-2013Ph.D. Thesis Committees, Vanderbilt UniversityDepartment of BioengineeringMolly James, 1999-2000 (withdrew)Department of ChemistryScott A. Miller, 2003-2006Gabriella Cseke, 2003-2006Elizabeth Bentzen, 2003-2006Artez Sims, 2011-2013Christine Markwalter, 2015-presentInterdisciplinary Materials ScienceChinmay Soman, 2006-2008Graduate Student Prequalifying Advisory Committees, Vanderbilt University• Devin Stauff, Department of Microbiology and Immunology, 2007Program in Human Genetics, Qualifying Exam Committees• Rafal Sebastian Sobota, 2012Ph.D. Thesis Committees at Other Universities• Tiffany Walker, Department of Biomedical Sciences, 2006-2012, Meharry Medical College• Aaron Lifland, Department of Biomedical Engineering, Georgia Tech, 2011-2014.MSCI or MPH mentoring committees• Mercedes Judkins, MD, Pediatric Intensive Care fellow, 2004-2006. Human metapneumovirusinfections in patients requiring intensive care.• Jennifer Domm, MD, Pediatric Hematology and Oncology fellow, 2004-2006. Humanmetapneumovirus infections in oncology patients.26• Brannon Alberty, MD, Pediatric Gastroenterology Fellow, 2004-2006, Immunologic basis ofinflammatory bowel disease.• Keipp Talbot, MD, Adult Infectious Diseases Fellow, 2004-2006, Molecular epidemiology of humancoronavirus infection• Brian Engelhardt, MD. Adult Hematology-Oncology Assistant Professor. 2006-2008, Role of Tregulatory cells in graft versus host disease.• Michael Rosen, MD, Pediatric Gastroenterology Fellow. 2007-2010, Role of NKT cells in the biology ofulcerative colitis. He was awarded the Vanderbilt 2007 Thomas Hazinski Scholarship, a ClinicalResearch Award from the American College of Gastroenterology, and a fellowship award from theNorth American Society for Pediatric Gastroenterology, Hepatology and Nutrition.Masters of Laboratory Science Thesis Committee• Jody Peters, 2004-2006.• Laura Hunt, 2006-2008.Infectious Diseases Fellow Mentoring Committees• Jennifer Schuster, MD, Pediatric Infectious Disease Fellow, 2012 – 2014.Bioinformatics Fellow Mentoring• Brett McKinney, PhD, NIH K25 Mentored Quantitative Research Career Development Award.Cytokine signaling networks and the smallpox vaccine, 2006 – 2009.Research Postdoctoral Fellow Mentoring Committees• Vaibhav Shah, Ph.D., Pathology, Microbiology and Immunology, 2012-present.Faculty Mentoring Committees• Natasha Halasa, M.D., M.P.H. Assistant Professor in Pediatrics, Infectious Diseases. 2005 – 2010.• Brian Engelhardt, M.D. Assistant Professor in Medicine, Hematology/Oncology. 2007 – present.• Nishitha Reddy, M.D. Assistant Professor in Medicine, Hematology/Oncology. 2008 – 2010.• Jonathan Irish, Ph.D. Assistant Professor in Cancer Biology, 2012 – present.COURSEWORK/LECTURESGraduate School, Residency, Fellowship Courses:• Founder and Director, 15-hour course in grant writing, Microbiology and Immunology 335,Department of Microbiology and Immunology. I developed this course and directed it for seven years,2004 – 2010.• “Molecular Virology” graduate course lecturer, 1998 – 2005, Co-Course Director 1999. Course Director,2000, 2002.• Molecular and Cellular Immunology M&IM 3283 graduate course lecturer, Yearly 1997 – present.• Interdisciplinary Graduate Program lecturer in Microbiology, Yearly 1998 – present• Coordinator, Vanderbilt Molecular Recognition Interest Group, 1998 – 2000.27• Foundations in Microbiology and Immunology, Microbiology and Immunology 334§ Virology Section lecturer 2001 – 2005; Section Director 2002. Toolbox lecturer, 2010, 2011.§ Immunology section lecturer, 2 sessions, 2004 – 2012.• “Managing a laboratory,” Masters in Clinical Investigation Lecture series, Mar 2006.• Epithelial Pathobiology graduate school course CBIO342, one lecture "Viruses and epithelial cells,"2007, 2008; “Aim High: Respiratory virus infection of epithelial cells,” Nov 2012.• Pathology course PATH351B, Cellular and Molecular Basis of Pathology, “Vaccine Research andDevelopment”, 1.5 hour lecture, 2008 – 2014.• Clinical and Translational Scientist Development Seminar Series, “Mentoring.” Sept 2010.• "Model Systems in Biomedical Research" IGP Module Course, 2015. “Human antibody responses toviruses.”• “Emerging Genomics Technologies”, Cell Biology 310 course, 2013 – present.• Clinical Pharmacology fellows series, “Human monoclonal antibodies as therapeutic molecules,” 2015-present.Undergraduate Courses• Freshman seminar series, “Vaccines for the Developing World,” Vanderbilt University, February 2011.• Special Topics in Drug Delivery, Biomedical Engineering 290A/395B Special Topics in Drug Delivery,“Vaccine design and testing,” yearly lecture, 2011 – present.Medical School Courses• “Microbial Topics” Small Group Leader, Department of Microbiology first year course for medicalstudents. Yearly 1997 – 2002.• Medical Microbiology Course, First year medical school, lecturer, 2003, 2004. “Acute Viral Infectionscan be limited to mucosal surfaces: Rotaviruses,” and “Orthomyxoviruses.”• "Microbes and Immunity" session leader, first year medical school course, 2015.High School and Middle School Teaching• Program for Talented Youth, Summer Enrichment Program, Nashville, TN. Course in "Nanomedicine".Co-taught this one-week course with David Wright, PhD, July 2007.• Young Scholars Medical Program, Vanderbilt University, July 2007, "Nanotechnology and Medicine."Lecture and laboratory experience for gifted high school students.• Research Explorers, Tennessee Council of the Boy Scouts of America, boys and girls in grades 9-12.Nanotechnology and infectious diseases lecture, February 2008.• Vanderbilt Virtual School, Televised national outreach to high school students, “Nanotechnology,Nanobiotechnology, and Nanomedicine.” Apr 2010 and Nov 2010.• School for Science and Math at Vanderbilt, “Human Immunology.” Nov 2010.Community Outreach“The Swine Origin Influenza Outbreak”, Adventure Science Center, Nashville, TN, April 2009.Press28• Emmy Award, Community Service category, Midsouth Regional Emmy Award for Nashville PublicTelevision: Children’s Health Crisis, March 2012.• Multiple appearances in local, national and international media venues, including National PublicRadio, CNN, CBS Evening News, BBC, Fox, New York Times, Wall Street Journal, El Mundo, CorreioBraziliense and others.• This Week in Virology podcast, link here, Apr 2015.CONTINUING MEDICAL EDUCATION• Vanderbilt Pediatric Grand Rounds• 2000 “Evidence based approach to treatment of the common cold.”• 2001 “CD40L: Master regulator of human immune responses.”• 2002 “Molecular basis of human immunodeficiencies.”• 2003 “Therapeutic monoclonal antibodies: Coming to a patient near you.”• 2004 “Nanomedicine: Big things on a small scale.”• 2005 “Getting a grip on life: Why infant antibodies induced by virus infection don’t functionwell”• 2006 “Cell biology of RSV infection: How viruses know where the top of a cell is?”• 2006 “Reinventing the wheel: Rotavirus vaccines”• 2014 “Ebola 2104: VUMC preparedness”• 1998 – 2013, Pediatric Faculty Research Conference, Annual presentations on RSV, humanmetapneumovirus, smallpox or rotavirus infections and human immune responses.• Infectious Diseases Grand Rounds, 2001 “Human monoclonal antibodies: State of the Art.” 2003“Human immune responses to smallpox vaccination.”• Amos Christie Symposium, 2003. “Human metapneumovirus infections in children.”• Bill Wilkerson Center, Apr 2003. “The child with CMV.” CE for physical therapists.• Vanderbilt Student Health Service, CME conferences 2001, “Osteomyelitis”, 2003 “Cat scratch disease”• Vanderbilt Neonatal Conference. 2003. “Neonatal candidiasis.” 1998 “Neonatal syphilis.”• General Clinical Research Center, June 2002, “Use of clinical databases for infectious diseaseepidemiology studies: Human metapneumovirus infections in children.”• Digestive Diseases Research Retreat 2003. “Rotavirus and immune factors.”• Infectious Diseases fellows’ conference, 2000 – 2002. “The academic physician career track.”• Pediatric Clinical Research Office lecture series for fellows, 2003 “Succeeding in academic medicine.”• “Update on Influenza,” Vanderbilt Canby Robinson Society, April 2006.• "Update of Influenza," 19th Annual Infectious Diseases in Children Symposium, Nov 2006.• Infectious Diseases Grand Rounds, “Broadly cross reactive antibodies to viruses: Are universal HIVand influenza vaccines on the way?” Sept 2010.CLINICAL TEACHING• Pediatric Infectious Diseases. Two months per year inpatient teaching service, 1996-2002; Two monthsper year outpatient teaching service 1996 – 2010.• General Pediatrics. One month per year as teaching and admitting physician, 1996 – 2001; Two-fourweeks a year as teaching attending, 2002 – 2005.29CURRENT RESEARCH FUNDING: PRINCIPAL INVESTIGATORR01 AI114816, NIAID/NIHMultiple PI: Crowe and Michael Diamond (WUSTL)Structural and functional basis of ultra potent CHKV neutralization by human mAbs02/10/2015 - 01/31/2020 $3,662,551The purpose of this grant is to study the structural and functional basis of ultra potent CHKV neutralization byhuman mAbs isolated from humans.U19 AI109711 NIAID/NIHAdvancement of Treatments for Ebola and Marburg Virus InfectionsPI: Geisbert (UTMB Galveston)Role: I am PI for Research Project 3: Therapeutic Human Monoclonal Antibody Treatments for Filoviruses.03/01/2014 - 02/28/2019Total U19 budget $26,000,000Subproject Annual Direct Cost: $700,000Subproject Annual Indirect Cost: $392,000Subproject Annual Total Cost: $1,092,000The purpose of this grant is to develop and advance treatments for Ebola and Marburg virus infection. This isa multi-investigator grant. Vanderbilt is conducting studies to isolate and characterize human monoclonalantibodies to filoviruses and their epitopes.R01 AI106002, NIAID/NIHMolecular Determinants of Cross-Reactive Antibody Response to Influenza in HumansPI: James E. Crowe, Jr.08/15/2012 – 07/31/2016Yearly Support (Direct Cost) $ 250,000Total Award Amount (Direct and Indirect) $ 1,560,000The purpose of this grant is to isolate human monoclonal antibodies to influenza, and to study influenzaspecific human B cell repertoires, with emphasis on broadly cross-reactive antibodies.U19 AI117905, NIAID/NIH $9,044,429Multiple PI: Crowe and Jens MeilerStructure Based Design of Antibodies and Vaccines06/01/2015 – 05/31/2020The purpose of this grant is to develop new computational modeling methods for the design of novelantibodies and antigens.Annual Supplement: Infrastructure and Opportunity Fund $314,000/yearR56 AI110750, NIAID/NIHHybrid Methods for Prediction and Design of Novel Human Influenza Antibodies09/05/2014 – 08/31/2015Role: Co-PI, with Jens MeilerTotal Award Amount $433,256The purpose of this award is to develop and implement new computational methods for design of antibodiesto influenza virus.HHSN272201400024C Contract, NIAID/NIHTitle: Genetic and Structural Basis for Virus NeutralizationProgram: B Cell Epitope Discovery and Mechanisms of Antibody Protection30Total Award Amount to VanderbiltRole: PIProject Period: 09/30/14 - 09/29/19Yr1 Direct cost: $541,588 Total directs for all years: $2,790,297Yr1 Indirect cost: $158,412 Total indirects for all years: $709,703Yr1 Total cost: $700,000 Total award $3,500,000This is a B cell epitope-mapping contract focused on H7 influenza epitopes.Supplement, August 1, 2015, for universal influenza vaccine development; $2,000,000HHSN272201400018C Contract, NIAID/NIHTitle: B Cell epitope mapping of viral and parasitic antigensProgram: B Cell Epitope Discovery and Mechanisms of Antibody ProtectionRole: Vanderbilt subcontract PI(overall PI is Daved Fremont, Washington University at St. Louis)Project Period: 09/30/14 - 09/29/19Yr1 Direct cost: $203,959 Total directs for all years: $917,199Yr1 Indirect cost: $116,256 Total indirects for all years: $522,801Yr1 Total cost: $320,215 Total award $1,440,000This is a B cell epitope mapping contract. Our site has a subcontract to isolate human monoclonal antibodies toJapanese encephalitis virus and dengue virus serotype 4.HHSN Contract HHSN272201400058C, NIAID/NIHTitle: B-cell Epitope Discovery and Mechanisms of Antibody Protection for HCV and EBOV Envelope proteinsProgram: B Cell Epitope Discovery and Mechanisms of Antibody ProtectionTotal Award Amount to VanderbiltRole: Vanderbilt subcontract PI (overall PI is Ben Doranz, Integral Molecular)Project Period: 09/30/14 - 09/29/19Direct cost (YR 1): $95,541 Total directs for all years: $281,081Yr 1 Indirect cost: $54,459 Total indirects for all years: $ 160,218Yr 1 Total cost: $150,000 Total award $441,299This is a B cell epitope mapping contract. Our site has a subcontract to isolate human monoclonal antibodiesto hepatitis C virus and to provide proteins for previously isolated human monoclonal antibodies to EbolaZaire virus.Supplement, August 1, 2015, for new human mAbs to Ebola from Nigerian survivors; $2,000,000.HHSN2720100007C (Rothman/Pekosz/JHU); Center of Excellence for Influenza Research and Surveillance(CEIRS)“The Human Influenza Immunome Project”Direct Cost First Year Award: $373,248Total First Year Award to Vanderbilt: $585,999Role: Vanderbilt subcontract PI (overall PI is Andrew Pekosz, Johns Hopkins University)The purpose of this subcontract is to perform and analyze high throughput sequencing experiments to definethe human B cell repertoire relevant to influenza virus.Defense Threat Reduction Agency (Department of Defense)Award Number: HDTRA1-13-1-0034“Human Monoclonal Antibodies against Ebola and Marburg Viruses”Role: PIDirect cost award for years 1 and 2: $ 1,954,992Total award: $ 4,422,20204/01/2013- 03/31/201831The purpose of this award is to isolate and characterize human monoclonal antibodies to Ebola and Marburgviruses from survivors of those infections.CURRENT RESEARCH FUNDING: CO-INVESTIGATORP01 AI106695, NIAID, NIHProtective immunity following dengue virus natural infections and vaccination07/29/2015 – 06/30/2020 $1,491,500 total to VUPI: Harris, U.C. BerkeleyRole: Co-investigatorThis is a program project to study human immune responses to dengue virus vaccination or infection. Our roleis to isolate human mAbs to dengue, and to study human antibody gene repertoires.DARPA 2/14/2014 – 02/13/2017Defense Advanced Research Projects Agency $953,758 total cost to VUOur subcontract: Ebola Virus Specific Human Antibodies from Survivors of Natural InfectionPI: Rafi Ahmed, Emory UniversityRole: Co-investigatorThis is a $10.8 million grant to study the human immune response to Ebola virus infection. Our role is to makehuman monoclonal antibodies from the blood of Ebola survivors treated at Emory University.W31P4Q-13-1-003 Defense Advanced Research Project Agency (DARPA)Immediate and Persistent E-DNA Protection Against DenguePI: Weiner, University of PennsylvaniaMy role: PI of the Vanderbilt subcontract site7/1/2014 to 6/30/2015 $282,821 year 1The purpose of this primary grant is to study the delivery of antiviral antibody genes by DNA. Oursubcontract site is working on anti-staphlococcal and anti-chikungunya antibodies, and antibody discoverytechnologies.Grant W31P4Q-15-1-0003 Defense Advanced Research Project Agency (DARPA)(Simon, Inovio) DARPA3/12/2015 to 1/7/2017 Total cost $843,000The purpose of this grant is to develop and test DNA vectored delivery of antibody genes in humans. Our roleis to provide antibody genes for human monoclonal antibodies to Ebola virus and Marburg virus.Bill and Melinda Gates FoundationEbola Human Antibody Initiative: Isolation of Ebola-reactive human antibodies from subjects withseroreactivityAtreca Consortium (Atreca, Inc./UCLA/Vanderbilt/BSRI)12/2014 - 11/2017Role: Co-InvestigatorThis is a grant to isolate and study Ebola antibodies from the cells of survivors in Democratic Republic of theCongo.R01 AI107731-01 (de Silva, UNC) 07/01/2013-06/30/2018NIH/NIAID $100,000/year direct costMolecular Basis of Dengue virus neutralization by human antibodiesRole: Co-InvestigatorThis is a grant to define the molecular basis of neutralization of dengue virus.CBRNE Mission Support Contract (ECBC/RDECOM)32U.S. Army Research and DevelopmentPrime contractor: ITT; Vanderbilt is subcontractorTotal award: $485 million.My role on this is as one of four Vanderbilt investigators proposing and performing laboratory based conceptsin microbiology and immunology as part of this defense related research contract.NIAID Vaccine and Treatment Evaluation Unit (VTEU) 09/13 – 08/22HHSN272201300023I $95,170,200Role: Co-InvestigatorThe VTEU, in existence for over 50 years, is a network of 9 academic centers whose work focuses on theevaluation of new vaccines and new therapeutics for infectious diseases.Role: Co-Investigator, to supervise and conduct immunology studies, especially studies of H3N2 variant andH7 virus antibody-mediated immunity.NIAID Vaccine and Treatment Evaluation Unit (VTEU) 11/07 - 09/15HHSN272200800007C $23,700,303Role: Co-InvestigatorThe VTEU is a network of 8 academic centers whose work focuses on the evaluation of new vaccines and newtherapeutics for infectious diseases, other than HIV/AIDS. My role is to supervise and conduct humanimmunology studies.5P30 DK058404-11, NIH/NIDDK (Peek) $737,850Molecular and Cellular Basis of Digestive Disease06/1/2012 - 05/31/2017Role: Core DirectorThis is our Digestive Diseases Research Center. My role is to direct the Flow Cytometry Shared Resource.5P30 CA068485-15, NIH/NCI (Pietenpol) $3,781,250Cancer Center Support Grant09/01/2010-08/31/2015This is a Cancer Center Support Grant from NCI that supports the Vanderbilt Ingram Cancer Center. I amDirector of the Flow Cytometry Shared Resource.2 R01 AI073755-06, NIAID/NIH (Diamond/Washington Univ. St. Louis)“Antibody-Based Protection Against Dengue Virus” VU=$30,000 direct/yrRole: Co-Investigator, PI of Vanderbilt subcontract06/18/2013 – 05/31/2018The goal of this grant is to study the function of antibodies against dengue virus.1 R43 AI118087-01, NIAID, NIHUniversal Flu Vaccine Based on Conformationally Locked Soluble Headless HAPI: Yondola, AvatarRole: Academic collaborator, making/providing HA-stem specific antibodies.02/17/15- 02/16/2017This is an SBIR grant led by Avatar Medical, LLC. to develop a universal influenza vaccine using a headlessHA construct.PREVIOUS RESEARCH FUNDING (with direct amounts):07/01/96 to 06/30/98“Ontogeny of specific antiviral B cells in human neonates” $ 130,000331996 Pfizer Scholars Program for New Faculty.Principal Investigator: James E. Crowe, Jr.07/01/96 to 06/30/99“Vaccines for neonates” $ 300,000The Memorial Foundation, Goodlettsville, TN.Served as startup funds for Crowe Lab (a competitive foundation award)06/1998 $ 30,000“Technologies for generation of single cell derived human B cell clones”Pasteur Merieux Connaught University Liaison Program AwardPrincipal Investigator: James E. Crowe, Jr.02/01/1998 to 01/31/2000 $ 100,000“Development of virus-specific B-cell immune responses in human neonates”Basil O’Connor Starter Scholar Research AwardMarch of Dimes Birth Defects FoundationPrincipal Investigator: James E. Crowe, Jr.01/1999 $ 1,000RSV neutralization assaysKaiser Permanente Vaccine Study Center, CA11/1/99 to 10/31/00 $ 45,065“Generating therapeutic human monoclonal respiratory syncytial virus (RSV) Abs using Xenomousetechnology”Abgenix, Inc.Principal Investigator: James E. Crowe, Jr.02/01/99 to 1/31/02 $ 264,458/yr“CD40L in allograft tolerance and viral immunity“5R01AI44078-02, NIAID, NIHPrincipal Investigator: Richard Pierson, MDMy role was that of a Co-investigator (5% effort)March 2001“QP21 Q-Pix Colony Picker” $ 113,681NIH NCRR Shared Instrument AwardPrincipal Investigator: Raymond L. Mernaugh, PhDMy role was that of a Co-investigator02/01/2001 to 01/31/2002 $ 91,374“The correlation between natural rotavirus infection and lymphocyte activation ”Wyeth Lederle Vaccines and PediatricsPrincipal Investigator: James E. Crowe, Jr.11/01/2000 to 10/31/2002 $ 183,820/yr“Defining epitope specificity and HLA restriction patterns in RSV-induced CD8+ T cells”Wyeth Lederle Vaccines and PediatricsPrincipal Investigator: James E. Crowe, Jr.10/01/1997 to 08/31/200334“Ontogeny of RSV-Specific B Cell Responses in Humans” $ 150,000/yrR01 HD36311, NICHD, NIHPrincipal Investigator: James E. Crowe, Jr.09/01/2000 to 08/31/2003 $ 150,000/yr“Respiratory virus neutralization mediated by intracellular antibodies”R21 DE14039-01, NIDR, NIHPrincipal Investigator: James E. Crowe, Jr.09/15/2000 to 09/14/2003 $ 144,061/yr“Human monoclonal antibodies that neutralize vaccinia virus”U01 AI48512-01, NIAID, NIHPrincipal Investigator: James E. Crowe, Jr.01/22/96 to 06/30/2003“Animal Models for RSV Pathogenesis” section $ 627,717/yrIn “Respiratory Pathogens Research Unit”N01-AI-65298, NIH-NIAIDPrincipal Investigator: Robert Couch, MDMy role was that of a Co-investigator.01/01/02 – 12/31/03 $ 50,000“Human metapneumovirus infection”Vanderbilt Intramural Research Program, Discovery AwardPrincipal Investigator: James E. Crowe, Jr.This grant provided support for molecular identification of isolates of a newly identified virus.MedImmune, Inc.Human metapneumovirus infections of childrenPI: James E. Crowe, Jr.Yearly Support (Direct Cost) $ 151,850Total Award Amount (Direct and Indirect) $ 242,96004/01/03 – 3/31/04This grant provided support for exploration of the genetic diversity of isolates of a newly identified virus.P30 DK-58404, NIDDK/NIHMolecular and Cellular Basis of Digestive DiseasesCo-Investigator; (PI is Raymond DuBois)Yearly Support (Direct Cost) $ 595,862Total Award Amount (Direct and Indirect) $ 2,980,28206/01/02 – 05/31/04 (our project)This was a Digestive Diseases Research Center Pilot and Feasibility Grant, entitled Intracellular neutralizationof rotavirus, for $25,000/year to study a novel method of virus neutralization by IgA antibodies.1PN1 EY-16567, NEI, NIHImmunomodulation on the Nanoscale: Vanderbilt Alliance for NanomedicinePI: James E. Crowe, Jr., MDYearly Support (Direct Cost) $ 50,000Total Award Amount (Direct and Indirect) $ 75,50009/30/04 – 03/31/0535This was a planning grant for an NIH Nanomedicine Center. I am the Director for the Vanderbilt Alliance forNanomedicine, a multi-disciplinary, multi-institution center involving Vanderbilt University Medical Center,Vanderbilt University, and Oak Ridge National Laboratory.“Epitope Discovery Award”, 2002-2004, Vanderbilt University Award $ 50,000PI: David Wright, PhDRole: Co-InvestigatorThe purpose was to develop new methods of epitope discovery using nanoparticles.1 S10 RR019032 Shared Instrumentation Award, NCRR, NIHHigh throughput flow cytometerPI: James E. Crowe, Jr.Total Award Amount $ 459,20704/01/2004 - 03/31/2005This application was for a new flow cytometer instrument for the institutional flow cytometry core lab forwhich I am the Director.The Defense Advanced Research Projects Agency (DARPA)“Network inference of human B cells using BioSPICE”Co-Investigator; (PI was Michael Simpson at ORNL)Yearly Support (Direct Cost) $ 150,000(Crowe lab portion only) $ 35,00003/01/05 – 06/30/06This was a project with scientists at Oak Ridge and UT to develop novel mathematical models for analyzingtime series data of B cell signaling networks.R03 TW-00149 (FIRCA), Fogarty Center and NIAID, NIH“Epitope specificity of RSV nucleoprotein-specific T-cells”PI: James E. Crowe, Jr.Yearly Support (Direct Cost) $ 32,000Total Award Amount (Direct and Indirect) $ 96,00007/01/02 – 06/30/05This was an award for study of RSV-specific T cell responses in subjects in South Africa.R01 AI-48677, NIAID, NIH“Novel methods for generation of human B cell hybridomas”PI: James E. Crowe, Jr.Yearly Support (Direct Cost) $ 225,000Total Award Amount (Direct and Indirect) $ 1,189,1252004 Supplemental Award $ 41,50009/01/2002 – 08/31/2006The purpose of this grant was to develop new methods for generation of human hybridomas. This was aBioengineering Research Grant award, principally aimed at development of electrofusion devices andprotocols.R01 AI-53222, NIAID, NIH“Human T cell responses to RSV”PI: James E. Crowe, Jr.Yearly Support (Direct Cost) $ 225,000Total Award Amount (Direct and Indirect) $ 1,176,37507/01/03 – 06/30/07This project investigated the specificity and phenotype of human T cell responses to respiratory syncytial36virus.Alnylam, Research Contract“Effect of inhibitory RNAs on RSV replication in cotton rats”09/15/06 - 09/14/07Annual Costs $ 15,971This was a research contract to study the effect of siRNAs on RSV replication.Role: PIR01, AI-57661, NIAID, NIH“Cell-mediated immune responses to vaccinia viruses”PI: James E. Crowe, Jr.Yearly Support (Direct Cost) $ 225,000Total Award Amount (Direct and Indirect) $ 1,189,1252004 Supplemental Award, direct $ 150,0009/15/03 –2/28/2008This grant was a biodefense related study of the human T cell response to vaccinia virus inoculation (forimmunization against smallpox).M01-RR-000095, NCRR, NIH GCRC Supplement Award“Human Immunology Core Laboratory”PI: James E. Crowe, Jr. (Jeff Balser was PI of the parent GCRC)Yearly Support (Direct Cost) $ 271,668Total Award Amount (Direct and Indirect) $ 317,54101/01/03 – 10/31/07This grant provided for support of a core laboratory aimed at increasing the use of human cytokine and T cellassays in the context of clinical trials.S10 RR023901, NCRR, NIH $ 425,546“Olympus FV1000 Confocal Fluorescence Microscope”04/01/07 - 03/31/08PI: James GoldenringRole: Co-InvestigatorThis was a shared instrumentation grant application for a confocal microscope.N01 AI-25462, Vaccine Treatment and Evaluation Unit, NIAID/NIH“Evaluation of control measures against infectious diseases other than AIDS”Co-Investigator; (PI was Kathryn Edwards)Yearly Support (Direct Cost) $ 2,628,646Total Award Amount (Direct and Indirect) $ 11,230,14306/01/2002 – 12/31/2008This was a vaccine testing center contract. The bulk of the work in the contract was aimed at testing vaccines inadults for purposes of biodefense. My role was to supervise and conduct immunology studies, especiallystudies of cell-mediated immunity.1UL 1RR024975 from the National Center for Research Resources, NIHVanderbilt Institute for Clinical and Translational Research2008 Equipment Awards1. Multiplex detection of human cytokines $25,0002. Image analysis of human cells infected with viruses $12,899NIAID Regional Centers of Excellence New Opportunities Award37“Passive immunotherapeutics for select agents”PI: James E. Crowe, Jr.Yearly Support (Direct Cost) $ 103,698Total Award Amount $ 318,00003/01/2007 - 02/28/2009This was a biodefense grant to develop human monoclonal antibodies to select agents.2008 Pfizer Visiting Professor: Infectious Diseases $ 7,500Role: Principal InvestigatorThis was a competitive visiting professor program grant we were awarded to support the visit of Dr. DennisBurton, PhD to visit the Vanderbilt Vaccine Center that I direct.U54 AI057157, NIAID/NIHRegion IV Southeast Regional Center of Excellence in Emerging Infections and BiodefenseCo-Investigator; (PI is Fred Sparling [UNC-CH])Yearly Support (Direct Cost to our Core) $ 156,00003/01/07 – 2/28/09This award was a multi-institutional award to support regional expertise in biodefense. I was the Director ofCore C, the Monoclonal Antibody and Biosensor Core.U19 AI-057229, NIAID, NIH“Protective mechanisms against a pandemic respiratory virus”Co-Investigator; (PI is Ann Arvin [Stanford])Yearly Support (Direct Cost) (our portion) $ 60,000Total Annual Award Amount $ 2,000,00009/01/03 – 08/31/08This was Project 3 (B Cell Immunity to Influenza) of a center for translational human immunology based atStanford. I am studying the molecular basis for heterosubtypic immunity by cloning B cells specific forinfluenza HA.U19 AI057229-05S1 $102,236A Type 3 supplement was awarded to Crowe on 9/25/08 for H5N1 human monoclonal antibody studies.N01 AI25462 (Edwards), NIH/NIAIDCISA Genomics InitiativeThe purpose of this project was to develop techniques for studying the association of genetic variation withadverse events following influenza vaccination.Role: Co-InvestigatorR01 AI 057933, NIAID, NIH“Human antibody responses to rotavirus”PI: James E. Crowe, Jr.Yearly Support (Direct Cost) $ 225,000Total Award Amount (Direct and Indirect) $ 1,189,12507/01/04 – 06/30/08 (no cost extension to 06/30/09)This project used single cell sorting techniques to isolate and analyze human rotavirus specific B cells in orderto determine the immunodominant gene segments used in the human rotavirus specific B cell repertoire.R01AI 59694, NIAID, NIH“Bioinformatics strategies for biodefense vaccine research”Role: Consultant; (PI is Jason Moore, PhD)Yearly Support (Direct Cost) $ 356,62538Total Award Amount (Direct and Indirect) $ 1,726,1817/1/04 – 6/30/08The purpose of this application was to develop computer algorithms to analyze complex protein array dataobtained for cytokines and chemokines made in response to vaccines relevant to biodefense. The data beinganalyzed is from my laboratory. I was supervising one of the bioinformatics faculty members.N01 AI40079, NIAID, NIH“Large-Scale Vaccinia Virus-Derived CTL Epitope Discovery”PI: Sebastian JoyceRole: Co-investigatorYearly Support (Direct Cost) $ 963,43209/04/2004 – 09/03/2009The goal of this contract was to identify CTL epitopes for vaccinia virus using a novel approach to identifynatural ligands.Role: Co-investigator.R01 EB 04537, NIBIB, NIH“Viral detection using fluorescent nanocrystals”PI: David WrightRole: Co-InvestigatorYearly Support (Direct Cost) $ 300,00009/15/06 - 08/31/09This was an application to develop quantum dot detection strategies for RSV proteins and RNAs.R01 AI 59597, NIAID, NIHAlphavirus-based Vaccine for Prevention of MPVPI: James E. Crowe, Jr.Yearly Support (Direct Cost) $ 250,000Total Award Amount (Direct and Indirect) $ 1,304,27403/15/05 – 02/28/09, no cost extension to 02/28/2010.The purpose of this application was to develop alphavirus-vectored MPV and RSV vaccines.R01 AI 59597-03S1 $145,86007/01/2007 – 02/28/09A Diversity Supplement to this grant for David Vigerust, PhD also was awarded, for training purposes.R01 AI 59597-03S2 $100,000A one-year supplement was awarded in 2007 for the study of HIV- specific B cell repertoires in response toRFA-AI-07-016 [NIAID Competing Supplements (Revisions) for B Cell Immunology and HIV-1 NeutralizingAntibody Projects (R01)].R03 AI068069, NIAID, NIHEpidemiology and Clinical Features of Human CoronavirusPI: John Williams, MD02/01/2007 – 01/31/2010Role: Consultant5P30 CA068485, NCI, NIH $ 3,448,549Cancer Center Support GrantPI: Jennifer Pietenpol, PhD09/28/2004 – 08/31/200939This was the Cancer Center Support Grant from NCI that supports the Vanderbilt Ingram Cancer Center. I wasDirector of the Flow Cytometry Shared Resource that became a new shared resource as of September 2004.R01 AG 15978, NIA, NIHPI: M.A. Westerink (Med. College of Ohio)Elderly Immune Response to Pneumoccoccal Polysaccharide09/01/06 - 08/31/10This was an application to study human B cells responses to pneumococcal polysaccharides.Role: ConsultantR43 AI-63681, NIAID, NIHA Mab Plantibody Cocktail for RSV ImmunoprophylaxisPI: Larry Zeitlin (Mapp Pharmaceuticals)I am the academic Co-InvestigatorYearly Support (Direct Cost) $ 300,000Yearly Support, Crowe portion (Direct Cost) $ 99,73212/01/05 – 11/30/08; no-cost extension to 11/30/09The purpose of this application was to develop human monoclonal antibodies directed to RSV and producedin plants as a prophylactic pharmaceutical for prevention of RSV disease.Role: Co-investigator.R21 AG 30321, NIA, NIHRespiratory Syncytial Virus Nanoparticle VaccinesRole: PIYearly Support (Direct Cost) $ 125,00009/30/2007-07/31/2009 (NCE to 07/31/2010)This was a grant to develop nanoparticle-based vaccines for RSV.S10 RR 026719, NCRR, NIHAcquisition of a ClonePix FL System02/01/2010 – 01/31/2011PI: Albert Reynolds, PhDRole: Co-InvestigatorThis was a shared instrumentation grant to obtain an automated cell cloning device.Burroughs Wellcome FundClinical Scientist Award in Translational ResearchImmunology and Cell Biology of Human Metapneumovirus InfectionsPI: James E. Crowe, Jr.Yearly Support (Direct Cost) $ 150,000Total Award Amount $ 750,00007/01/2005 – 06/30/2010This was an application to support a training program for physician scientists in the study of humanmetapneumovirus infections.R21 AI083574Rotavirus VP6 Specific Human IgA AntibodiesRole: PITotal Support (Direct Cost) $ 275,00007/01/2009-06/30/2011This was a grant to study intracellular neutralization of rotavirus by IgA antibodies, and to develop bispecificscFv that mimic antiviral IgAs.40P01 AI 058113, NIAID, NIHMolecular and Biological Characterization of Pandemic FluPI: Adolfo Garcia-Sastre, Mt. Sinai School of Medicine.My role: PI of B Cell Project on this P01Total annual support to our laboratory: $ 230,250Duration: 2009-2011.U54 AI 057157, NIAID, NIH, SupplementProteins for Dengue ProjectThe purpose of this supplement is to support equipment and supplies for large-scale production of denguevirus reagents for our RCE project (above).Total award: $126,903Role: PI2009-2010P30 AI 054999, NIAID, NIHVanderbilt-Meharry Center for AIDS ResearchCo-Investigator; (PI is Richard D’Aquila)Yearly Support (Direct Cost) $ 528,468Total Award Amount (Direct and Indirect) $ 2,291,51705/15/2003 to 08/31/2011This was a center award to enhance the institutional environment for studies related to the pathogenesis ofHIV infection. I was a co-investigator, helping to direct the immunopathogenesis laboratory.5P30 DK058404-10, NIH/NIDDK (Peek) $737,850Molecular and Cellular Basis of Digestive Disease06/1/2007 - 05/31/2012Role: Core DirectorThis is our Digestive Diseases Research Center. My role was to direct the flow cytometry shared resource.NIH S10 “GeneStor”. PI: Jeffrey G. Sumrall, submitted March 2012. Role: Co-InvestigatorVanderbilt Ingram Cancer Center Support Grant pilot project“Human neonatal control of transforming growth factor β”Role: PITotal Award: $35,00009/1/2011 – 08/31/2012This was a pilot project award to explore the mechanism for why infants do not regulate TGF β in the samemanner as adults.Innovation and Discovery in Engineering and Science (IDEAS) $ 100,000/yearA Multiplexed Diagnostic for the Detection of Respiratory Viruses”David Wright (chemistry) with Frederick Haselton (biomedical engineering); and James Crowe (Pediatrics) –Project involving detection of respiratory viruses using nanodevices.July 1, 2010-June 30, 2012U01 AI 78407, NIAID, NIHClonal Analysis of the Human B Cell Response to HIVPI: James E. Crowe, Jr.02/01/2008 – 02/28/2013Yearly Support (Direct Cost) $ 479,50041Total Award Amount (Direct and Indirect) $ 2,397,500The purpose of this grant was to isolate human monoclonal antibodies to HIV, and to study HIV specifichuman B cell repertoires.- 3 U01 AI 78407-02S1, Administrative supplement $ 882,14109/28/2009 – 08/31/2012The purpose of this supplement was to use 454 high throughput sequence analysis for identification of HIVspecifichuman monoclonal antibodies.- 3 U01 AI078407-03S1, Administrative supplement $ 7,75006/01/2010 – 09/30/2010The purpose of this supplement was to hire one undergraduate research assistant for the summer to assist withthe project.- 3 U01 AI078407-03S2, Administrative supplement $ 51,30709/07/2010 - 09/06/2011The purpose of this supplement was to support one underrepresented minority graduate student for training.S10 RR 027977, NCRR, NIH“Multi-Laser Flow Cytometer for Polychromatic Analysis.”Role: PIThis was a Shared Instrumentation Grant application for a custom five-laser LSRII cytometer.Total Award $ 482,250NIAID, NIH ARRA administrative award for supplemental funding $ 499,170“Alphavirus-based Vaccine for Prevention of MPV Infection”Role: PI7/26/10 - 7/25/2012The purpose of this supplement to our Regional Centers of Excellence award was to support the production ofexperimental vaccine lots for RSV and MPV with testing for immunogenicity and protective efficacy innonhuman primates.1S10 OD 012324-01Acquisition of a super-resolution optical microscopePI: Matt TyskaMy role: Major UserTotal annual award: $600,0002012This was a Shared Instrumentation Grant application for a super-resolution optical microscope.2013 Administrative Supplement, Scientific Research Meeting $15,000The purpose of this supplement was to conduct a research-planning meeting in Chicago for aninterdisciplinary group to develop Chikungunya and dengue virus antibodies and vaccines.PI: Crowe1G20RR030956-01, NCRR, NIHVANTAGE: Consolidation to Create the Vanderbilt Technologies for Advanced GenomicsPI: Susan Wente, PhD04/25-2010 – 04/24/2012Role: Co-InvestigatorThis was a major core renovation grant to integrate our flow cytometry core with genomics core services.42March of Dimes Foundation“Epithelial cell stress response and RSV infection”Role: PITotal Award: $240,0002010-2013The purpose of this grant was to study the role of stress granule formation in RSV replication in epithelial cells.3UL1 RR 024975-03S4 NCRR, NIH“Project Management for Translational Science”The Vanderbilt Institute for Clinical and Translational Research (VICTR) UL1Direct - $189,680, Indirect - $104,798, Total - $294,478PI: Gordon BernardMy role: Co-investigator, PI of Project that is target of the supplementThe purpose of this supplement was to support a Project Manager to move our experimental RSV vaccinecandidate into clinical trials.R21 AI092268, NIAID/NIHEpitope shifting and antibody maturation during rotavirus infectionPI: Ben Spiller,My role: Co-investigator$194,882HHSN272200900055C Contract, NIAID/NIH (Integral Molecular)B Cell Epitope Discovery and Mechanisms of Antibody ProtectionRole: PI of Vanderbilt subcontract07/01/2012 -06/30/2013HHSN272200900055C Contract, NIAID/NIH (PI: Doranz; Integral Molecular)“Antibodies to Chikungunya virus and hepatitis C virus”Federal Direct Costs to VU: $128,074Total Award: $179,303Role: Vanderbilt PI of subcontract07/01/2012-06/30/2013This was a B cell epitope-mapping contract; we had a subcontract to develop human monoclonal antibodies tohepatitis C and Chikungunya virusesU54 AI 057157, NIAID, NIHRegion IV Southeast Regional Center of Excellence in Emerging Infections and BiodefenseCo-Investigator; (PI is Fred Sparling [UNC-CH])Yearly Support (Direct support to our laboratory): $ 172,90009/04/09 – 2/28/14This award was a multi-institutional award to support regional expertise in biodefense. I am the projectdirector for Project 9.1, “Genetic and Structural Determinants of Human Antibodies to Dengue Virus.”R01 AI 059694, NIAID, NIHBioinformatics Strategies: Biodefense Vaccine ResearchPI: Jason Moore, DartmouthMy role: ConsultantTotal annual award: $488,0322009-2014P01 AI 078064, NIAID, NIH43Programming HIV Immunity for Broadly Neutralizing Antibodies by VaccinationCo-Investigator; (PI is Nancy Haigwood [Oregon Primate Center]; VUMC PI is Spyros Kalams)Total support: $ 1,683,417Direct annual cost to our laboratory: $ 83,0052/1/09 – 1/31/14The overall goal was to design novel vaccines based on Env genes derived from virions (plasma RNA, notcellular DNA) from HIV-infected subjects who develop broad Nabs in an accelerated fashion (<3 years). Ourpart of the project is to make human mAbs from HIV-infected individuals.R01 AI 090656 NIAID, NIH (HITIT award) VU: $93,000 directs/yearBroadly Reactive Antibodies against Chimeric Virus-Host AntigensPI: Donald Forthal, UC-Irvine07/01/2010 - 06/30/2014Role: Co-Investigator.The purpose of this grant was to determine whether humans infected with HIV make antibody responses toantigens that are chimeras of virus and host proteins.R21 AI098592, NIAID/NIH (Spearman/Emory) VU-$75,000 direct/yrHIV-specific B cell repertoire in humans following cross-clade immunization07/01/2012-06/30/2014Role: Co-InvestigatorThe purpose of this grant was to determine the molecular basis for cross-clade responses in HIV vaccinatedindividuals.N01 AI 25462, Vaccine Treatment and Evaluation Unit, NIAID, NIHEvaluation of control measures against infectious diseases other than AIDSCo-Investigator; (PI is Kathryn Edwards)Yearly Support (Direct Cost) $ 3,102,081Total Award Amount (Direct and Indirect) $ 23,700,00011/01/2007 – 10/31/2014This was a vaccine testing center contract. The bulk of the work in that contract was aimed at testing vaccinesin adults for purposes of biodefense.HHSN272200900047C Contract, NIAID/NIHGenetic and Structural Basis for Virus NeutralizationB Cell Epitope Discovery and Mechanisms of Antibody ProtectionRole: PIAnnual award: $ 660,590Total Award: $ 5,281,90609/30/2009 -09/29/2014This was a B cell epitope-mapping contract focused on H5 influenza and poxvirus epitopes5T32 AI 89554, NIAID, NIHVirology Training ProgramRole: PI of the Training Program, and Faculty MentorTotal Award: $796,86105/01/2010-04/30/2015This was a training grant program to train PhD candidate students in molecular and cellular virology research.Annual Costs - Federal Direct Costs $172,928, Federal F&A Costs $8,714, Total Budget $181,642Defense Threat Reduction Agency (Department of Defense)Award Number: HDTRA1-10-1-006744Molecular and Structural Basis for Fine Specificity of Antiviral AntibodiesRole: PITotal Award $2,000,0002010-2015The purpose of this award was to isolate and study human monoclonal antibodies to the 2009 pandemicinfluenza virus pH1N1.R01 GM 094198, NIGMS, NIH Direct cost $227,125/yearSingle RNA Sensitive Probes for Studying Viral Replication and BuddingPI: Philip Santangelo, Georgia TechRole: Co-investigator7/1/2010-6/30/2015The purpose of this grant was to develop novel imaging probes for RNA virus genomes in live cells.R21 AI103834-01, NIAID/NIHHuman Neutralizing Monoclonal Antibodies for Rift Valley Fever VirusPI: James E. Crowe, Jr.06/01/2013-05/31/2015Total Award Amount (Direct and Indirect) $462,799The purpose of this grant was to isolate human monoclonal antibodies to Rift Valley fever virus.FUNDING AWARDED FOR TRAINING IN THE CROWE LABORATORY05/1999 - 8/1999 $ 3,000Howard Hughes Medical Institute Undergraduate Summer Research Fellowship, for support of Michael Jolly07/1999 - 06/2001 $ 24,000/yrDeutsche Forschungsgemeinschaft Program AwardTraining award for support of ID fellow Hendrik Weitkamp, MD08/1999 - 07/2001 $ 24,000/yrViruses, Cancer and Nucleic Acids Training Grant Award for PhD graduate student Sean Brock07/2000 - 06/2002 $ 24,000/yrCellular and Molecular Microbiology Training Grant Award for PhD graduate student Nicole Kallewaard05/2000 - 04/2002 $ 14,700/yr“Epitope Specificity and HLA restriction patterns in respiratory syncytial virus (RSV) induced CD8+ T-cells inSouth African adults”, for PhD student Marietjie Venter, Polio Research Foundation07/2000 - 06/2002 $ 40,000/yrAventis Pasteur Fellowship in Pediatrics, Infectious Diseases Society of AmericaTraining award for support of ID fellow John Williams, MD07/01/2000 - 06/30/2001 $ 33,815/yrMolecular Basis of Infectious Diseases Training Grant Award for postdoctoral research fellow Michael Rock,PhD06/01/2001 - 08/15/2001 $ 2,500Society for Pediatric Research (SPR) Student Research Program Award for Washington University Medicalstudent Joyce Pingsterhaus4506/01/2001 - 08/15/2001 $ 2,500SPR Student Research Program Award for Nebraska University Medical student Elizabeth Bures07/01/2000 - 06/30/2001 $ 42,500/yrMolecular Basis of Infectious Diseases Training Grant Award for postdoctoral research fellow John V.Williams, MD12/00 $ 1,000Postdoctoral Travel Award, Seventh International Symposium on Double-Stranded RNA Viruses, Palm Beach,Aruba, December, 2000, fellow Hendrik Weitkamp, MD07/01/2001 - 06/30/2002 $ 40,000/yrBayer/Harold Neu Postdoctoral Fellowship Award, Infectious Diseases Society of America, Training awardfor support of ID fellow Hendrik Weitkamp, MD05/01 $ 2,000Travel award, Mead Johnson Nutritional Perinatal & Developmental Medicine Symposium "EmergingInfections in the Newborn Period", Aspen, Colorado, May 2001, fellow Hendrik Weitkamp. MDMay-August 2002 $ 3,000Immunobiology Training grant support for bioengineering student McLean CobleJune 2002 $ 800Young Investigator Travel Award, Hendrik Weitkamp, Society for Mucosal ImmunologyJuly 2002 $ 1,000American Society for Virology Travel Awards for Nicole Kallewaard, Sean BrockJuly 2002Infections in Immunodeficient Hosts Travel Award, John Williams $ 2,500October 2002Vanderbilt PhD dissertation enhancement award for Sean Brock $ 1,500Summer 2003American Society of Microbiology Undergraduate Research Award $ 4,000Josh Heck“Human Metapneumovirus Infection” $ 100,000Principal Investigator: John V. Williams, MDR03 AI54790, NIAID, NIH04/01/2003 to 3/31/2005I was the faculty mentor; he obtained this grant as a fellow in my laboratory.“Determinants of Protective Immunity to Human Metapneumovirus“ $ 300,000Principal Investigator: John V. Williams, MDK08 AI56170, NIAID, NIH2003-2006I was the K08 mentor for Dr. Williams; he obtained this grant as a fellow in my laboratory.200446Vanderbilt PhD dissertation enhancement award for Nicole Kallewaard, $ 1,5002004-2005K12 RR017697 (PI: Nancy Brown, MD)Vanderbilt Mentored Clinical Research Scholar Program"The Prevalence and Clinical Spectrum of human metapneumovirus in a Pediatric Hematology-OncologyPopulation"Jennifer Domm, MD, Fellow in Pediatric OncologyI was the MSCI mentor for Dr. Domm.2004-2006MedImmune Fellowship Award for Pediatric Research"Human Metapneumovirus Infections in Pediatric Intensive Care Unit Patients"Mercedes Judkins, MD, Fellow in Pediatric Critical CareI was the MSCI mentor for Dr. Judkins.2005-2007K12 RR017697 (PI: Nancy Brown)Vanderbilt Mentored Clinical Research Scholar Program"Epidemiology and Clinical Features of Human Coronavirus Infection"H. Keipp Talbot, MD, Fellow in Adult Infectious Diseases07/01/05 - 06/30/08 $100,500/yrPSDP/K12 DH00850, Pediatric Scientist Development Program"Genetic and Molecular Basis of Infant Antibody Responses to Viral Infections"Christopher Keefer, MD, Pediatric Infectious Diseases Fellow2005-2007MedImmune Pediatric Infectious Diseases Society Fellowship AwardRSV Neutralizing Antibodies $35,000Christopher Keefer, MD, Pediatric Infectious Diseases Fellow07/01/07 – 02/28/09 $145,860NIH Diversity Supplement to my 5 R01 AI59597-03 grantDavid Vigerust, PhD, Research Postdoctoral FellowDavid is a highly-talented first-generation Mexican-American scientist.May – August, 2007American Society of Microbiology Undergraduate Research Award $ 4,000Jon HedgecockMay 3–May 6, 2008 $ 1,000Pediatric Academic Societies Young Investigator’s Travel Award, Annual Meeting, Honolulu, HawaiiMark Hicar, MD, PhD2008 Keystone Symposia scholarship $ 1,000Fellows and New Investigators Workshop on Grantsmanship and Career Research Opportunities inHIV/AIDS Research, Mar 26 - Apr 1, 2008, Banff, Alberta.Mark Hicar, MD, PhDSummer 2009 $ 5,000SPR Student Research Program Award47Alexander Thurman, Indiana University School of Medicine, medical studentSummer 2009 $ 4,000Germs and Defense Summer Program Award, NIAIDChelsey Huffman, Cumberland University undergraduateF32 AI080117, NIAID, NIH, Postdoctoral research awardHuman Host Responses to Respiratory Syncytial Virus InfectionNatalie Thornburg, Ph.D.09/30/2009 - 09/29/2011American Society for Cell Biology (ASCB) Predoc Travel AwardMichael Lindquist2009 ASCB Annual Meeting, San Diego, CA, December 5-9, 2009Malnutrition, Gut-Microbial Interactions and Mucosal Immunity to Vaccines, New Delhi, IndiaMohammed AiyegboKeystone Symposia Underrepresented Minority Scholarship, $1200Nov 7 - Nov 11, 2011K08 AI 083078, Mark Hicar, M.D., Ph.D.Project Title: Antibodies Recognizing Quaternary Differences in HIV Envelope Glycoproteins2009-201407/31/2012 – Transfer to SUNYBudget Period: 08/01/2011 – 07/31/2012; Project Period: 09/22/2009 – 07/31/2012Annual Cost: Federal Direct Costs $118,300, Federal F&A Costs $9,464, Total Budget $127,764Vanderbilt Program in Microbial Pathogenesis mini-sabbatical award, 2012-13Jennifer Pickens, PhD. $4,000.U54 AI57157-10-SE-CD-006, SERCEB Career Development AwardPI: Scott A. Smith, M.D., Ph.D.Project Title: Characterization of rare neutralizing human mAbs to dengue virusesProject Period: 03/01/2011 – 08/31/2012Annual Direct Costs $91,554, Federal F&A Costs $51,270, Total Budget $142,824My role: MentorK08AI103038PI: Scott A SmithProject Title: Key determinants of dengue virus neutralization by naturally occurring humanmAbsBudget Period: 08/13/2012 – 07/31/2013Project Period: 08/13/2012 – 07/31/2017Annual Cost: Federal Direct Costs $116,800, Federal F&A Costs $9,344, Total Budget $126,144My role: MentorMentor for Successful NIH Loan Repayment Program Competitive AwardsBrian Engelhardt, MDMark Hicar, MD, PhDChristopher Keefer, MD48Keipp Talbot, MDJohn V. Williams, MDScott Smith, MD, PhDDaniel Dulek, MDPATENTS AND PATENT APPLICATIONS PENDINGA) For human monoclonal antibodies against RSV - NIH E-001-1996 patent familyU.S. Patent Serial #08/162,102 entitled HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES TORESPIRATORY SYNCYTIAL VIRUS. Issue date 6/9/98. Inventors: Dennis Burton, Carlos Barbas, Robert M.Chanock, Brian R. Murphy, and James E. Crowe, Jr.US 2012/0087909 A1. NEUTRALIZING MONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIALVIRUS - Pending. Inventors: Glenn Pilkington, Page Gilmour, James Crowe, Jr., Brian Murphy, and RobertChanockMONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS AND USES THEREOF, Inventor:James E. Crowe, Jr., Filed July 2007. US Patent number 7,867,497; Issued January 11, 2011. PCT2008/077370.B) For biologically derived RSV strains - NIH E-123-1992/0,1,2,3 patent familyUSSN 08/327,263, entitled ATTENUATED RESPIRATORY SYNCYTIAL VIRUS VACCINE COMPOSITIONS -Pending. Inventors: Brian Murphy, Robert Chanock, James Crowe, Jr., Mark Connors.USSN 08/453,294, entitled ATTENUATED RESPIRATORY SYNCYTIAL VIRUS VACCINE COMPOSITIONS -Pending. Inventors: Brian Murphy, Robert Chanock, James Crowe, Jr., Mark Connors, Lee Hsu, and A.R.Davis.USSN 08/453,304, entitled ATTENUATED RESPIRATORY SYNCYTIAL VIRUS VACCINE COMPOSITIONS -Pending. Same inventors as 08/453,294C) For recombinant RSV strains - NIH E-142-1996/0,1,2 patent familyUSSN 60/021,773, a provisional patent application entitled RATIONAL DESIGN OF ATTENUATEDRESPIRATORY SYNCYTIAL VIRUS VACCINES -Converted to an ordinary application. Inventors: BrianMurphy, Peter Collins, Stephen Whitehead, James Crowe, Jr., Katalin JuhaszUSSN 60/0469141, a provisional patent application entitled PRODUCTION OF INFECTIOUS RESPIRATORYSYNCYTIAL VIRUS FROM CLONED NUCLEOTIDE SEQUENCES - Pending. Inventors: same as 60/021,773USSN 60/047,634, provisional application PRODUCTION OF INFECTIOUS RESPIRATORY SYNCYTIALVIRUS FROM CLONED NUCLEOTIDE SEQUENCES. Inventors: B. Murphy, P. Collins, S. Whitehead, J.Crowe, Jr., K. Juhasz and A. Bukreyev, Filed May 23, 1997D) For RSV antibodies - NIH E-045-1996 patent familyE) For RSV antibodies - NIH E-032-1993 patent family49F) For alphavirus vectored RSV and MPV vaccinesVACCINES FOR RSV AND MPV. Inventors: James E. Crowe, Jr., Hoyin Mok, Robert E. Johnston, Nancy L.Davis, John Williams. Filed November 11 2007. PCT/US08/077721 filed 09/25/08. Application serial number12/238,130. European Patent Application No. EP08833916.3.G) For virus-like particle vaccinesVIRUS LIKE PARAMYXOVIRUS PARTICLES AND VACCINES. Inventors: James E. Crowe, Jr., Hoyin Mok.Filed May 30, 2008, No. 61/057,689. Permanent application filed June 1, 2009 as Application Serial No.12/455,584.H) For influenza vaccineUSSN 60/802.667, RECOMBINANT INFLUENZA H5 HEMAGGLUTININ PROTEIN AND NUCLEIC ACIDCODING THEREFOR." Inventors: James E. Crowe, Jr. and John V. Williams, Filed May 23, 2006.I) For dendrimer vaccinesDENDRITIC MOLECULAR INTRACELLULAR TRANSPORTERS AND METHODS OF MAKING ANDUSING SAME. Inventors: Eva M. Harth, James E. Crowe, Jr., Kui Huang, Heidi E. Hamm, Filed August 2006.J) For antibodies to influenza virusMONOCLONAL ANTIBODIES TO INFLUENZA H1N1 VIRUS AND USES THEREOF. Inventors: James E.Crowe, Jr., Jens Krause, Christopher Basler. US Patent 8,894,997, issued 11/25/2014.INFLUENZA VIRUS ANTIBODIES AND IMMUNOGENS AND USES THEREFOR. Inventors: James E.Crowe, Jr., Jens C. Krause, David L. Blum. Filed 09/30/2010. US patent application 13/877,163.K) For antibodies to human metapneumovirusUS20110135645, Anthony R. Williamson, Zhifeng Chen, Pietro Paolo Sanna, Dennis R. Burton, James E.Crowe, Jr., John V. Williams; Publication date 06/09/2011; Filing date 10/04/2007L) For dengue virus epitopesA Novel Quaternary Dengue Virus Epitope. The University of North Carolina at Chapel Hill and VanderbiltUniversity; Aravinda deSilva, Scott A. Smith, James E. Crowe, Jr. Application Number: 61/619,247;Filed: 4/2/2012; Patent Type: US Provisional.M) For Ebola virus human antibodiesU.S. Provisional Patent Application Serial No. 62/138,522Entitled: “ANTIBODY-MEDIATED NEUTRALIZATION OF EBOLAVIRUSES” By James E. Crowe, Jr., etal. March 26, 2015N) For Marburg virus human antibodiesU.S. Provisional Patent Application Serial No. 62/120,65750Entitled: “ANTIBODY-MEDIATED NEUTRALIZATION OF MARBURG VIRUS” By James E. Crowe, Jr., et al.February 25, 2015.O) For Chikungunya virus human antibodiesU.S. Provisional Patent Application Serial No. 62/147,354Entitled: “ANTIBODY-MEDIATED NEUTRALIZATION OF CHIKUNGUNYA VIRUS” By James E. Crowe, Jr.,et al. April 14, 2015P) For dengue virus human antibody 2D22U.S. Provisional Patent Application Serial No. 62/192,429Entitled: “ENGINEERED ANTIBODIES AGAINST DENGUE VIRUS” By James E. Crowe, Jr., et al.LICENSURERecombinant respiratory syncytial virus fusion protein. Evogenix. 2006. Nonexclusive research license. JamesCrowe, Jr./Vanderbilt University.Recombinant respiratory syncytial virus fusion protein. MedImmune. 2008. Nonexclusive research license.James Crowe, Jr./Vanderbilt University.Recombinant respiratory syncytial virus fusion protein. Merck. 2008. Nonexclusive research license. JamesCrowe, Jr./Vanderbilt University.Recombinant respiratory syncytial virus fusion protein. Anaptys. 2009. Nonexclusive research license. JamesCrowe, Jr./Vanderbilt University.Diagnostic antibody for influenza H1N1 infection. Becton Dickinson. 2009. Nonexclusive research license.James Crowe, Jr./Vanderbilt University.Sequence-optimized human metapneumovirus fusion (F) gene and expressed protein. MedImmune. 2008.Nonexclusive research license. James Crowe, Jr./Vanderbilt University.Recombinant respiratory syncytial virus fusion protein. BEI Resources/ATCC. 2011. Nonexclusive researchlicense. James Crowe, Jr./Vanderbilt University.Human monoclonal antibodies to dengue virus. Sanofi Pasteur. 2014-2016. Nonexclusive research license.James Crowe, Jr./Vanderbilt University.Human monoclonal antibodies to dengue virus. Glaxo Smith Kline. 2015. Nonexclusive research license. JamesCrowe, Jr./Vanderbilt University.Human monoclonal antibodies to chikungunya virus. Sanofi USA. 2015-2017. Option to exclusive licensure.James Crowe, Jr./Vanderbilt University.Human monoclonal antibodies to dengue virus. Takeda Vaccines. Inc. 2015. Nonexclusive research license.James Crowe, Jr./Vanderbilt University.Human monoclonal antibodies to dengue virus. Moderna. 2015. Nonexclusive research license. James Crowe,Jr./Vanderbilt University.5152BIBLIOGRAPHYUnique Identifiers• ORCID ID: 0000-0002-0049-1079• ResearcherID: B-5549-2009• Scopus Author ID: 26642993000• International Standard Name Identifier (ISNI) 0000 0003 5201 8432Metrics• H-index: 53; cited 9,487 times [(Google Scholar, (01/16/2016)]• Google Scholar, i10 index (papers with more than 10 citations) = 154 (01/16/2016)• H-index: 44 [Thomsen Reuters, Science Citation Index; (01/16/2016)]• ResearchGate score 45.34 (01/16/2016); >97.5% of members.ORIGINAL REPORTS1. Barbas CF III, Crowe JE Jr, Cababa D, Jones TM, Zebedee SL, Murphy BR, Chanock RM, Burton DR. Humanmonoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus Fglycoprotein and neutralize infectivity. Proceedings of the National Academy of Sciences USA 1992; 89: 10164-8.2. Crowe JE Jr, Barbas CF III, Bui P, Cababa D, Jones TM, Zebedee SL, Murphy BR, Chanock RM, Burton DR.Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus Fglycoprotein and neutralize infectivity. In Brown F, Chanock RM, Ginsberg HS, Lerner RA, eds. Vaccines 93:Modern Approaches to New Vaccines Including Prevention of AIDS. Cold Spring Harbor, NY: Cold SpringHarbor Laboratory 1993; 7-11.3. Crowe JE Jr, Collins PL, London WT, Chanock RM, Murphy BR. A comparison in chimpanzees of theimmunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutantvaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 1993; 11: 1395-404.4. Crowe JE Jr., Murphy BR, Chanock RM, Williamson RA, Barbas CF III, Burton DR. Recombinant humanRSV monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs ofrespiratory syncytial virus-infected mice. Proceedings of the National Academy of Sciences USA 1994; 91:1386-90.5. Crowe JE Jr, Bui PT, London WT, Davis AR, Hung PP, Chanock RM, Murphy BR. Satisfactorily attenuatedand protective mutants derived from a partially attenuated cold passaged respiratory syncytial virus mutantby introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 1994; 12: 691-99.6. Crowe JE Jr, Murphy BR, Chanock RM, Williamson A, Barbas CF III, Burton DR. Human RSV monoclonalantibody Fab cloned from a combinatorial library and produced in E. coli is effective therapeutically whenintroduced directly into the lungs of RSV-infected mice. In Brown F, Chanock RM, Ginsberg HS, Norrby E,eds. Vaccines 94: Modern Approaches to New Vaccines Including Prevention of AIDS. Cold Spring Harbor:Cold Spring Harbor Laboratory Press 1994; 315-20.537. Crowe JE Jr, Bui PT, Davis AR, Chanock RM, Murphy BR. A further attenuated derivative of a coldpassagedtemperature-sensitive mutant of human respiratory syncytial virus (RSV cpts-248) retainsimmunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine1994; 12: 783-90.8. Crowe JE Jr, Cheung PYK, Wallace E, Larrick JW, Chanock RM, Murphy BR, Fry K. Isolation andcharacterization of a chimpanzee monoclonal antibody to the G-glycoprotein of respiratory syncytial virus.Clinical and Diagnostic Laboratory Immunology 1994; 1: 701-6.9. Kulkarni, AB, Collins PL, Bacik I, Yewdell JW, Bennick JR, Crowe JE Jr., Murphy BR. Cytotoxic T cellsspecific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistanceinduced by immunization with M2 encoded by a recombinant vaccinia virus. Journal of Virology 1995; 69:1261-4.10. Hsu K-HL, Crowe JE Jr, Lubeck MD, Davis AR, Hung PP, Chanock RM, Murphy BR. Isolation andcharacterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis ofthe incompletely attenuated RSV A2 ts-1NG1 mutant virus. Vaccine 1995; 13: 509-15.11. Crowe JE Jr, Bui PT, Siber GR, Elkins WR, Chanock RM, Murphy BR. Cold-passaged, temperature sensitivemutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective inseronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 1995;13: 847-55.12. Connors M, Crowe JE Jr, Firestone CY, Murphy BR, Collins PL. A cold-passaged, attenuated strain ofhuman respiratory syncytial virus contains mutations in the F and L genes. Virology 1995; 208: 478-84.13. Crowe JE Jr, Bui PT, Firestone CY, Connors M, Elkins WR, Chanock RM, Murphy BR. Live subgroup Brespiratory syncytial virus (RSV) vaccines are attenuated, genetically stable, and immunogenic in rodents andnonhuman primates. Journal of Infectious Diseases 1996; 173: 829-39.14. Crowe JE Jr, Firestone C-Y, Whitehead SS, Collins PL, Murphy BR. Acquisition of the ts phenotype by achemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from theacquisition of a single mutation in the polymerase (L) gene. Virus Genes 1996; 13: 271-3.15. Firestone, C.Y., Whitehead, S., Collins, P.L., Murphy, B.R., Crowe, JE Jr. Nucleotide sequence analysis ofthe respiratory syncytial virus (RSV) subgroup A cold-passaged (cp), temperature sensitive (ts) cpts-248/404live attenuated virus vaccine candidate. Virology 1996; 225: 419-22.16. Juhasz K, Whitehead SS, Bui PT, Biggs JM, Boulanger CA, Crowe JE Jr, Collins PL, Murphy BR. Thetemperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccinecandidate, designated cpts530, results from a single amino acid substitution in the L protein. Journal ofVirology 1997; 71: 5814-9. Byline correction 71: 8953.17. Karron RA, Wright PF, Crowe JE Jr, Clements ML, Thompson J, Makhene M, Casey R, Murphy BR.Evaluation of two live cold-passaged, temperature-sensitive respiratory syncytial virus (RSV) vaccines inchimpanzees and human adults, infants and children. Journal of Infectious Diseases 1997; 176: 1428-36.18. Crowe JE Jr, Murphy BR, Chanock RM, Duan L, Pomerantz R, Gilmour PS, Pilkington G. Isolation of asecond recombinant human respiratory syncytial virus (RSV) monoclonal antibody fragment (Fab RSVF2-5)that exhibits therapeutic efficacy in vivo. Journal of Infectious Diseases 1998; 177: 1073-6.5419. Crowe JE Jr, Firestone C-Y, Crim R, Beeler JA, Burton DR, Chanock RM, Murphy BR. Monoclonal antibodyresistant mutants selected with an respiratory syncytial virus (RSV) neutralizing human antibody Fabfragment (Fab19) define a unique epitope on the fusion (F) glycoprotein. Virology 1998; 252: 373-5.20. Whitehead SS, Firestone C-Y, Karron RA, Crowe JE Jr., Elkins WR, Collins PL, Murphy BR. Addition of amissense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccinecandidate cpts248/404 increases its attenuation and temperature sensitivity. Journal of Virology 1999; 73: 871-7.21. Crowe JE Jr, Randolph V, Murphy BR. The live attenuated subgroup B respiratory syncytial virus vaccinecandidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the tsphenotype following replication in vivo. Virus Research 1999; 59: 13-22.22. Sakurai H, Williamson RA, Crowe JE, Beeler JA, Poignard P, Bastidas RB, Chanock RM, Burton DR.Human antibody responses to mature and immature forms of viral envelope in RSV infection: Significance forsubunit vaccines. Journal of Virology 1999; 73: 2956-62.23. Pastey MJ, Crowe JE Jr, Graham BS. RhoA Interacts with the fusion glycoprotein of respiratory syncytialvirus and facilitates virus-induced syncytium formation. Journal of Virology 1999; 73: 7262-70.24. Fisher RG, Crowe JE, Johnson TR, Tang YW, Graham BS. Passive IgA monoclonal antibody is no moreeffective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus. Journal ofInfectious Diseases 1999; 180: 1324 -7.25. Pastey MK, Gower TL, Spearman PS, Crowe JE Jr, Graham BS. A RhoA derived peptide inhibits syncytiumformation induced by respiratory syncytial virus and parainfluenza virus type 3. Nature Medicine 2000; 6: 35-40.26. Weitkamp J-H, Tang Y-W, Haas DW, Midha NK, Crowe JE Jr. Recurrent Achromobacter xylosoxidansbacteremia associated with persistent lymph node infection in a patient with Hyper IgM Syndrome. ClinicalInfectious Diseases 2000; 31: 1183-7.27. Peters TR, Brumbaugh DE, Lawton AR, Crowe JE Jr. Recurrent pneumococcal arthritis as the presentingmanifestation of X-linked agammaglobulinemia. Clinical Infectious Diseases 2000; 31: 1287-8.28. Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE Jr., Boyce TG, Halburnt LL, Reed GW,Whitehead SS, Anderson EL, Wittek AE, Casey R, Eichelberger M, Thumar B, Randolph VB, Udem SA,Chanock RM, Murphy BR. Evaluation of a live, cold-passaged temperature-sensitive, respiratory syncytialvirus (RSV) vaccine in infancy. Journal of Infectious Diseases 2000; 182: 1331-42.29. Crowe JE Jr, Firestone C-Y, Murphy BR. Passively acquired antibodies suppress local and systemicantibody responses, but not cell-mediated protective efficacy, in mice immunized with live attenuated RSVvaccines. Journal of Immunology, 2001; 167:3910-18.30. Weitkamp J-H, Crowe JE Jr. Blood donor leukocyte reduction filters as a source of human B lymphocytes.Biotechniques 2001; 31: 464-6.31. Peters TR, Jennings MT, Crowe JE Jr. Pneumocystis carinii pneumonia in a girl with a midbrain glioma.Pediatric Hematology and Oncology, 2002; 19:141-3.5532. Brock S, McGraw P, Wright PF, Crowe JE Jr. The human polymeric immunoglobulin receptor facilitatesinvasion of epithelial cells by Streptococcus pneumoniae in a strain-specific and cell-type specific manner.Infection and Immunity 2002; 70:5091-5.33. Crowe JE Jr., Sanella EC, Pfeiffer, Zorn G, Azimzadeh A, Miller GG, Newman R, and Pierson RN III. CD154blockade following cardiac allotransplantation inhibits the humoral immune response to influenza vaccine.American Journal of Transplantation 2003; 3:680-8.34. Weitkamp J-H, Kallewaard N, Kusuhara K, Feigelstock D, Feng N, Greenberg HB, Crowe JE Jr. Generationof recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected withfluorescent virus-like particles. Journal of Immunological Methods 2003; 275:223-37.35. Venter M, Rock MT, Puren AJ, Tiemessen CT, Crowe JE Jr. Respiratory syncytial virus nucleoproteinspecificcytotoxic T cell epitopes in a South African population of diverse HLA types are conserved incirculating field strains. Journal of Virology 2003; 77:7319-29.36. Rock MT, Crowe JE Jr. Identification of a novel HLA-A*01-restricted CTL epitope in the respiratorysyncytial virus fusion protein. Immunology 2003; 108:474-80.37. Halasa NB, Whitlock JA, McCurley TL, Smith J, Zhu Q, Ochs H, Dermody TS, Crowe JE Jr. Fatalhemophagocytic lymphohistiocytosis associated with Epstein-Barr Virus infection in a patient with a novelmutation in the SLAM-Associated Protein. Clinical Infectious Diseases 2003; 37:E136-41.38. Weitkamp JH, Kallewaard N, Kusuhara K, Bures E, Williams JV, LaFleur B, Greenberg HB, Crowe JE Jr.Infant and adult human B cell responses to rotavirus share common immunodominant variable generepertoires. Journal of Immunology 2003; 171: 4680-8.39. Brock S, Goldenring J, Crowe JE Jr. Apical recycling systems regulate directional budding of respiratorysyncytial virus from polarized epithelial cells. Proceedings of the National Academy of Sciences USA. 2003;100:15143-8.40. Williams JV, Harris PA, Tollefson SJ, Halburnt-Rush LL, Pingsterhaus JM, Edwards KM, Wright PF, CroweJE Jr. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children.New England Journal of Medicine 2004; 350: 443-50.**Cited: 5,820 times as of 01/07/201541. Rock MT, Yoder SM, Talbot TR, Edwards KM, Crowe JE Jr. Adverse events following smallpoximmunizations are associated with alterations of systemic cytokine levels. Journal of Infectious Diseases 2004;189; 1401-1410.42. Suara RO, Crowe JE Jr. Effect of zinc salts on respiratory syncytial virus replication, Antimicrobial Agentsand Chemotherapy 2004; 48:783-90.43. Talbot RR, Stapleton JT, Brady RC, Winokur PL, Bernstein DI, Germanson T, Yoder SM, Rock MT, Crowe JrJE, Edwards KM. Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: Arandomized controlled trial. Journal of the American Medical Association 2004; 292:1205-12.44. Kallewaard N, Bowen AL, Crowe JE Jr. Cooperativity of actin and microtubules in RSV replication.Virology 2005; 331:73-81.45. Tai JH, Williams JV, Edwards KM, Wright PF, Crowe JE Jr, Dermody TS. Prevalence of reovirus-specificantibody responses in young children in Nashville, TN. Journal of Infectious Diseases 2005; 191:1221-4.5646. Shaklee JF, Talbot TT, Muldowney JA, Vaughan DE, Butler J, House F, Crowe JE Jr, Smith LH, EdwardsKM. Smallpox vaccination does not elevate systemic levels of prothrombotic proteins associated with ischemiccardiac events. Journal of Infectious Diseases 2005; 191: 724-30.47. Chen X, Rock MT, Hammonds J, Tartaglia J, Shintami A, Currier J, Slike B, Crowe JE Jr, Marovich M,Spearman P. Pseudovirion particle production by a live poxvirus HIV vaccine vector enhances humoral andcellular immune responses. Journal of Virology 2005; 79:5537-47. PMC ID: 1082749.48. Rock MT, Yoder S, Wright PF, Talbot T, Edwards KM, Crowe JE Jr. Differential regulation of granzymeand perforin in effector and memory T cells following smallpox immunization. Journal of Immunology 2005;174:3757-64.49. Williams JV, Heymann PW, Tollefson SJ, Carper HT, Patrie J, Crowe JE Jr. Human metapneumovirusinfection in children hospitalized for wheezing. Journal of Allergy and Clinical Immunology 2005; 115:1311-2.50. Weitkamp JH, Kallewaard NL, Bowen AL, LaFleur BJ, Greenberg HB, Crowe JE Jr. VH1-46 is the dominantimmunoglobulin heavy chain gene segment in rotavirus -specific memory B cells expressing the intestinalhomingreceptor α4β7. Journal of Immunology 2005; 174:3454-60.51. Williams JV, Crowe JE Jr, Enriquez R, Minton P, Peebles S Jr, Hamilton RG, Higgins S, Griffin M, HartertTV. Human metapneumovirus plays an etiologic role in acute asthma hospitalizations in adults. Journal ofInfectious Diseases 2005; 192:1149-53. PMC ID: 1476781.52. Weitkamp JH, LaFleur BJ, Crowe JE Jr. Natural evolution of a human virus-specific antibody generepertoire by somatic hypermutation requires both hotspot-directed and randomly-directed processes, HumanImmunology, 2005; 66:666-76.53. Bentzen EL, House F, Utley TJ, Crowe JE Jr, Wright DW. Progression of respiratory syncytial virusinfection monitored by fluorescent quantum dot probes. Nano Letters 2005; 5:591-5.54. Williams JV, Martino R, Rabella N, Otegui M, Parody R, Heck JM, Crowe JE Jr. A prospective studycomparing human metapneumovirus with other respiratory viruses in adults with hematological malignanciesand respiratory tract infections. Journal of Infectious Diseases 2005; 192:1061-65.55. Rutigliano JA, Rock MT, Johnson AK, Crowe JE Jr, Graham BS. Identification of an H-2b-restricted CD8+cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus. Virology 2005; 337:335-43.56. Brock SC, Heck JM, McGraw PA, Crowe JE Jr. The transmembrane domain of the RSV F protein is anorientation-independent apical plasma membrane sorting sequence. Journal of Virology 2005; 79:12528-35.PMC ID: 1211512.57. Williams JV, Tollefson S, Johnson JE, Crowe JE Jr. The cotton rat (Sigmodon hispidus) is a highly permissivesmall animal model of human metapneumovirus infection, pathogenesis and protective immunity. Journal ofVirology 2005; 79:10944-51. PMC ID:1193579.58. Martino R, Porras RP, Rabella N, Williams JV, Ramila E, Margall N, Labeaga R, Crowe JE Jr, Coll P, Sierra J.Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratorytract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologicmalignancies. Biology of Blood and Marrow Transplantation 2005; 11:781-96.5759. Bentzen EL, House FS, Utley TJ, Crowe JE Jr, Wright DW. Detection of viral infections using colloidalquantum dots. Proceedings of SPIE V 2006; 6096:609611.60. Williams JV, Wang CK, Yang CF, Tollefson SJ, House FS, Heck JM, Chu M, Brown JB, Lintao LD, QuintoJD, Chu D, Spaete RR, Edwards KM, Wright PF, Crowe JE Jr. The role of human metapneumovirus in upperrespiratory tract infections in children: a 20-year experience. Journal of Infectious Diseases 2006; 193:387-95.PMC ID: 1586246.61. Bowen AL, Tian C, Lafleur B, Crowe JE Jr. Transcriptional control of activation-induced cytidinedeaminase (AID) and error-prone DNA polymerases is functionally mature in the B cells of infants at birth.Human Immunology 2006; 67:43-46.62. McKinney BA, Crowe JE Jr, Voss HU, Crooke PS, Barney N, Moore JH. Hybrid grammar-based approachto nonlinear dynamical system identification from biological time series. Physics Reviews E Statistical,Nonlinear, and Soft Matter Physics. 2006; 73:021912-1 to -7.63. Weitkamp JH, LaFleur BJ, Crowe JE Jr. Rotavirus-specific CD5+ B cells from young children exhibit adistinct antibody repertoire compared to CD5- B cells. Human Immunology 2006; 67:33-42.64. Rock MT, Yoder SM, Talbot TR, Edwards KM, Crowe JE Jr. Cellular immune responses to diluted andundiluted Aventis Pasteur smallpox vaccine. Journal of Infectious Diseases 2006;194:435-443.65. McKinney BA, Reif DM, Rock MT, Edwards KM, Kingsmore SF, Moore JH, Crowe JE Jr. Cytokineexpression patterns associated with systemic adverse events following smallpox immunization. Journal ofInfectious Diseases 2006; 194:444-53. PMC ID: 1620015.66. Venkataraman S, Allison D, Qi H, Morrell-Falvey JL, Kallewaard NK, Crowe JE Jr, Doktycz MJ. Automatedimage analysis of atomic force microscopy images of rotavirus particles. Ultramicroscopy 2006; 106:829-37.67. Reif DM, Motsinger AA, McKinney BA, Crowe JE Jr, Moore JH. Feature selection using a random forestclassifier for the integrated analysis of multiple data types. Proceedings of the IEEE Symposium onComputational Intelligence in Bioinformatics and Computational Biology 2006, pp. 171-178.68. Tian C, Kron GK, Dischert KM, Higginbotham JN, Crowe JE Jr. Low expression of the interleukin (IL)-4receptor alpha chain and reduced signalling via the IL-4 receptor complex in human neonatal B cells.Immunology 2006; 119:54-62. PMC ID: 1782340.69. Miller SA, Tollefson S, Crowe JE Jr., Williams JV, Wright DW. Examination of a fusogenic hexameric corefrom human metapneumovirus and identification of a potent synthetic peptide inhibitor from the heptadrepeat 1 region. Journal of Virology 2007; 81:141-9. PMC ID: 1797239.70. Cseke G, Wright DW, Tollefson SJ, Johnson JE, Crowe JE Jr, Williams JV. Human metapneumovirus fusionprotein vaccines that are immunogenic and protective in cotton rats. Journal of Virology 2007; 81:698-707. PMCID: 1797435.71. Tian CT, Kron GC, Dischert KM, Higginbotham JN, Shepherd BE, Crowe JE Jr. Evidence for preferential Iggene usage and differential TdT and exonuclease activities in human naive and memory B cells. MolecularImmunology 2007; 44:2173-83. PMC ID: 1859862.72. Greenbaum JA, Andersen PH, Blythe M, BuiH-H, Cachau RE, Crowe J, Davies M, Kolaskar AS, Lund O,Morrison S, Mumey B, Ofran Y, Pellequer J-L, Pinilla C, Ponomarenko JV, Raghava GPS, van RegenmortelMHV, Roggen E, Sette A, Schlessinger A, Sollner J, Zand M, Peters B. Towards a consensus on datasets and58evaluation metrics for developing B cell epitope prediction tools. Journal of Molecular Recognition 2007; 20:75–82.73. Lee S, Miller SA, Wright DW, Rock MT, Crowe JE Jr. Tissue-specific regulation of the pattern of CD8+ Tlymphocyte immunodominance in respiratory syncytial virus infection. Journal of Virology 2007; 81:2349-58.PMC ID: 1865932.74. Williams JV, Chen Z, Cseke G, Wright DW, Keefer CJ, Tollefson SJ, Podsiad A, Shepherd B, Crowe JE Jr,Williamson RA. A recombinant human monoclonal antibody to human metapneumovirus fusion protein thatneutralizes virus in vitro and is effective therapeutically in vivo. Journal of Virology 2007; 81:8315-24. PMC ID:1951312.75. McKinney BA, Reif DM, White BC, Crowe JE Jr, Moore JH. Evaporative cooling feature selection forgenotypic data involving interactions. Bioinformatics 2007; 23:2113-20.76. McKinney BA, Kallewaard NL, Crowe JE Jr, Meiler J. Using the natural evolution of a rotavirus-specifichuman monoclonal antibody to predict the complex topography of a viral antigenic site. Immunome Research2007; 3:8. PMC ID: 2042970.77. Mok H, Lee S, Utley TJ, Shepherd BE, Polosukhin VV, Collier ML, Davis NL, Johnston RE, Crowe JE Jr.Venezuelan equine encephalitis replicon particle vaccines encoding respiratory syncytial virus surfaceglycoproteins induce mucosal responses and protection in mice and cotton rats. Journal of Virology 2007;81:13710–22. PMC ID: 2168850.78. Tian C, Luskin GK, Dischert KM, Higginbotham JN, Shepherd BE, Crowe JE Jr. Immunodominance of theVH1-46 antibody gene segment in the primary repertoire of human rotavirus-specific B cells is reduced in thememory compartment through somatic mutation of nondominant clones. Journal of Immunology 2008;180:3279-88.79. Kallewaard NL, McKinney BA, Gu Y, Chen A, Prasad BVV, Crowe JE Jr. Functional maturation of thehuman antibody response to rotavirus. Journal of Immunology 2008; 180:3980-9.80. Reif DM, McKinney BA, Motsinger AA, Chanock SJ, Edwards KM, Rock MT, Moore JH, Crowe JE Jr.Genetic basis for adverse events following smallpox vaccination. Journal of Infectious Diseases 2008; 198:16-22. PMC ID: 2746083.Accompanying editorial by Relman.81. Yu X, McGraw PA, House FS, Crowe JE Jr. An optimized electrofusion-based protocol for generating virusspecifichuman monoclonal antibodies. Journal of Immunological Methods 2008; 336:142-151. PMC ID:2519117.82. Utley TJ, Ducharme N, Varthakavi V, Shepherd B, Santangelo P, Lindquist M, Goldenring JR, Crowe JE Jr.Respiratory syncytial virus uses a Vps4-independent budding mechanism controlled by Rab11-FIP2.Proceedings of the National Academy of Sciences USA 2008; 105:10209-14. PMC ID: 2481327.83. Yu X, Tsibane T, McGraw PA, House F, Keefer CJ, Hicar MD, Tumpey T, Pappas C, Perrone, Martinez O,Stevens J, Wilson I, Aguilar, Altschuler E, Basler C, Crowe JE Jr. Neutralizing antibodies derived from the Bcells of 1918 influenza pandemic survivors. Nature 2008; 455:532-536. PMC ID: 2848880. Corrigendum: Nature.2012 Sep 26. doi: 10.1038/nature11235.Faculty of 1000 Biology Must Read84. Mok H, Tollefson SJ, Podsiad AB, Shepherd BE, Polosukhin VV, Johnston RE, Williams JV, Crowe JE Jr. An59alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice andcotton rats. Journal of Virology 2008; 82:11410-8. PMC ID: 2573258.85. Mok H, Lee S, Wright DW, Crowe JE Jr. Enhancement of the CD8+ T cell response to a subdominantepitope of respiratory syncytial virus by deletion of an immunodominant epitope. Vaccine 2008; 26:4775-82.PMC ID: 2561208.86. Derdowski A, Peters TR, Glover N, Qian R, Williams JV, Burnett A, Utley T, Spearman P, Crowe JE Jr. Thehuman metapneumovirus nucleoprotein and phosphoprotein interact and provide the minimal requirementsfor inclusion body formation. Journal of General Virology 2008; 89: 2698 – 2708. PMC ID: 2876975.Cover illustration.87. Reif DM, Motsinger-Reif AA, McKinney BA, Rock MT, Crowe JE Jr, Moore JH. Integrated analysis ofgenetic and proteomic data identifies biomarkers associated with adverse events following smallpoxvaccination. Genes and Immunity 2009; 10:112-119. PMC ID: 2692715.88. McKinney BA, Crowe JE Jr, Guo J, Tian D. Capturing the spectrum of interaction effects in geneticassociation studies by simulated evaporative cooling network analysis. PLoS Genetics 2009; 5(3): e1000432.PMC ID: 2653647.89. Nam KT, Lee H-J, Mok H, Romero-Gallo J, Crowe JE Jr, Peek RM Jr, and Goldenring JR. Amphiregulindeficientmice develop spasmolytic polypeptide expressing metaplasia, intestinal metaplasia and invasiveneoplasia. Gastroenterology 2009; 136:1288-96, PMC2844775.90. Talbot HK, Crowe JE Jr, Edwards KM, Griffin MR, Zhu Y, Weinberg G, Szilagy PG, Hall CB, Podsiad AB,Iwane M, Williams JV. Coronavirus infection and hospitalizations for acute respiratory illness in youngchildren. Journal of Medical Virology 2009; 81:853-856. PMC ID: 2767383.91. Moore ML, Chi MH, Luongo C, Lukacs NW, Polosukhin VV, Huckabee MM, Newcomb DC, Buchholz UJ,Crowe, JE Jr, Goleniewska K, Williams JV, Collins PL, Stokes Peebles RS Jr. A chimeric A2 strain respiratorysyncytial virus (RSV) with the fusion protein of RSV strain Line 19 exhibits enhanced viral load, mucus, andairway dysfunction. Journal of Virology 2009; 83:4185-94. PMC ID: 2668460.92. Talbot HK, Shepherd BE, Crowe JE Jr, Griffin MR, Edwards KM, Podsiad AB, Tollefson SJ, Wright PF,Williams JV. The pediatric burden of human coronaviruses evaluated over 20 years. Pediatric InfectiousDiseases 2009; 28:682-687. PMC ID: 2765860.93. Santangelo PJ, Lifland AW, Curt P, Sasaki Y, Bassell GJ, Lindquist ME, Crowe JE Jr. MTRIPs: Singlemolecule sensitive probes for imaging native RNA in live cells. Nature Methods 2009; 6:347-9. PMID: 19349979.94. Williams JV, Weitkamp J-H, Blum DL, LaFleur BJ, Crowe JE Jr. The human neonatal B cell response torespiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations.Molecular Immunology 2009; 47:407-414. PMC ID: 2788105.95. Yang C-F, Wang CK, Tollefson SJ, Piyaratna R, Lintao LD, Chu M, Liem A, Mark M, Spaete RR, Crowe JEJr, Williams JV. Genetic diversity and evolution of human metapneumovirus fusion protein over twenty years.Virology Journal 2009; 6:138, PMC ID: 2753315.96. Williams JV, Edwards KM, Weinberg GA, Iwane MK, Griffin MR, Hall CB, Zhu Y, Szilagyi PG, Wang CK,Yang C-F, Silva D, Ye D, Chu M, Ta A, Spaete RR, Crowe JE Jr. Population-based incidence of humanmetapneumovirus in hospitalized children. Journal of Infectious Diseases 2010; 201:1890-8, PMC ID: 2873123.6097. Krause JC, Tumpey TM, Huffman CJ, McGraw PA, Pearce MB, Tsibane T, Hai R, Basler CF, Crowe JE Jr.Naturally-occurring human monoclonal antibodies potently neutralize both 1918 and 2009 A (H1N1)pandemic influenza viruses. Journal of Virology 2010; 84: 3127-30, PMC ID: 2826039.98. Xu R, Ekiert DC, Krause JC, Palese P, Crowe JE Jr, Wilson IA. Structural basis of pre-existing immunity tothe 2009 H1N1 pandemic influenza virus. Science 2010; 328:357-60. PMC ID: 2897825.99. Hicar MD, Chen X, Briney B, Hammonds J, Wang J-J, Kalams S, Spearman PW, Crowe JE Jr. Pseudovirionparticles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizingmonoclonal antibodies against HIV. Journal of Acquired Immunodeficiency Syndrome 2010; 54:223-235. PMCID: 2930513.100. Davis NA, Crowe JE Jr., Pajewski NM, McKinney BA. Surfing a genetic association interaction network toidentify modulators of antibody response to smallpox vaccine. Genes and Immunity 2010; 11:630-6. PMC ID:3001955.101. Lindquist ME, Lifland AW, Utley TJ, Santangelo PJ, Crowe JE Jr. Respiratory syncytial virus induces hostRNA stress granules to facilitate viral replication. Journal of Virology 2010; 84:12274-84. PMC ID: 2976418.Priority Paper, reviewed in Future Virology 2011; 6:295-298.102. Thornburg N, Shepherd BE, Crowe JE Jr. TGF-β is a major regulator of altered neonatal human immuneresponses following respiratory syncytial virus infection of dendritic cells. Journal of Virology 2010; 12895-902.PMC ID: 3004333.103. Pishchany G, McCoy AL, Torres VJ, Krause JC, Crowe JE Jr, Fabry ME, Skaar EP. Specificity for humanhemoglobin enhances Staphylococcus aureus virulence. Cell Host Microbe 2010; 8:544-550. PMC ID: 3032424.104. Engelhardt BG, Jagasia M, Bratcher NL, Greer JP, Jiang A, Kassim AA, Lu P, Schuening F, Yoder SM, RockMT, Crowe JE Jr. Regulatory T cell expression of CLA or α4β7 and skin or gut acute GVHD outcomes. BoneMarrow Transplantation 2011; 46:436-42. PMC ID: 3217583.105. Monsalvo AC, Batalle JP, Krause JC, Klemenc J, Zea J, MaskinB, Bugna J, Rubinstein C, Aguilar L, DalurzoL, Libster R, Savy V, Baumeister E, Aguilar L, Cabral G, Font J, Solari L, Weller K, Johnson J, Echavarria M,Edwards KM, Chappell JD, Crowe JE Jr, Williams JV, Melendi GA, Polack FP. Severe pandemic 2009 H1N1influenza disease due to pathogenic immune complexes. Nature Medicine 2011; 17:195-9. PMC ID: 3034774.106. Krause JC, Ekiert DC, Tumpey TM, Smith PB, Wilson IA, Crowe JE Jr. An insertion mutation that distortsantibody binding site architecture enhances function of a human antibody. mBio 2011; 2:e00345-10. PMC ID:3037006.107. Lindquist ME, Mainou B, Dermody T, Crowe JE Jr. Activation of protein kinase R is required forinduction of stress granules by respiratory syncytial virus but dispensable for viral replication. Virology 2011;413:103–110. PMC ID: 3072468.108. Joyner AS, Willis JR, Crowe JE Jr, Aiken C. Maturation-induced cloaking of neutralization epitopes onHIV-1 particles. PLoS Pathogens 2011; 7(9): e1002234. doi:10.1371/journal.ppat.1002234. PMC ID: 3169560.109. Rock MT, McKinney BA, Yoder SM, Prudom CE, Wright DW, Crowe JE Jr. Identification of potentialhuman respiratory syncytial virus and metapneumovirus T cell epitopes using computational prediction andMHC binding assays. Journal of Immunological Methods 2011; 374:13-17. PMC ID: 3220792.61110. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Briney BS, Smith SA, Basler CF, Crowe JE Jr. Epitopespecifichuman antibody repertoires diversify by B cell intraclonal sequence divergence and interclonalconvergence. Journal of Immunology 2011; 187:3704-11. PMC ID: 3178754.Featured in Journal of Immunology “In this Issue” highlights and the Immunocast podcast.111. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF, Crowe JE Jr. A broadly neutralizing humanmonoclonal antibody that recognizes a conserved, novel epitope on the globular head of influenza H1N1 virushemagglutinin. Journal of Virology 2011; 85:10905-08. PMC ID: 3187471.112. Zhang GL, Ansari HR, Bradley P, Cawley GC, Hertz T, Hu X, Huang JC, Jojic N, Kim Y, Kohlbacher O, LundO, Lundegaard C, Magaret CA, Nielsen M, Papadopoulos H, Raghava GPS, Tal V-S, Xue L, Yanover C, Zhang H,Zhu S, Rock MT, Crowe JE Jr, Panayiotou C, Polycarpou MM, Duch W, Brusic V. Machine learning competitionin immunology – Prediction of HLA class I molecules. Journal of Immunological Methods 2011; 374:1-4. PMID:21986107.113. Smith SA, Zhou Y, Olivarez NP, Broadwater AH, de Silva AM, Crowe JE Jr. Persistence of circulating Bmemory cell clones with potential for dengue virus disease enhancement for decades following infection.Journal of Virology 2012; 86:2665-75. PMC ID: 3302281.114. Wen X, Krause JC, Leser JC, Lamb RA, Williams JV, Crowe JE Jr, Jardetsky TS. The structure of the humanmetapneumovirus fusion protein in complex with a human neutralizing antibody. Nature Structural andMolecular Biology 2012; 19:461-3. PMC ID: 3546531.114. Dochow M, Krumm SA, Crowe JE Jr, Moore ML, Plemper RK. Independent structural domains inparamyxovirus polymerase proteins. Journal of Biological Chemistry 2012; 287: 6878-6891. PMC ID: 3307299.115. Shaikh FY, Cox RG, Lifland AW, Hotard AL, Williams JV, Moore ML, Santangelo PJ, Crowe JE Jr. Acritical phenylalanine residue in the respiratory syncytial virus fusion protein cytoplasmic tail mediatesassembly of internal viral proteins into viral filaments and particles. mBio 2012; 3(1):e00270-11. doi: 10.1128.PMC ID: 3280462.116. Engelhardt BG, Griffith ML, Crowe JE Jr, Kassim AA, Lu P, Weitkamp JH, Moore D, Yoder S, Rock MT,Jagasia SM, Jagasia M. Predicting post-transplant diabetes mellitus by regulatory T cell phenotype: Implicationsfor metabolic intervention to modulate alloreactivity. Blood 2012; 119:2417-21. PMC ID: 3311262.117. de Alwis AR, Smith SA, Olivarez NP, Messer WB, Hynh JP, Wahala WMPB, White LJ, Baric RS, Crowe JEJr, de Silva AM. Molecular basis of dengue virus neutralization by human antibodies. Proceedings of theNational Academy of Sciences USA, 2012; 109:7439-44. PMC ID: 3358852.Faculty of 1000 Exceptional selection118. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Albrecht R, Blum D, Ramos I, Fernandez-Sesma A,Edwards KM, García-Sastre A, Basler CF, Crowe JE Jr. Human monoclonal antibodies to pandemic 1957 H2N2influenza virus target the receptor-binding domain. Journal of Virology 2012; 86:6334-40. PMC ID: 3372199.119. Briney BS, Willis JR, McKinney BA, Crowe JE Jr. High-throughput antibody sequencing reveals geneticevidence of global regulation of the naïve and memory repertoires that extends across individuals. Genes andImmunity 2012; 13:469-73. PMID: 22622198. PMC Journal - In Process.120. Briney BS, Willis JR, Crowe JE Jr. Human peripheral blood antibodies with long HCDR3s are establishedprimarily at original recombination using a limited subset of germline genes. PLoS ONE 2012; 7:e36750. PMCID: 3348910.62121. Briney BS, Willis JR, Hicar MD, Thomas, JW II, Crowe JE Jr. Frequency and genetic characterization ofnon-12/23 recombinants in the human peripheral blood antibody repertoire. Immunology 2012; 137:56-64.PMC ID: 3449247.122. Briney BS, Willis JR, Crowe JE Jr. Location and length distribution of somatic hypermutation-associatedDNA insertions and deletions reveals regions of antibody structural plasticity. Genes and Immunity 2012;13:523-9. PMC ID: 3449029.123. Lifland A, Jung J, Alonas E, Zurla C, Crowe JE Jr, Santangelo P. Human respiratory syncytial virusnucleoprotein and inclusion bodies antagonize the innate immune response mediated by MDA5 and MAVS.Journal of Virology 2012; 86:8245-58. PMC ID: 3421640.124. Shaikh FY, Utley TJ, Craven RE, Rogers MC, Lapierre LA, Goldenring JR, Crowe JE Jr. Respiratorysyncytial virus assembles into structured filamentous virion particles independently of host cytoskeleton andrelated proteins. PLoS ONE 2012; 7:e40826. PMC ID: 3396619.125. Engelhardt BG, Sengsayadeth SM, Jagasia M, Savani BN, Kassim AA, Lu P, Shyr Y, Yoder SM, Rock MT,Crowe JE Jr. Tissue-specific regulatory T cells: Biomarker for acute graft-versus-host disease and survival.Experimental Hematology 2012; 40:974-982.e1. PMC ID: 3611587.126. Hayakawa M, Toda N, Carrillo N, Thornburg NJ, Crowe JE Jr, Barbas CF III. Chemically programmedantibody is a long-lasting and potent inhibitor of influenza neuraminidase. ChemBioChem 2012; 13: 2191–2195.PMC ID: 3517015.127. Hotard AL, Shaikh FY, Lee S, Yan D, Teng MN, Plemper RK, Crowe JE Jr, Moore ML. A stabilized RNAvirus reverse genetics system amenable to recombination mediated mutagenesis. Virology 2012; 434:129-36.PMC ID: 3492879.128. Tsibane T, Ekiert DC, Krause JC, Martinez O, Crowe JE Jr*, Wilson IA*, Basler CF*. Influenza humanmonoclonal antibody 1F1 interacts with two major antigenic sites and residues mediating human receptorspecificity in H1N1 viruses. PLoS Pathogens 2012; 8: e1003067. doi:10.1371/journal.ppat.1003067. PMC ID:3516549.*corresponding129. Thornburg N, Hayward SL, Crowe JE Jr. Respiratory syncytial virus regulates human microRNAsmanner using mechanisms involving interferon beta and NF-κB. mBio 2012 3(6). doi:pii: e00220-12. PMC ID:3529541.130. Benhnia MR, Maybeno M, Blum D, Aguilar-Sino R, Matho M, Head S, Felgner PL, Zajonc DM, KoriazovaL, Kato S, Burton DR, Xiang Y, Crowe JE Jr, Peters B, Crotty S. Unusual features of vaccinia virus extracellularvirion form (EV) neutralization resistance revealed in human antibody responses to the smallpox vaccine.Journal of Virology 2013; 87:1569-85. PMC ID: 3554146.131. Xu R, Krause JC, McBride R, Paulson JC, Crowe JE Jr*, Wilson IA*. A recurring motif for antibodyrecognition of the most conserved portion of the receptor-binding site of influenza hemagglutinin. NatureStructural and Molecular Biology 2013; 20:363-70. PMC ID: 3594569.*corresponding132. Zeitlin L, Bohorov O, Bohorova N, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Barnard DL, BatesJT, Crowe JE Jr, Piedra PA, Gilbert BE. Prophylactic and therapeutic testing of Nicotiana-derived anti-RSVhuman monoclonal antibodies in the cotton rat model. mAbs 2013; 5:2, 1-7. PMC ID: 3893236.63133. Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, Crowe JE Jr. Human monoclonalantibodies derived from memory B cells following live attenuated dengue virus vaccination or naturalinfection exhibit similar characteristics. Journal of Infectious Diseases, 2013; 207:1898-908. PMC ID: 3654755.Faculty of 1000 selection.134. Bates JT, Keefer CJ, Utley TJ, Correia BE, Schief WR, Crowe JE Jr. Reversion of somatic mutations of therespiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship betweenassociation rate and neutralizing potency. Journal of Immunology 2013; 190:3732-9. PMC ID: 3608519.135. Gilchuk P, Spencer CT, Conant SB, Hill T, Niu X, Zheng M, Erickson J, Boyd K, McAfee K, Oseroff C,Hadrup SR, Bennink JR, Hildebrand W, Edwards K, Crowe JE Jr, Williams JV,Buus S, Sette A, Schumacher TN, Link AJ, Joyce S. Discovering protective T-cell responses by interrogatingnaturally processed antigenic determinants. Journal of Clinical Investigation, 2013; 123:1976-87. PMC ID:3635741.136. Aiyegbo MS, Sapparapu G, Spiller BW, Eli IM, Williams DR, Kim R, Lee DE, Liu T, Li S, Woods VL Jr,Nannemann DP, Meiler J, Stewart PL, Crowe JE Jr. Human rotavirus VP6-specific antibodies mediateintracellular neutralization by binding to a quaternary structure in the transcriptional pore. PLoS ONE 2013;8:e61101. PMC ID: 3650007.137. Willis JR, Briney BS, DeLuca SL, Crowe JE Jr, Meiler J. Human germline antibody gene segments encodepolyspecific antibodies. PLoS Computational Biology 2013; 9(4): e1003045. PMC ID: 3636087.138. Stone JW, Thornburg NJ, Blum DL, Kuhn SJ, Wright DW, Crowe JE Jr. Gold nanorod vaccine forrespiratory syncytial virus. Nanotechnology 2013; 24:295102. PMC ID: 3754908.- Short-listed, 2013 Institution of Chemical Engineers (IChemE) Awards for chemical engineering innovation andexcellence, in the Health & Safety Category.139. Thornburg NJ, Blum DL, Belser JA, Tumpey TM, Desphande S, Fritz GA, Krause JC, Winarski KL, SpillerBW, Nannemann DP, Meiler J, Crowe JE Jr. Human antibodies that neutralize respiratory droplettransmissible H5N1 influenza viruses. Journal of Clinical Investigation 2013; 123:4405-9. PMC ID: 3784541.140. Sapparapu G, Sims AL, Aiyegbo MS, Shaikh FY, Harth EM, Crowe JE Jr. Intracellular neutralization of avirus using a cell-penetrating molecular transporter. Nanomedicine (Lond) 2014; 9:1613-24. PMID: 24195674.PMC Journal - In Process.141. Hong M, Lee PS, Hoffman RM, Zhu X, Krause JC, Laursen NS, Yoon SI, Song L, Tussey L, Crowe JE Jr,Ward AB, Wilson IA. Antibody recognition of the pandemic H1N1 influenza hemagglutinin receptor bindingsite. Journal of Virology 2013; 87:12471-80. PMC ID: 3807900.142. Smith SA, de Alwis AR, Kose N, Harris E, Ibarra K, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM,Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE Jr. The potent and broadly neutralizing human denguevirus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II ofthe envelope protein. mBio 2013; 4(6). doi:pii: e00873-13.10. PMC ID: 3870244.143. Alonas E, Lifland AW, Gudheti M, Vanover D, Jung J, Zurla C, Kirschman J, Fiore VF, Douglas A, BarkerH, Moore ML, Crowe JE Jr, Santangelo PJ. Combining single RNA sensitive probes with subdiffraction-limitedand live-cell imaging enables the characterization of virus dynamics in cells. ACS Nano 2013; 8:302-15. PMCID: 3906890.64144. Aiyegbo MS, Eli IM, Spiller BW, Williams DR, Kim R, Lee DE, Liu T, Li S, Stewart PL, Crowe JE Jr.Differential accessibility of a rotavirus VP6 epitope in trimers comprising Type I, II, or III channels as revealedby binding of a human rotavirus VP6-specific antibody. Journal of Virology 2014; 88: 469-476. PMC ID:3911710.145. Correia BE, John T. Bates JT, Loomis RJ, Baneyx G, Jardine JG, Rupert P, Carrico C, Correnti C,Kalyuzhniy O, Vittal V, Connell MJ, Stevens E, Schroeter A, Chen M, MacPherson S, Adachi Y, Holmes MA, LiY, Klevit RE, Graham BS, Wyatt RT, Baker D, Strong RK, Crowe JE Jr, Johnson PR, Schief WR. Proof ofprinciple for epitope-focused vaccine design. Nature 2014; 507:201-6. PMC ID: 4260937.Faculty of 1000 selection.146. Fibriansah G, Tan J, de Alwis R, Smith SA, Ng T-S, Kostyuchenko V, Ibarra K, Harris E, de Silva A, CroweJE Jr, Lok S-M. A potent anti-dengue human antibody preferentially recognizes the conformation of E proteinmonomers assembled on the virus surface. EMBO Molecular Medicine 2014; 6:358-71. PMC ID: 3958310.Faculty of 1000 selection.147. Messer WB, de Alwis R, Yount BL, Royal SR, Huynh JP, Smith SA, Crowe JE Jr, Doranz BJ, Kahle KM,Pfaff JM, White LJ, Sariol CA, de Silva AM, Baric RS. Dengue virus envelope protein domain I/II hingedetermines long-lived serotype-specific dengue immunity. Proceedings of the National Academy of SciencesUSA 2014; 111:1939-44. PMC ID: 3918811.148. Bates JT, Keefer CJ, Slaughter JC, Kulp DW, Schief WR, Crowe JE Jr. Escape from neutralization by therespiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in onrateof binding to the fusion protein. Virology 2014; 454-455:139-44. PMC ID: 4004766.149. Dulek DE, Newcomb DC, Toki S, Goliniewska K, Cephus J, Reiss S, Bates JT, Crowe JE Jr, Boyd K, MooreML, Zhou W, Peebles RS Jr. STAT4-deficiency fails to induce lung Th2 or Th17 immunity following primary orsecondary respiratory syncytial virus challenge but enhances the lung RSV-specific CD8+ T cell immuneresponse to secondary challenge. Journal of Virology 2014; 88:9655-72. PMC ID: 4136353.150. Briney BS, Willis JR, Finn JA, McKinney BA, Crowe JE Jr. Tissue-specific expressed antibody variable generepertoires. PLoS One 2014; 9(6):e100839. doi: 10.1371/journal.pone.0100839. PMC ID: 4067404.151. Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE Jr. Isolation of dengue virus-specificmemory B cells with live virus antigen from human subjects following natural infection reveals the presence ofdiverse novel functional groups of antibody clones. Journal of Virology 2014; 88(21):12233-41. PMC ID:4248927.152. de Alwis AR, Williams KL, Schmid MA, Wang W, Smith S, Crowe JE Jr., Harris E, Bhumi P, de Silva AM.Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immunesera. PLoS Pathogens 2014, 10(10):e1004386. PMC ID: 4183589.153. Hotard AL, Lee S, Currier MG, Crowe JE Jr, Sakamoto K, Newcomb DC, Peebles RS Jr, Plemper RK,Moore ML. Identification of residues in the human respiratory syncytial virus fusion protein that modulatefusion activity and pathogenesis. Journal of Virology 2015 ;89 :512-22. PMC ID: 4301159154. Flyak, AI, Ilinykh PA, Murin CD, Garron T, Shen X, Fusco ML, Hashiguchi T, Bornholdht ZA, SlaughterJC, Sapparapu G, Ksiazek TG, Ward AB, Ollmann Saphire E, Bukreyev A, Crowe JE Jr. Mechanism of humanantibody-mediated neutralization of Marburg virus. Cell 2015; 160: 893 – 903. PMC ID: 4344968.Journal cover65155. Hashiguchi T, Fusco ML, Bornholdht ZA, Lee JE, Murin CD, Flyak AI, Li S, Matsuoka R, Kohda D, YanagiY, Sanner M, Ward AB, Crowe JE Jr, Ollmann Saphire E. Structural basis for Marburg and Ebola virus crossreactivityby a human survivor antibody. Cell 2015; 160: 904 – 912. PMC ID: 4344967.Journal cover156. Fibriansah G, Tan JL, Smith SA, de Alwis R, Ng T-S, Kostyuchenk VA, Jadi RS, Petra Kukkaro P, de SilvaAM, Crowe JE Jr, Lok S-M. Extremely potent human antibody neutralizes dengue virus serotype 3 by bindingacross three surface proteins. Nature Communications, 2015; 6:6341. PMC ID: 4346626.157. Hooper KA, Crowe JE Jr, Bloom JD. Influenza viruses with receptor-binding N1 neuraminidases occursporadically in several lineages and replicate to wild-type levels in tissue culture or mice. Journal of Virology2015; 89:3737-45. PMC ID: PMC4403400.158. Keitel WA, Jackson LA, Edupuganti S, Winokur P, Mulligan MJ, Thornburg NJ, Patel SM, Rouphael NG,Wanger N, Lai L, Bangaru S, McNeal MM, Bellamy AR, Hill HR, for the VTEU H3N2v Vaccine Study WorkGroup [Atmar RL, El Sahly HM, Ellebedy AH, Kelley C, Edwards KM, Crowe JE Jr]. Safety andimmunogenicity of a subvirion monovalent unadjuvanted inactivated influenza A/H3N2 variant (H3N2v)vaccine in healthy persons ≥ 18 years old. Journal of Infectious Diseases 2015; 212:552-561. PMC ID 4539893.159. Willis JR, Sapparapu G, Moola S, Julien J-P, Singh V, King HG, Xia Y, Pickens JA, Labranche CC, Finn JS,Briney BS, Montefiori DC, Wilson IA, Meiler J, Crowe JE Jr. Redesigned PG9 variant monoclonal antibodiesthat exhibit enhanced HIV neutralizing potency and breadth. Journal of Clinical Investigation 2015; 125:2523-31. PMC ID 4497764160. Sevy AM, Jacobs TM, Crowe JE Jr, Meiler J. Design of protein multi-specificity using an independentsequence search reduces the barrier to low energy sequences. PLoS Computational Biology 2015;11(7):e1004300. PMC ID 4493036.161. Fibriansah G, Ibarra KD, Ng T-S, Smith SA, Tan JL, Lim X-N, Ooi JSG, Kostyuchenko VA, Wang J, de SilvaAM, Harris E, Crowe JE Jr*, Lok S-M*. CryoEM structure shows antibody neutralizes dengue virus serotype 2by locking E protein dimers. Science 2015; 349:88-91. PMC ID 4672004.162. Callaway JB, Smith SA, McKinnon KP, de Silva AM, Crowe JE Jr, Ting J.P.-Y. Spleen tyrosine kinasemediates elevated secretion of IL-1beta by primary human monocytes after antibody-enhanced dengue virusinfection. Journal of Biological Chemistry 2015; 28:17306–17320. PMC ID 4498069.163. Winarski KL, Thornburg NJ, Yu Y, Sapparapu G, Crowe Jr JE, Spiller BW. Vaccine-elicited antibody thatneutralizes influenza H5N1 and variants binds the receptor site and polymorphic sites. Proceedings of theNational Academy of Sciences USA 2015; 112:9346-51. PMC ID 4522792.164. Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Ashbrook AW, Kahle KM,Fong RH, Swayne S, Doranz BJ, McGee CE, Heise MT, Pal P, Brien JD, Austin SK, Diamond MS, Dermody TS,Crowe JE Jr. Broad and ultrapotent human monoclonal antibodies with therapeutic activity againstchikungunya virus. Cell Host and Microbe 2015; 18:86–95. PMC ID 4501771.165. Chukwuma VU, Hicar MD, Chen X, Nicholas KJ, Joyner A, Kalams SA, Landucci G, Forthal DN,Spearman PW, Crowe JE Jr. Association of VH4-59 antibody variable gene usage with recognition of animmunodominant epitope on the HIV-1 Gag protein. PLoS ONE 2015;10(7):e0133509. PMC ID 4520566.166. Callaway JB, Widman DG, Smith SA, McKinnon KP, Dittmer DP, Crowe JE Jr, de Silva AM, Ting JP-Y.Source and purity of dengue-viral preparations impact requirement for enhancing antibody to induce elevatedIL-1β secretion: A primary human monocyte model. PLoS ONE 2015;10(8):e0136708. PMC ID 4547738.66167. Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Sariol CA, Crowe JE Jr, deSilva AM, Baric RS. A new quaternary structure epitope on dengue virus serotype 2 is the target of durabletype specific neutralizing antibodies. mBio 2015; 6: p. e01461-15. PMC ID 4620467.168. Long F, Fong RH, Austin SK, Chen Z, Klose T, Fokine A, Liu Y, Porta J, Sapparapu G, Akahata W, DoranzBJ, Crowe JE Jr, Diamond MS, Rossmann MG. Cryo-EM structures elucidate neutralizing mechanisms of antichikungunyahuman monoclonal antibodies with therapeutic activity. Proceedings of the National Academyof Sciences USA 2015; 112:13898-13903. PMID: 26504196. PMC Journal - In Process.169. Fox JM, Long F, Edeling MA, Lin H, Duijl-Richter MKS, Fong RH, Smit JM Doranz BJ, Crowe JE Jr,Fremont DH, Rossmann MG, Diamond MS. Protective monoclonal antibodies recognizing multiplearthritogenic alphaviruses bind a single epitope and inhibit both viral entry and egress. Cell 2015; 163:1095-1107. PMC ID 4659373.170. Smith SA, Nivarthi U, de Alwis R, Kose N, Sapparapu G, Bombardi R, Kahle K, Pfaff JM, Swayne S,Doranz B, de Silva A, Crowe JE Jr. Diverse naturally-occurring dengue virus prM-specific human monoclonalantibodies with virus replication enhancing properties recognize a single immunodominant antigenic site. Inpress, Journal of Virology 2015; 90:780-789. PMID: 26512092. PMC Journal - In Process.171. Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh PA, KuzminaN, Branchizio A, King H, Brown L, Bryan C, Davidson E, Doranz BJ, Slaughter JC, Sapparapu G, Klages C,Ksiazek TG, Saphire EO, Ward AB, Bukreyev A, Crowe JE Jr. Cross-reactive and potent neutralizing antibodyresponses in human survivors of natural Ebolavirus infection. In press, Cell 2016. PMC Journal - In Process.172. Hicar MD, Chen X, Kalams SA, Sojar H, Landucci G, Forthal DN, Spearman PW, Crowe JE Jr. Lowfrequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitopetargeting antibodies containing large numbers of somatic mutations. Molecular Immunology 2016 70:94–103.PMID: 26748387, PMC Journal - In Process.173. Bates JT, Pickens JA, Schuster JE, Johnson M, Tollefson SJ, Williams JV, Davis NL, Johnston RE, Schultz-Darken N, Slaughter JC, Smith-House F, Crowe JE Jr. Immunogenicity and efficacy of alphavirus-derivedreplicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates. Inpress, Vaccine 2016. PMC Journal - In Process.174. Bornholdt ZA, Ndungo E, Fusco ML, Bale S, Flyak A, Crowe JE Jr, Chandran K, Ollmann Saphire E. HostprimedEbola virus GP exposes a hydrophobic NPC1 receptor-binding pocket, revealing a target for broadlyneutralizing antibodies. In press, mBio 2016.175. Thornburg NJ, Zhang H, Bangaru S, Sapparapu G, Kose N, Lampley RM, Bombardi RG, Yu Y, Graham S,Branchizio A, Yoder SM, Rock MT, Creech CB, Edwards KM, Lee D, Li S, Wilson IA, García-Sastre A, AlbrechtRA, Crowe JE Jr. H7N9 influenza virus neutralizing antibodies that possess few somatic mutations. In press,Journal of Clinical Investigation 2016.176. Ilinykh P, Shen X, Flyak AI, Kuzmina N, Ksiazek TG, Crowe JE Jr, Bukreyev A. Chimeric filoviruses foridentification and characterization of monoclonal antibodies. In press, Journal of Virology 2016.177. Engelhardt BG, Jung DK, Jagasia M, Savani BN, Chinratanalab W, Cornell RF, Goodman S, Greer JP,Kassim AA, Sengsayadeth S, Yoder SM, Rock MT, Crowe JE Jr. Early Th1 immunity promotes tolerance andmay impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantation. In press,Haematologica 2016.67IN PREPARATION OR SUBMITTEDClark KB, Hsiao H-M, Bassit L, Crowe, JE Jr, Shinazi R, Perng G-C, Villinger F. Characterization of denguevirus 2 growth in megakaryocyte-erythrocyte progenitor cells. Submitted, Virology.Finn J, Leman JK, Willis JR, Cisneros A III, Crowe JE Jr, Meiler J. Improving loop modeling of the antibodycomplementarity-determining region 3 using knowledge-based restraints. Submitted, PLoS ComputationalBiology.Hicar MD, Chen X, Sulli S, Barnes T, Goodman J, Sojar H, Briney B, Willis J, Kalams SA, Doranz BJ, SpearmanP, Crowe JE Jr. Human antibodies that recognize novel immunodominant quaternary epitopes on the HIV-1Env protein. Resubmitted, PLoS One.Wirawan M, Zhang Q, Smith SA, Ng T-S, Kostyuchenko VA, Fibriansah G, Crowe JE Jr*, Lok S-M*. Immaturedengue virus-anti-prM structures at different pH show how antibody renders virus infectious. ScienceAdvances 2015; submitted. *corresponding.Messer WB, Yount BL, Royal SR, de Alwis RA, Widman DG, Smith SA, Crowe JE Jr, Pfaff JM, Kahle KM,Doranz BJ, Ibarra KD, Harris E, de Silva AM, Baric RS. Functional transplant of a dengue virus type 3 humanantibody epitope into dengue virus type 1complex DENV3-specific antibody epitope between dengue virusserotypes. Submitted, Journal of Virology.Yen J, Dower K, Rock MT, Davies H, Tsang S, Yoder S, Karem K, Montoya J, Dekker C, Crowe JE Jr, Felgner P,Relman D, Rubins K. Smallpox vaccination with the attenuated, replication-competent LC16m8 vaccinia viruselicits human antibody and gene expression changes similarly to DryVax. In preparation.Verma A, Okula A, Kuivaniemi H, Tromp G, Carey D, Gerhard GS, Crowe JE Jr, Ritchie MD, Pendergrass SA.Phenome-wide association study to explore relationship between immune system related genetic loci andcomplex traits and diseases. Genes and Immunity 2015; in revision.Fibriansah G, Lim E, Ng T-S, Tan JL, Smith SA, Kostyuchencko VA, Anand GS, de Silva AM, Crowe JE Jr*, LokS-M*. A dengue human antibody binds to partially hidden epitopes and exhibits differential neutralizationdepending on virus morphology. *corresponding.Willis JR, Finn JA, Briney BS, Sapparapu G, Singh V, King HG, LaBranche CC, Montefiori DC, Meiler J, CroweJE Jr. Long antibody HCDR3s from HIV-naïve donors mediate HIV neutralization. In revision, Proceedings ofthe National Academy of Sciences USA.INVITED REVIEWS1. Chanock RM, Crowe JE Jr, Murphy BR, Burton DR. Human monoclonal antibody Fab fragments clonedfrom combinatorial libraries: Potential usefulness in prevention and/or treatment of major human viraldiseases. Infectious Agents and Disease 1993; 2: 118-31.2. Murphy BR, Hall SL, Kulkarni AB, Crowe JE Jr, Collins PL, Connors M, Karron RA, Chanock RM. Anupdate on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3(PIV3) vaccines. Virus Research 1994; 32: 13-36.683. Murphy BR, Crowe JE Jr, Lubeck MD, Hsu K-HL, Hall SL, Karron RA, Clements ML, Wright PF, Belshe RB,Chanock RM. Live attenuated vaccines for respiratory syncytial virus (RSV) and parainfluenza virus type 3(PIV 3). Report of the 104th Ross Conference on Pediatric Research, Ross, 1994, pp 173-8.4. Crowe JE Jr, Current approaches to the development of vaccines against disease caused by respiratorysyncytial virus (RSV) and parainfluenza virus (PIV). Vaccine 1995; 13: 415-21.5. Crowe JE Jr, Wright P, Clements ML, Karron RA, Collins P, Murphy B. Live attenuated respiratory syncytialvirus candidates that are satisfactorily attenuated and genetically stable. In: Vaccines, One Hundred Years AfterLouis Pasteur. The Year of Louis Pasteur International Symposia. Institut Pasteur, Paris, pp 211-13, 1995.6. Crowe JE Jr. The role of antibodies in respiratory viral immunity. Seminars in Virology 1996; 7: 273-83.7. Crowe JE Jr. Immune responses of infants to infection with respiratory viruses and live attenuatedrespiratory virus candidate vaccines. Vaccine 1998; 16: 1423-32.8. Crowe JE Jr. Host responses to respiratory virus infection and immunization. Current Topics inMicrobiology and Immunology 1999, volume 236 on Defense of Mucosal Surfaces: Pathogenesis, Immunity andVaccines, eds. Kraehenbuhl J-P and Neutra MR, pp.191-214.9. Weitkamp J-H, Crowe JE Jr. Current approaches to vaccine development against disease caused byrespiratory syncytial virus (RSV). Monatsschrift Kinderheilkunde (German Journal of Pediatrics) 2000; 148:980-9.Cover illustration.10. Crowe JE Jr. The influence of maternal antibodies on neonatal immunization against respiratory viruses.Clinical Infectious Diseases 2001; 1720-7.11. Crowe JE Jr., Suara RO, Brock S, Kallewaard N, House F, Weitkamp J-H. Genetic and structuraldeterminants of virus neutralizing antibodies. Immunologic Research 2001; 23:135-45.12. Pierson RN III, Crowe JE Jr, Pfeiffer S, Atkinson J, Azimzadeh, A, Miller GG. CD40-Ligand in primatecardiac allograft and viral immunity. Immunologic Research 2001; 23:253-62.13. Crowe JE Jr. Respiratory syncytial virus vaccine development. Vaccine 2002; 20: S32-37.14. Crowe JE Jr., Williams JV. Immunology of viral respiratory tract infection in infancy, PaediatricRespiratory Reviews 2003; 4:112-9.15. Crowe JE Jr. Human metapneumovirus as a major cause of human respiratory tract disease. PediatricInfectious Diseases Journal 2004; 23: S215-21.16. Crowe JE Jr. Human metapneumovirus infections. In: UpToDate, Rose, BD (ed), Wellesley, MA, 2005;Twenty biannual updates 2005 to present.17. Bentzen E, Wright DW, Crowe JE Jr. Nanoscale tools for rapid diagnosis of viruses. Future Virology 2006;1:769-781.18. Crowe JE Jr. Recent advances in the study of human antibody responses to influenza virus using optimizedhuman hybridoma approaches. Vaccine 2009; 27S:G47–G51. PMC28359906919. Hicar MD, Kalams SA, Spearman PW, Crowe JE Jr. Emerging studies of human HIV-specific antibodyrepertoires. Vaccine 2010; 28S: B18-B23. PMC2879399.20. Engelhardt BG, Crowe JE Jr. Homing in on acute graft-versus-host disease: Tissue-specific Tregs and Th17cells. In press, Current Topics in Microbiology and Immunology 2010; 870:121-146.21. Stone JW, Crowe JE. Research highlights. Nanomedicine (Lond). 2011; 6:15-7. PMID: 21182414.22. Graham BS, Crowe JE Jr. Tribute to David T. Karzon, MD and Robert M. Chanock, MD. Vaccine 2011:29:3725-27.23. Crowe JE Jr. Influenza virus resistance to human neutralizing antibodies. mBio 2012; 3(4): p. e00213-12,PMCID: 3419524.24. Briney BS, Crowe JE Jr. Secondary mechanisms of affinity maturation in the human antibody repertoire.Frontiers in Immunology 2013 4:42. doi:10.3389/fimmu.2013.00042.25. Shaikh FY, Crowe JE Jr. Molecular mechanisms driving respiratory syncytial virus assembly. FutureMicrobiology 2013; 8:123-31. doi: 10.2217/fmb.12.132. PMC3577052.26. Crowe JE Jr. Universal Influenza Vaccines: Primum non nocere. Science Translational Medicine, 2013;5:200fs34. PMID: 2398639627. Finn JA, Crowe JE Jr. Impact of new sequencing technologies on studies of the human B cell repertoire.Current Opinion in Immunology 2013; 25:613-8. PMC ID: 3882336.28. Crowe JE Jr. Vaccine approaches targeting RSV infection. Current Opinion in Immunology, submitted.29. Almagro JC, Gilliland GL, Breden F, Scott J, Sok D, Pauthner M, Reichert JM, Helguera G, Andrabi R,Mabry R, Bléry M, Voss JE, Laurén J, Abuqayyas L, Barghorn S, Ben-Jacob E, Crowe JE, Huston JS, JohnstonSA, Krauland E, Lund-Johansen F, Marasco WA, Parren PW, Xu KY.Antibody Engineering & Therapeutics, December 8-12, 2013, Huntington Beach, CA. MAbs 2014; 6:577-618.PMID: 24589717.30. Smith S, Crowe JE Jr. Use of human hybridoma technology to isolate human monoclonal antibodies.Microbiology Spectrum 2014; 3(1):AID-0027-2014. doi:10.1128/microbiolspec.AID-0027-2014.31. Krause JC, Crowe JE Jr. Committing the oldest sins in the newest kind of ways-Antibodies targeting theinfluenza virus type A hemagglutinin globular head. Microbiology Spectrum 2014; doi:10.1128/microbiolspec.AID-0021-2014.32. Simões EA, DeVincenzo JP, Boeckh M, Bont L, Crowe JE Jr, Griffiths P, Hayden FG, Hodinka RL, SmythRL, Spencer K, Thirstrup S, Walsh EE, Whitley RJ. Challenges and opportunities in developing respiratorysyncytial virus therapeutics. Journal of Infectious Diseases 2015; 211 Suppl 1:S1-S20. PMID: 25713060.33. Crowe JE Jr, Koff WC. Deciphering the human immunome. Expert Reviews in Vaccines 2015Nov;14(11):1421-1425. PMID: 26485213.BOOK EDITOR70Editors: Crowe JE Jr, Boraschi D, Rappuoli R. Antibodies for Infectious Diseases. ASM Press, Washington, DC,2015.BOOK CHAPTERS1. Murphy BR, Hall SL, Crowe JE Jr, Collins PL, Subbarao EK, Connors M, London WT, Chanock RM. “Theuse of chimpanzees in respiratory virus research”. In Erwin J, Landon JC, editors. Chimpanzee Conservationand Public Health: Environments for the Future. 1992; 21-8.2. Crowe JE Jr, Murphy BR. “Vaccines against respiratory syncytial virus and parainfluenza type 3”, in NewGeneration Vaccines, 2nd edition, Levine MM, Woodrow GC, Kaper JB, Cobon GS. 1997; 711-25.3. Crowe JE Jr, Englund JA. “Future Prevention Strategies,” in Contemporary Diagnosis and Management ofRespiratory Syncytial Virus Infection, editors Weisman LE and Groothuis JR, 2000, pp 176-200.4. Crowe JE Jr, Collins PL, Murphy BR. Chapter 52: “Vaccines against respiratory syncytial virus andparainfluenza type 1-3”, in New Generation Vaccines, 3rd edition, 2003, Levine MM, Kaper JB, Rappuoli R, LiuM, Good M, Marcel Dekker, pp. 621-39.5. Crowe JE Jr, Weitkamp J-H, Williams JV. “B Cell Development”, Section XX, DevelopmentalImmunobiology Chapter 155 in Polin /Fox/Abman: Fetal and Neonatal Physiology, 3rd edition, 2003, pp. 1518-22.6. Lawton AR, Crowe JE Jr. “Ontogeny of Immunity”. Chapter 1 of Immunologic Disorders in Infants andChildren, 5th edition, Eds. Stiehm, Ochs, Winkelstein, 2004, pp. 3-19.7. Crowe JE Jr. “Viral pneumonias.” Chapter 28, in Kendig's Disorders of the Respiratory Tract in Children,Ed. Thomas Boat, Victor Chernick, Robert Wilmott, Andrew Bush. Saunders W. B. Co., 2005, pp. 433-440.8. Williams JV, Crowe JE Jr. “Paramyxoviruses: Measles, Mumps, and Respiratory Syncytial Virus.” Chapter34, in Schaecter’s Mechanisms of Microbial Disease, 4th ed, editors Engleberg, DiRita, Dermody. Lippincott,Williams, and Wilkins, Baltimore, 2007, pp 347-56.9. Tang YW, Crowe JE Jr. “Respiratory syncytial virus and human metapneumovirus.” Chapter in Manual ofClinical Microbiology, 9th edition, 2007, vol. 2, pp.1361-77.10. Crowe JE Jr. Nelson's Textbook of Pediatrics, 18th ed., Chapter 258, ”Human Metapneumovirus”, 2007,pp. 1391-93.11. Graham BS, Crowe JE Jr. ”Immunization against viral diseases." Chapter in Field's Virology, 5th ed., Ed.Knipe, Howley, Griffin, Lamb, Martin, Roizman, and Straus, Lippincott, Williams, and Wilkins, Baltimore,2007, vol. 1, pp. 487– 538.12. Collins PL, Crowe JE Jr. ”Respiratory Syncytial Virus and Human Metapneumovirus." Chapter in Field'sVirology, 5th ed., Ed. Knipe, Howley, Griffin, Lamb, Martin, Roizman, and Straus, Lippincott, Williams, andWilkins, Baltimore, 2007, vol. 2, pp. 1601– 46.13. Peters TR, Crowe JE Jr. ”Human metapneumovirus.” Chapter in Principles and Practice of PediatricInfectious Diseases, (Long SS, Prober CG, Pickering LK, eds.), Churchill-Livingstone, New York 2007.7114. Williams JV, Crowe JE Jr. ”Respiratory syncytial virus.” Chapter in Principles and Practice of PediatricInfectious Diseases, (Long SS, Prober CG, Pickering LK, eds.), Churchill-Livingstone, New York 2007, 3rdedition.15. Crowe JE Jr. American Academy of Pediatrics. “Human Metapneumovirus.” In: Pickering LK, Baker CJ,Long SS, McMillan JA, eds. Red Book, 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk GroveVillage, IL, 2006, pp. 460-461.16. Crowe JE Jr. ”Human respiratory viruses.” Chapter 488. In: Granoff A, Webster R, eds. Encyclopedia ofVirology, Third Edition, Elsevier, 2007.17. Crowe JE Jr. ”Croup.” Chapter in Encyclopedia of Molecular Mechanisms of Disease, Lang F., ed.,Springer, 2008.18. Crowe JE Jr. ”Prevention of fetal and early life infections through maternal-neonatalimmunization.” Chapter 38 in Infectious Diseases of the Fetus and Newborn Infant, 7th edition, J Remington, JOKlein, CB Wilson, V. Nizet, B. Maldonado, eds., Elsevier, Philadelphia, p. 489-515, 2011.19. Crowe JE Jr. American Academy of Pediatrics. “Human Metapneumovirus.” In: Pickering LK, Baker CJ,Long SS, McMillan JA, eds. Red Book, 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk GroveVillage, IL, 2009, pp. 463-464.20. Tang YW, Crowe JE Jr. “Respiratory syncytial virus and human metapneumovirus.” Chapter 81 in JamesVersalovic, ed., Manual of Clinical Microbiology, 10th edition, 2011.21. Crowe JE Jr. "Human metapneumovirus”, Chapter in Nelson's Textbook of Pediatrics, 19th ed., Chapter,Kliegman RM, Stanton B, St. Geme J and Schor N, eds., 2011.22. Crowe JE Jr. “Respiratory syncytial virus”, Chapter in Nelson's Textbook of Pediatrics, 19th ed., Chapter,Kliegman RM, Stanton B, St. Geme J and Schor N, eds., 2011.23. Crowe JE Jr. “Viral pneumonias.” Chapter 28, Pages 453-460, in Kendig's Disorders of the RespiratoryTract in Children, 8th Edition, Editors: Thomas Boat, Victor Chernick, Robert Wilmott, Andrew Bush. Elsevier,2012.24. Crowe JE Jr. American Academy of Pediatrics. “Human Metapneumovirus.” Editors: Pickering LK, BakerCJ, Long SS, McMillan JA. Red Book, 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk GroveVillage, IL, 2012.25. Williams JV, Crowe JE Jr. ”Respiratory syncytial virus.” In: Principles and Practice of Pediatric InfectiousDiseases, Editors Long SS, Prober CG, Pickering LK, eds.), 4th edition, Churchill-Livingstone, New York 2012.26. Williams JV, Crowe JE Jr. “Metapneumoviruses.” In: Samal S, editor. The Biology of Paramyxoviruses, 1stedition, Horizon Scientific Press, 2011.27. Williams JV, Crowe JE Jr. “Paramyxoviruses: Measles, Mumps, and Respiratory Syncytial Virus.” Chapter34, in Schaecter’s Mechanisms of Microbial Disease, 5th ed, Editors: Engleberg, DiRita, Dermody. Lippincott,Williams, and Wilkins, Baltimore, 2012.28. Graham BS, Crowe JE Jr. “Tribute to David T. Karzon, MD and Robert M. Chanock, MD.” Vaccine 2011; 29:3725-27.7229. Graham BS, Crowe JE Jr. ”Immunization against viral diseases." Chapter in Field's Virology, 6th ed.,editors Knipe, Howley, Griffin, Lamb, Martin, and Roizman, Lippincott, Williams, and Wilkins, Baltimore,2012.30. Williams JV, Crowe JE Jr. “Respiratory syncytial virus and human metapneumovirus.” Viral Infections inHumans: Epidemiology and Control, 5th ed., editors Kaslow, Richard A., Stanberry, Lawrence R., Le Duc,James W., Springer, 2014.31. Engelhardt BG, Crowe JE Jr. “Exposure to family members: infections and recent live vaccinations.”Chapter 13 in Blood and Marrow Transplantation Long Term Management: Prevention and Complications,First Edition, Bipin Savani, editor, John Wiley and Sons, 2013.32. Crowe JE Jr. ”Prevention of fetal and early life infections through maternal-neonatalimmunization.” Chapter in Infectious Diseases of the Fetus and Newborn Infant, 8th edition, J Remington, JOKlein, CB Wilson, V. Nizet, B. Maldonado, eds., Elsevier, Philadelphia, 2014.33. Crowe JE Jr. “Respiratory syncytial virus”, Chapter in Nelson's Textbook of Pediatrics, 20th ed., Chapter260, Kliegman RM, Stanton B, St. Geme J and Schor N, eds., 2015.34. Crowe JE Jr. "Human metapneumovirus”, Chapter in Nelson's Textbook of Pediatrics, 20th ed., Chapter261, Kliegman RM, Stanton B, St. Geme J and Schor N, eds., 2015.35. Krause JC, Crowe JE Jr. ”Committing the oldest sins in the newest kind of ways---antibodies targeting theinfluenza virus type A hemagglutinin globular head.” Antibodies for Infectious Diseases, 1st edition, Crowe JEJr, Boraschi D, Rappuoli R, eds., 2014, ASM Press.36. Smith SA, Crowe JE Jr. “Use of human hybridoma technology to isolate human monoclonal antibodies.”Antibodies for Infectious Diseases, 1st edition, Crowe JE Jr, Boraschi D, Rappuoli R, eds., 2015, ASM Press.37. Crowe JE Jr. “Human respiratory viruses”, Chapter 2600, Reference Module in Biomedical Research,Elsevier, 2014. Crowe J.E. Human Respiratory Viruses. Reference Module in Biomedical Sciences. doi:10.1016/B978-0-12-801238-3.02600-3.38. Alvarado G, Crowe JE Jr. Development of human monoclonal antibodies against respiratory syncytialvirus using a high efficiency human hybridoma technique. Book chapter in Methods in Molecular Biology:Human Respiratory Syncytial Virus: Methods and Protocols, eds. R.A. Tripp and P. Jorquera, Humana Press,2015.39. Crowe JE Jr. American Academy of Pediatrics. “Human Metapneumovirus.” Editors: Kimberlin DK, BradyMT, Jackson MA, Long SS. Red Book, 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk GroveVillage, IL, 2015.40. Crowe JE Jr. “Host Defense Mechanisms Against Viruses.” Chapter in Fetal and Neonatal Physiology, 5thedition, Editors: Polin R, Abman S, Benitz W, Rowitch D. Elseiver, 2016, submitted.41. Crowe JE Jr. Editor: Brunton L. “Immunostimulants and Vaccines” Chapter in 13th edition. Goodman &Gilman's The Pharmacological Basis of Therapeutics, 2016, pending.42. Crowe JE Jr. American Academy of Pediatrics. “Human Metapneumovirus.” Editors: Kimberlin DK, BradyMT, Jackson MA, Long SS. Red Book, 2018 Report of the Committee on Infectious Diseases. 31st ed. Elk GroveVillage, IL, 2018, pending.73EDITOR OF SPECIAL JOURNAL ISSUES1. Pediatric Infectious Diseases Journal, Proceedings of the Fourth International Congress on RespiratoryViruses, November, 2004. Editor of full issue.2. Seminars in Pediatric Infectious Diseases, special issue on Emerging Vaccines for Mucosal Infections,October, 2006. Editor of full issue.3. Stone JW, Crowe JE Jr. Research highlights. Nanomedicine 2011; 6:15-16.CORRESPONDENCE1. Ho H-K, Principi N, Esposito S, Bosis S, Williams JV, Crowe JE Jr. Human metapneumovirus and lowerrespiratory tract disease in children. New England Journal of Medicine 2004; 350:1788-90.2. Williams JV, Heymann PW, Crowe JE Jr. Reply: Wheezing in hMPV infection. Journal of Allergy andClinical Immunology, 2006; 117:223-4.3. Williams JV, Crowe JE Jr. Reply to Schlabach et al.: Human metapneumovirus infection as an emergingpathogen causing acute respiratory distress syndrome. Journal of Infectious Diseases 2011; 203:296.BOOK REVIEWSCrowe JE Jr. Vaccines: Frontiers in Design and Development. Clinical Infectious Diseases 2006; 43:119.EDITORIALS1. Crowe JE Jr, Edwards KM. Emerging vaccines for mucosal infections. Seminars in Pediatric InfectiousDiseases, 2006; 17:185-6.2. Crowe JE Jr. Genetic predisposition for adverse events after vaccination. Journal of Infectious Diseases 2007;196:176-177. PMID: 17570102.3. Crowe JE Jr. Perspective: Crowd sourcing immunity. Science 2013; 340:692-693. PMID: 23661747.PUBLISHED IMAGESBiology Image Libraryhttp://www.biologyimagelibrary.com/imageID=50120 - RSV filamentsShort-listed Biology Image Library Image Award 2010http://www.biologyimagelibrary.com/imageID=50121 - Rotavirus DLP/antibody complex 1http://www.biologyimagelibrary.com/imageID=50122 - Rotavirus DLP/antibody complex 2http://www.biologyimagelibrary.com/imageID=50123 - Rotavirus DLP/antibody complex 3WEBINARS74“Epitope mapping of neutralizing antibodies to pathogenic viruses: A critical tool for rational vaccine designand evaluation.” Epitope Mapping in Antibody Therapeutics and Vaccine Development: The EvolvingLandscape. Genetic Engineering & Biotechnology News Webinar. June 9, 2015. Online.INVITED PRESENTATIONS / EXPERT PANELS1992• World Health Organization meeting, "Development of Vaccines Against Diseases Caused byRespiratory Syncytial Virus and Parainfluenza Type 3 Virus," April 21-22, 1992, Geneva, Switzerland.• Modern Approaches to New Vaccines Including Prevention of AIDS, September 16-20, 1992, ColdSpring Harbor, NY.1993• World Health Organization / National Institutes of Health / Centers for Disease Control Meeting, TheProtective and Disease Enhancing Immune Response to RSV, May 26-27, 1993, Bethesda, MD.• American Society for Virology 12th Annual meeting, July 10-14, 1993, Davis, CA.• Modern Approaches to New Vaccines Including Prevention of AIDS, September 20-24, 1993, ColdSpring Harbor, NY.• IBC Antiviral Technology and Therapeutics Meeting, October 28-29, 1993, Washington, DC.• Pediatric Grand Rounds, November 23, 1993, Minneapolis Children's Medical Center, Minneapolis,MN.1994• Diagnon/Bioqual Corporation, Rockville, MD, January 13, 1994.• World Health Organization meeting, "Development of Vaccines against Diseases caused by RespiratorySyncytial Virus and Parainfluenza Virus Type 3,” March 27, 1994, Nyon, Switzerland.• Infectious Diseases Grand Rounds, May 18, 1994, Vanderbilt University Medical Center, Nashville, TN.• American Society for Virology 13th Annual meeting, July 9-13, 1994, Madison, WI.• NIH Research Festival, September 21, 1994, Bethesda, MD.• Ebon Research Systems, Bethesda, MD, October 27, 1994.• Pediatric Infectious Diseases Conference, December 2, 1994, Johns Hopkins University Medical Center,Baltimore, MD.1995• Vaccine Symposium, Society for Pediatric Research, San Diego, CA, May 11, 1995.• "Vaccines, 100 Years after Louis Pasteur" Symposium, Institut Pasteur, Paris, France, September 24-28,1995.1996• Biomedical Primate Research Centre, Rijswijk, Netherlands, May 4-8, 1996.199775• Immunity in Early Life International Symposium, Annecy, France, Fondation Marcel Merieux,November 18, 1997.1998• Society for Pediatric Research, New Orleans, LA. May 4, 1998.1999• First Global Conference on Vaccines and Immunisation, University of Manchester, U.K. Sept. 6-9, 1999.2000• Plenary speaker, Society for Pediatric Research, Boston, MA. May 13, 2000.• NIAID/NICHD Funding Priority Meeting: Developing Immune System: Frontiers in Knowledge, 9/20-21/2000, Arlington, VA.• NIAID Orthopoxvirus Research Group Annual Meeting, 10/11/2000, Bethesda, MD.• III International Symposium on Respiratory Viral Infections, St. Lucia, West Indies, December 1-3, 2000.2001• The 5th European Conference on Vaccinology, March 21-23, 2001, Lucerne, Switzerland;• Presidential Plenary session talk, Society for Pediatric Research, April 30, 2001, Baltimore, MD,• Pediatric Research Seminar, October 26, 2001, Mercy Children’s Hospital, Kansas City, MO.• Pediatric Infectious Diseases Research Seminar, Children’s Hospital, Cincinnati, OH, December 12,2001.2002• University of Connecticut Center for Immunotherapy, April 4, 2002, Hartford, CT.• International Congress of Mucosal Immunology, Orlando, FL, June 2002.• Amos Christie Pediatric Society, October 12, 2002, Nashville, TN.• 40th meeting, Infectious Diseases Society of America, October 26, 2002, Chicago, IL.• MedImmune Satellite meeting on Metapneumovirus, Fifth International Symposium on RespiratoryViral Infections, Dominican Republic, Dec 7, 2002.2003• 7th Annual Meeting of Acute Respiratory Infections Panel, Yokohama, Japan, January 8-10, 2003.• International Symposium on Infection and Immunity in Childhood and the International Symposiumon Graduate Medical Education for Pediatricians at the 106th Annual Meeting of the Japan PediatricSociety April 25-27, 2003, Fukuoka, Japan, invited speaker.• FASEB Summer Research Conference, Gastrointestinal Tract X: Physiology and Pathophysiology of GIEpithelia, July 19-24, 2003, Tucson, Arizona, invited speaker.• Viral Respiratory Infections: New Pathogens and Special Populations Session, 43rd ICAAC, Sept 14-17,2003, Chicago, IL, invited speaker.76• “Immune responses of infants and children to respiratory virus infection or vaccination.” ViralVaccines meeting, Barcelona, Spain, October 24-28, 2003, invited speaker, session moderator, meetingscientific advisor.• 14th IBC Antibody Engineering Meeting, San Diego, CA, November 30-December 3, 2003, invitedspeaker.2004• NVAC Newborn Vaccines Meeting. Bethesda, MD, March 1-4, 2004, invited speaker.• ASM Biodefense Meeting, March 7-10, 2004, invited speaker.• NIH Vaccine Testing and Evaluation Unit Investigator meeting, Bethesda, MD, March 30-31, 2004,invited speaker, organizer Cell-Mediated Immunity session.• National Center for Biodefense meetings Bethesda, MD, April 20-21, 2004, invited speaker.• Third Annual International Congress on Respiratory Viruses, Chicago, IL April 24-26, 2004, Co-Chair ofthe meeting, and speaker.• Lysosomes and Endocytosis Gordon Conference, Andover, NH, June 27-July2, 2004, invited speaker.• Center for Vaccine Development, University of Maryland, Baltimore, MD, July 14, 200• 42nd Annual Meeting of the Infectious Diseases Society of America (IDSA), September 30 - October 3,2004, Boston, MA.• Plenary session speaker, Association for Molecular Pathology 2004 meeting, Los Angeles, CA,November 11-13, 2004.2005• Frontiers in Neonatal and Infant Immunity. Madrid, Spain. March 18-20, 2005.• Eighth Annual Conference on Vaccine Research, Baltimore, MD, May 9 -11, 2005.• NIH Vaccine Research Center Seminar Series, Bethesda, MD, June 7, 2005.• The 2005 Henry Shinefield Lecture, CDC-National Immunization Program, Clinical ImmunizationSafety Assessment (CISA) Network National Meeting, June 13-14, 2005, Nashville, TN.• Center for Investigating Viral Immunity and Antagonism Symposium, Mt. Sinai School of Medicine,New York, New York, July 15, 2005.• Respiratory Syncytial Virus 2005 Symposium, September 15-18, 2005, at Keble College, Oxford, UK,invited speaker.• New and Emerging Infections in Children Symposium, 45th Interscience Conference on AntimicrobialAgents and Chemotherapy (ICAAC), December 16-19, 2005 in Washington, DC.• 16th Annual IBC Antibody Engineering Meeting, San Diego, CA, December 5-8, 2005.2006• 2nd ASM - IEEE EMBS Conference on Bio, Micro and Nanosystems, January 15-18, 2006, San Francisco,CA.• E. Mead Johnson Award lecture, Society for Pediatric Research, San Francisco, CA, May 1, 2006.• NIAID Antibody Epitope Prediction Tool Evaluation Workshop, Bethesda, MD, September 7-8, 2006.• SERCEB 4th Annual Meeting, Gainesville, Florida, October 17, 2006.200777• Infectious Diseases Division of the University of Texas Southwestern Medical Center at Dallas, January11, 2007.• Speaker Lecture Series, Department of Infectious Diseases, University of Georgia, Athens, GA, January23, 2007.• St. Jude/Pediatric Infectious Diseases Society Annual Research Conference, Memphis, TN, February 9,10, 2007.• Tenth Annual Conference on Vaccine Research, National Foundation for Infectious Diseases, April 30 –May 2, 2007, Baltimore MD.• NIH Human Immunology Centers U19 National Meeting, May 3, 2007, Stanford University, Stanford,CA.• 70th Perinatal & Developmental Symposium, Park City, Utah, May 31-June 3, 2007.• Postdoctoral Fellows Association invited lecturer, The Danny Thomas Lecture, St. Jude Children'sResearch Hospital, Memphis, TN, June 22, 2007.• Approaches to the study of human antibody responses to viruses Meeting, Chapel Hill, NC, July 10,2007.• The Jack Light Lecture, Cedars Sinai Medical Center/UCLA Pediatrics Program, Los Angeles, CA,September 27, 2007.• Pathogenesis Affinity Seminar Series, The Scripps Research Institute, La Jolla, CA, October 9, 2007.• SERCEB Biodefense Center Annual Meeting, October 16, 2007, Nashville, TN.• Microbiology and Immunology Research Seminar, University of Texas Health Sciences Center at SanAntonio, November 8, 2007.• Pediatric Grand Rounds, University of Texas Health Sciences Center at San Antonio, November 9, 2007.• Infection and Immunity in the Etiology of Leukemia Conference, University of California at SanFrancisco, November 16, 2007.• Center for Immunology and Microbial Diseases invited lecturer, Albany Medical College, Albany, NY,November 19, 2007.• Center for Translational Research on Human Immunology and Biodefense, Dana Farber, HarvardMedical School, Boston, MA, January 11, 2008.2008• MedImmune, Inc., February 6, 2008.• Plenary Session speaker, Southern Society for Pediatric Research Annual Meeting, New Orleans, LA,February 23, 2008.• Keystone Symposium on HIV Vaccines: Progress and Prospects, March 27 - April 1, 2008, Banff,Alberta.• R & D Retreat, International AIDS Vaccine Initiative, White Plains New York, March 12-14, 2008.• Neutralizing Antibody Consortium Meeting, International AIDS Vaccine Initiative, April 28-29, 2008,La Jolla, CA.• American Society for Microbiology 108th General Meeting, Boston, MA, June 1- 5, 2008.• Infant Foundation, Buenos Aires, Argentina, July 23, 2008.• Driscoll Children's Hospital, Corpus Christi, Texas, August 1, 2008.• The XIV International Congress of Virology, Istanbul August 10-15, 2008.• Conference for Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, MN, September8, 2008.• US-Japan Cooperative Medical Science Program AIDS Panel Meeting on Awaji Island (Hyogo, Japan),September 10th and 11th, 2008.78• HIV B Cell Immunology Vaccine Workshop Meeting Bethesda, MD November 3-5, 2008.• The 14th International Conference on Human Antibodies & Hybridomas. Nov. 12-14 2008, New YorkUniversity, NY.2009• Program in Immunology Seminar Series, University of Alabama at Birmingham, January 15, 2009.• Program in Microbial Pathogenesis, Meharry Medical College, Nashville, TN, February 6, 2009.• Fifth Annual Protein Engineering Summit, Boston, MA, April 6-10, 2009.• Department of Microbiology, Baylor Medical College, Houston TX, April 16, 2009.• Fourth Semmering Vaccine Symposium, Baden, Austria, April 23-25.• Novartis, Cambridge, MA, June 8, 2009.• NYU School of Medicine Immunology Club Seminar Series, New York, NY, June 18, 2009.• Third annual Immunobiology of Influenza Virus Infection meeting, Athens, GA, July 26-28, 2009.• American Society for Virology 28th Annual Meeting, The University of British Columbia, July 11 - 15,2009.• Department of Immunology Easton Seminars, University of Toronto, Toronto, Canada, September 14,2009• Microbiology & Molecular Genetics (MMG) Seminar, Emory University, Atlanta, GA, Sept. 21, 2009.• MedImmune Science Symposium. Mountain View, CA, September 30, 2009.• Plenary speaker, Infectious Diseases Society of America, Philadelphia, PA, Oct. 29, 2009.• NIH Memory B Cell Development Meeting, Bethesda, MD, November 3 - 4, 2009.• IBC Antibody Engineering Meeting, December 6-10, 2009, San Diego, CA.2010• National Regional Centers of Excellence in Biodefense Annual Meeting, Las Vegas, NV, April 12, 2010.• Norman Siegel Award Lecture. American Pediatrics Society Meeting, Vancouver, Canada, April 29-May 4, 2010• American Association of Immunologists, Baltimore, MD, May 9-11, 2010.• The Search for Broadly Protective Anti-HIV Antibodies NIH meeting, June 29-30, 2010, Bethesda, MD.• NIAID RCE Workshop: Dengue Virus Infection & Immunity, Portland, OR, August 24-25, 2010.• SERCEB Annual Meeting, October 4, 2010, Chapel Hill, NC.• OMRF Annual Anthrax Meeting, Oklahoma City, OK, October 12, 2010.• 7th Annual RSV International Symposium, December 2-5, 2010.2011• Oregon State University, Corvalis, OR, January 12, 2011.• Keystone Symposium, Antibodies as Drugs, Feb 6 - 11, 2011, Keystone, Colorado.• Frontiers in Science Symposium, annual AMSPDC/PSDP meeting, March 4-5, 2011, San Diego, CA.• La Jolla Institute for Allergy and Immunology’s (LIAI) Seminar Series, February 23, 2011.• University of Washington, Seattle, WA, March 31, 2011.• Plenary Session, Society for Pediatric Research, Denver, CO, May 1, 2011.• Fourteenth Annual Conference on Vaccine Research, National Foundation for Infectious Diseases,Bethesda, Maryland, May 17, 201179• Department of Defense, DTRA-CB Basic Research Review, Springfield, VA, July 18-29, 2011.• Vienna Biocenter, Vienna Austria, July 28, 2011.• Plenary session, 5th Vaccine and ISV Conference, in Seattle, WA, October 2-4, 2011.2012• Molecular Genetics and Microbiology. UT-Austin, Austin, TX, February 1, 2012.• Vaccine Research Center, NIH, Bethesda, MD, February 14, 2012.• 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, March 8, 2012.• Gordon Conference: Biology of Acute Respiratory Infection, Ventura, CA, March 11-16, 2012.• Symposium on Immunologic Diseases and Basic Immunology, University of Alabama at Birmingham,Birmingham, AL, June 9-10.• NIH/FDA 2012 Universal Influenza Vaccines Meeting, Bethesda, MD, June 19-20, 2012.• American Society of Virology, Madison, WI, July 21, 2012.• Defense Threat Reduction Agency, Springfield, VA, July 23, 2012.• Wellcome Trust experts meeting, Understanding Bottlenecks in the Discovery of New Therapies forRSV, London, UK, Sept. 10-11, 2012.• AIDS Vaccine 2012, Boston, MA, September 12, 2012.• The Scripps Research Institute, La Jolla, CA, September 24, 2012.• RSV 2012: 8th Annual Respiratory Syncytial Virus Symposium, Sante Fe, NM, September 27-30, 2012.• SERCEB Annual Meeting, October 1-2, 2012, Chapel Hill, NC.• Institute of Human Virology 14th Annual International Meeting, Baltimore, MD, October 16, 2012.• University of Iowa, November 1, 2012.• Cent Gardes: HIV Vaccine Conference: The B cell response to HIV and HIV vaccines: From broadlyneutralizing to non-neutralizing antibodies, Veyrier du Lac, France, November 5-7, 2012.• 11th International Symposium on Double-Stranded RNA Viruses, San Juan, Puerto Rico, November 27-December 1, 2012.• University of Puerto Rico, San Juan, PR, November 28, 2012.2013• 11th ASM Biodefense and Emerging Infections Conference, Washington, DC, February 24-27, 2013.• Department of Medicine Grand Rounds, University of CA – Irvine, April 16, 2013.• Institute for Immunology Seminar, University of CA – Irvine, April 17, 2013.• Epithelial Biology Center Symposium 2013, Nashville, TN, April 18, 2013.• NIAID National Institutes of Health Dengue Vaccine Initiative, International Vaccine Institute,Consultation on Dengue Vaccines, Rockville, MD, June 26-28, 2013.• Plenary Session, American Society for Virology, Penn State University, State College, PA, July 20-24,2013.• Plenary Speaker, Duke CHAVI-ID Annual Retreat and Meeting, Durham, NC, September 29-October 2,2013• RSV Vaccines for the World, Porto, Portugal, October 14-16, 2013.• Cold Spring Harbor course on Phage Display of Antibodies and Peptides, Cold Spring Harbor, NY,Nov 13, 2013.• 2013 Antibody Engineering & Therapeutics, Huntington Beach, CA, Dec 9, 2013.201480• Keystone Symposium on Pathogenesis of Respiratory Viruses, January 20, 2014, Keystone, Colorado,USA.• National Institutes of Health, NIAID, February 24, 2014, Bethesda, MD.• Ohio Virology Association. Columbus, OH. March 13, 2014.• Center for Vaccines and Immunity, Nationwide Children's Hospital Research Institute, Columbus, OH.March 14, 2014.• Washington University at St. Louis, March 28, 2014.• Southeastern Biosafety Association (SEBSA). Nashville, TN, May 1, 2014.• Plenary Speaker, Vanderbilt University Pediatric Department Research Retreat, May 17, 2014.• Third Annual Symposium on Respiratory Virus Pathogenesis, Buenos Aires, Argentina, May 15, 2014.• NIH Think Tank “B cell Help - HIV Vaccines, Bethesda, MD, May 21-22, 2014.• NIAID and FDA workshop on “Common Barriers in Vaccine Research and Development”, Rockville,MD, June 19-20, 2014.• 11th International Symposium on Rotavirus, Delhi, India, Sept 3-5, 2015.• DTRA 2014 Basic Research, Falls Church, VA, Sept 15, 2014.• Prophylactic Options to Environmental and Contagious Threats (PROTECT) Program Meeting -Antibody Discovery, Cambridge, MA, September 28–30, 2014.• 12th Global Experts' Meeting (GEM) on Respiratory Viruses, Athens, Greece, October 22-23, 2014.• Baylor College of Medicine, Department of Molecular Virology and Microbiology Seminar, October 30,2014 and Pediatric Grand Rounds, October 31, 2014.• 9th Respiratory Syncytial Virus Symposium, Stellenbosch, South Africa, November 9-13, 2014.• Speaker and Panelist, “Epidemics, Pandemics, and Outbreaks of Contagious Diseases”, Frontiers inHealth Innovation Session, Third Annual Global Action Summit 2014, Nashville, TN, November 16,2014.• Center for Strategic and International Studies, "U.S. Leadership on Ebola in West Africa and at Home”meeting, Nashville, TN, November 21, 2014.2015• Keystone Symposium on Viral Immunity, Breckenridge, CO, January 11-16, 2015.• 17th International Conference on Emerging Infectious Diseases (EID) meeting, Taipei, Taiwan, January26-28, 2015.• Plenary speaker, FILO 2015 - 7th International Symposium on Filoviruses, March 25-28, 2015,Washington, DC.• 18th Annual Conference on Vaccine Research, Bethesda, MD, April 13-15, 2015.• Keynote Speaker, 2015 National Interagency Confederation for Biological Research (NICBR) SpringResearch Festival (for NCI/USAMRIID/USDA/NIAID), May 4th, 2015, Frederick, MD.• 2015 Chemical and Biological Defense Science and Technology (CBD S&T) Conference, St. Louis, MO,May 12-14, 2015.• Plenary speaker, American Society for Gene and Cell Therapy meeting, New Orleans, LA, May 16,2015.• Gordon Conference on Viruses and Cells, Girona, Spain, June 21-25, 2015.• 14th Annual Dengue Course, Havana, Cuba, August 9-16, 2015.• Washington University in St. Louis, Microbiology, St. Louis, MO, September 30, 2015.• International Symposium on Flaviviruses: Structure and Immunity, October 8-10, 2015, Vienna,Austria.81• DARPA Protect Meeting, Cambridge, MA, October 13, 2015.• U.S. Senate NIH Caucus, Washington, DC, November 17, 2015. Joint presentation on “NIH Fundingand the Promise of Biomedical Research” to U.S. Senators with Tony Fauci, MD.• University of Pennsylvania, December 1, 2015.2016• Pending, UTMB Infectious Diseases & Immunity Colloquium, Galveston, TX, January 26, 2016.• Pending, 2016 ASM Biodefense and Emerging Diseases Research Meeting, Arlington, VA, February 9,2016.• Pending, Plenary speaker, annual PIDS/St Jude Research Conference, Memphis, TN, March 4-5, 2016.• Pending, Partnership for Dengue Control, Dengue Immune Correlates of Protection meeting, LesPensières, France, March 8-9, 2016.• Pending, Grand Rounds, Department of Pediatrics, University of New Mexico, Albuquerque, NM,March 24, 2016.• Pending, The Flexner Dean’s Lecture, Vanderbilt University, March 21, 2016.• Pending, Plenary speaker, Academic Drug Discovery Consortium at the American Society forPharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology April 7, 2016,San Diego, CA.• Pending, Influenza Immunology: Data, Systems and Models, Yale University, June 24, 2016.• Pending, 9th Options for the Control of Influenza meeting, Chicago, IL, August 24-28, 2016.